Top

Naval G. Daver, M.D.

Department of Leukemia, Division of Cancer Medicine

About Dr. Naval G. Daver

Dr. Naval Daver is a Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, TX. He is a clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myeloid disease and is principal investigator on more than 25 ongoing institutional, national, and international clinical trials in these diseases, including multiple registration and label enabling trials.

These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune, and cytotoxic agents, and identifying and overcoming mechanisms of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint, CD47, NK and T-cell based approaches, as well as combinations of targeted and apoptotic therapies in AML, and he is leading a number of these trials at MDACC. Dr. Daver has published more than 400 peer-reviewed manuscripts and is on the editorial board of numerous hematology journals. He also serves as Chair on numerous national and international meetings and educational platforms.

Meet Naval Daver, M.D.

In the News

Illustration of red blood cells floating in the bloodstream with blue cancer cells

Second-generation inhibitors may change prognosis for patients with FLT3-positive acute myeloid leukemia

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Director, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Director, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2004	Grant Medical College and Sir J.J. Group of Hospitals, Mumbai, IN, MD
1998	D.G. Ruparel College, Mumbai, IN, BA, BA

Postgraduate Training

2008-2011	Clinical Fellowship, Fellowship Oncology - Hematology, Baylor College of Medicine, Houston, Texas
2005-2008	Clinical Residency, Internal Medicine Residency, Baylor College of Medicine, Houston, Texas
2004-2005	Research Fellowship, Research Assistant, Baylor College of Medicine, Houston, Texas

Licenses & Certifications

2011	American Board of Oncology
2011	American Board of Hematology
2011	Texas Medical Board
2008	American Board of Internal Medicine

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2023

Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2017

Administrative Appointments/Responsibilities

Advisory Board, HealthTree for AML Community Program, Houston, TX, 2022 - Present

Extramural Institutional Committee Activities

Co-Chair, MD Anderson Cancer Center Daiichi Sankyo - Leukemia Alliance Joint Steering Committee for Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, 2018 - 2025

Director, Leukemia Research Alliance Program, The University of Texas MD Anderson Cancer Center, 2018 - Present

Co-Principal Investigator, MD Anderson Pfizer Alliance, The University of Texas MD Anderson Cancer Center, 2016 - Present

Member, MD Anderson Cancer Center CRC 2 Member, The University of Texas MD Anderson Cancer Center, 2016 - Present

Member, MD Anderson Cancer Center Immunotherapy platform - BMS Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present

Senate, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2014 - Present

CO-Chair, MD Anderson Cancer Center BMS -Leukemia Alliance Joint Steering Committee for Leukemia, The University of Texas MD Anderson Cancer Center, 2014 - Present

Member, Fellowship Steering Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present

Co-Leader, MD Anderson Department of Leukemia Fellowship Steering Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present

Honors & Awards

2022	MDACC Faculty Scholar Award FY
2021 - 2024	Chair, Novartis Siremadlin Global Clinic Trial Steering Committee
2021 - 2024	Journal of Hematology Oncology, Editorial Board Member
2020 - 2024	Blood and Cancer Journal, Editorial Board Member
2020 - 2024	Chair, International Working Group Acute Leukemia (iwAL), post ASH Annual Meeting
2020 - 2024	Executive Scientific Steering Committee, Karyopharm, Member
2020 - 2024	Leukemia and Lymphoma, Editorial Board Member
2020 - 2024	SOHO Scientific Committee Steering Committee Member
2020 - 2021	Faculty Educator of the Year, Physicians Education Resource (PER)
2019 - 2024	Frontiers in Oncology, Editorial Board Member
2017 - 2024	Steering Committee Member, International Working Group Acute Leukemia (iwAL)
2016 - 2024	Ladies Leukemia League Grant for AML therapy
2015 - 2024	Leukemia SPORE Career Development Award, SPORE Career Development
2007 - 2008	Residency Assistance Program, Baylor College of Medicine
2007 - 2008	State Medical Jeopardy Winners, Baylor College of Medicine Jeopardy Team
2004	Distinction in Medicine and Obstetrics/Gynecology, Grant Medical College, Mumbai, India
2004	Valedictorian, Class of 2004, Grant Medical College
2003	Distinction Ophthalmology and ENT, Grant Medical College, Mumbai, India
2001	Distinction in Pathology and Pharmacology, Grant Medical College, Mumbai, India
1999	Distinction in Anatomy and Physiology, Grant Medical College, Mumbai, India

Professional Memberships

American Association of University Professors

2023 - Present

Giants of Cancer Care® Selection Committee

2023 - Present

Society of Hematologic Oncology

2020 - Present

CME Advisory Committee

2018 - Present

Society of Immunotherapy

2015 - Present

European Hematology Association

2014 - Present

European Society of Medical Oncology

2014 - Present

SWOG Committee Member

2013 - Present

American Society of Hematology

2008 - Present

American Society of Clinical Oncology

2008 - Present

Selected Presentations & Talks

Local Presentations

2017. Checkpoint Inhibitors in Hematologic Malignancies. Conference. Checkpoint Inhibitors in Hematologic Malignancies. Houston, TX, US.
2016. Update on checkpoint clinical trials in AML. Conference. Update on checkpoint clinical trials in AML. Houston, TX, US.
2016. Presenter. Conference. Presenter. Houston, TX, US.
2016. N/A. Conference. N/A. Houston, TX, US.
2016. Session Chair. Conference. Session Chair. Houston, TX, US.

Regional Presentations

2022. Update on CD47 Targeting Antibodies. Conference. Update on CD47 Targeting Antibodies. Houston, UT, US.

National Presentations

2025. Optimizing Frontline Therapy for FLT3 Mutated AML Patients Eligible for Intensive. Panelist. AML-ALL US Focus Meeting 2025. Marina Del Ray, California, US.
2025. Efficacy of macrophage checkpoint Clever-1inhibition with bexmarilimab plusazacitidine in myelodysplasticsyndrome: Results from the ph1/2BEXMAB study. Poster. ASCO 2025. Chicago, Illinois, US.
2025. Treatment of Secondary AML from MDS and MPN. Invited. 6th Annual MPN-MDS MPN-MDS US Focus Meeting 2025. Austin, TX, US.
2024. Patients (pts) with Optimized Hemophagocytic Lymphohistiocytosis (HLH) Inflammatory (OHI) Index-Confirmed Diagnosis of Malignancy-Associated HLH (mHLH) and Emapalumab Treatment. Poster. 66th ASH Annual Meeting and Exposition. San Diego, California, US.
2024. Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML. Poster. 66th ASH Annual Meeting and Exposition. San Diego, California, US.
2024. Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study. Poster. 66th ASH Annual Meeting and Exposition. San Diego, California, US.
2024. AML Panel Discussion Daiichi Sankyo. Panelist. Phoenix, Arizona, US.
2024. Menin Inhibition. Panelist. 6th International Workshop on Acute Leukemias. Phoenix, Arizona, US.
2024. Special session on regulatory endpoints in AML. Panelist. 6th International Workshop on Acute Leukemias. Phoenix, Arizona, US.
2024. Frontline Approaches for FLT3-mutant AML. Invited. 6th International Workshop on Acute Leukemias. Phoenix, Arizona, US.
2024. Updates on established therapies in AML – Part 2. Panelist. 6th International Workshop on Acute Leukemias. Phoenix, Arizona, US.
2024. AML in 2024 - A Focus on Targeted and Immune Therapies. Conference. AE Grounds. New York, NY, US.
2024. Progress in AML and Unanswered Questions for the Future. Conference. First Annual HemOnc Pulse Live Meeting. Chicago, IL, US.
2024. Optimizing and future directions with CAR-T/NK therapies in AML. Conference. iwCAR-T 2024. Miami, FL, US.
2024. Insights into the Evolving Treatment Paradigm of Acute Myeloid Leukemia. Conference. ACCC 50th Annual Meeting & Cancer Center Business Summit (AMCCBS) Pre-Conference: Clinical Updates from San Diego on Hematologic Malignancies. Washington, DC, US.
2023. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III (Oral Presentation). Conference. 65th Annual ASH Meeting. San Diego, US.
2023. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II. Conference. 65th Annual ASH Meeting. San Diego, US.
2023. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Uses of Approved Therapeutic Agents (Oral Presentation). Conference. 65th Annual ASH Meeting. San Diego, US.
2023. Myelodysplastic Syndromes – Clinical and Epidemiological (Poster). Conference. 65th Annual ASH Meeting. San Diego, US.
2023. Physicians’ Education Resource®, LLC (PER®) AML Session (Oral Presentation). Conference. 65th Annual ASH Meeting. San Diego, US.
2023. Cellular Therapy in AML: Overcoming Challenges. Conference. Seattle Cellular Therapy Summit. Seattle, WA, US.
2023. Upfront Triplets vs Sequential Therapies for the Treatmeant of AML: The Case for Upfront Triplets. Conference. AML ALL US Focus Meeting. La Jolla, CA, US.
2023. Personalizing and Optimizing Frontline Therapy of AML in 2023. Conference. Hematology Grand Rounds. Salt Lake City, UT, US.
2023. Assassins for Hire: Weaponizing Natural Killer Cells. Conference. 27th Annual Acute Leukemia Forum. Carlsbad, CA, US.
2023. FLT3 Inhibitors in AML: New Directions and Combination Strategies. Conference. 3rd Biennial Leukemia Symposium. Miami, FL, US.
2022. Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study (Oral Presentation). Conference. 64th ASH Annual Meeting and Exposition. New Orleans, LA, US.
2022. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML (Oral Presentation). Conference. 64th ASH Annual Meeting and Exposition. New Orleans, LA, US.
2022. Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) (Oral Presentation). Conference. 64th ASH Annual Meeting and Exposition. New Orleans, LA, US.
2022. Let’s Talk: Community Perspectives on Acute Myeloid Leukemia and Myelodysplastic Syndrome. Conference. 64th ASH Annual Meeting and Exposition. New Orleans, LA, US.
2022. Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax (Oral Presentation). Conference. 64th ASH Annual Meeting and Exposition. New Orleans, LA, US.
2022. Identification and Characterization of a Retrospective Cohort of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Patients in the US (Poster). Conference. 64th ASH Annual Meeting and Exposition. New Orleans, LA, US.
2022. Clinical Characteristics and Overall Survival Among Acute Myeloid Leukemia (AML) Patients with TP53 Gene Mutation (TP53m) or Chromosome 17p Deletion (17p del) (Oral Presentation). Conference. 64th ASH Annual Meeting and Exposition. New Orleans, LA, US.
2022. Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)–Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m) (Poster). Conference. 64th ASH Annual Meeting and Exposition. New Orleans, LA, US.
2022. A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (Poster). Conference. 64th ASH Annual Meeting and Exposition. New Orleans, LA, US.
2022. Trial in Progress: An Open-Label Phase II Study of Relatlimab with Nivolumab in Combination with 5-Azacytidine for the Treatment of Patients with Relapsed/Refractory and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AARON) (Poster). Conference. 64th ASH Annual Meeting and Exposition. New Orleans, LA, US.
2022. Nature of Clinical Response and Depth of Molecular Response in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated with Magrolimab with Azacitidine (Poster). Conference. 64th ASH Annual Meeting and Exposition. New Orleans, LA, US.
2022. Translating the Current Evidence to Resource Constraint Setting. Conference. Second Annual Meeting in Association with the Society of Hematologic Oncology. Mumbai, US.
2016. Phase IB/II Study of Nivolumab in Combination with AZA in Patients with Relapsed AML. Conference. 58th ASH Annual Meeting and Exposition. San Diego, CA, US.
2016. Lone Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory AML Patients Treated with SGI-110 in Phase 2 Studies. Conference. 58th ASH Annual Meeting and Exposition. San Diego, CA, US.
2016. Ruxolitinib in Combination with 5-Azacytidine as therapy for Patients with Myelofibrosis. Conference. 58th ASH Annual Meeting and Exposition. San Diego, CA, US.
2016. Next checkpoints: A Look at future immunotherapeutic drug development in hematologic malignancies. Conference. 58th ASH Annual Meeting and Exposition. New York, NY, US.
2016. MDS/MPN. Conference. MPN Practitioner Conference. Brooklyn, NY, US.
2016. n/a. Conference. n/a. Atlanta, GA, US.
2015. N/A. Conference. N/A. New Orleans, LA, US.
2014. n/a. Conference. n/a. San Francisco, CA, US.
2011. n/a. Conference. n/a. San Diego, CA, US.

International Presentations

2025. Understanding the AML treatment landscape for the patient eligible for intensive chemotherapy. Invited. EHA 2025. Milano, IT.
2025. The treatment landscape for the patient eligible for intensive chemo. Invited. EHA 2025. Milan, IT.
2024. Updates in AML 2024 with a Focus on Menin as a Therapeutic Target. Invited. The 86th Annual Meeting of the Japanese Society of Hematology. Kyoto, JP.
2024. Which Patients with Newly Diagnosed AML Should Receive a Venetoclax Based Regimen in 2024. Invited. AML-ALL EU Focus Meeting 2024. London, GB.
2024. BCL2 Combinations in AML. Conference. 11th SOHO Turkiye Meeting. Istanbul, TR.
2024. Novel Targeted Therapies. Conference. 11th SOHO Turkiye Meeting. Istanbul, TR.
2024. Progress and Current Treatment with Targeted Therapies in AML. Conference. 6th Annual MENA Forum, Hikma Cancer Network. Lisbon, PT.
2024. Targeting FLT3 Mutations in AML: Review of Current Knowledge and Evidence. Conference. Astellas FLT3 AML Lecture. Tapei, TW.
2024. Targeting FLT3 Mutations in AML: Review of Current Knowledge and Evidence. Conference. Astellas FLT3 AML Lecture. Tapei, TW.
2024. Targeting FLT3 Mutations in AML: Review of Current Knowledge and Evidence. Conference. 2024 Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation and the Hematology Society of Taiwan. Kaohsiung, TW.
2024. Venetoclax Based Regimens in AML: Understanding Resistance and Building Novel Combinations. Conference. First Asia Pacific Symposium on Acute Myeloid Leukemia – from Biology, Translational Research to Clinical Trials and Advanced Practices. Hong Kong, CN.
2024. MDM2 degrader in myeloid malignancies. Conference. 11th Whistler Global Summit on Hematologic Malignancies. Whistler, CA.
2024. Update on menin targeting and current agents in development in AML. Conference. 11th Whistler Global Summit on Hematologic Malignancies. Whistler, CA.
2024. Treatment for MDS with mTP53 / DEC+VENET?. Conference. 3rd Regional Symposium on Myelodysplastic Syndromes (MDSR 2024). Kyoto, JP.
2023. Myelodysplastic Syndromes – Clinical and Epidemiological (Oral Presentation). Conference. 6th International Conference Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment. San Diego, US.
2023. Targeting TP53. Conference. 6th International Conference Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment. Estoril, PT.
2023. Mechanisms of Resistance and Novel Combinations with Venetoclax Based Therapies in aml. Conference. AML-ALL EU Focus 2023. London, GB.
2023. Updates in AML Management in 2023 - Investigational Approaches. Conference. Joint COMydAL, COLYM, MPNCo&D and 6th Annual Meeting of the International Academy for Clinical Hematology (IACH). Paris, FR.
2023. David Grimwade Lecture. Conference. 5th AML Academy. Birmingham, GB.
2023. Optimizing doublet and triplet combinations in AML: improving efficacy while maintaining safety. Conference. 5th International Workshop on Acute Leukemias. San Diego, US.
2023. Magrolimab Combinations. Conference. 5th International Workshop on Acute Leukemias. San Diego, US.
2023. A clinical investigator’s perspective on endpoints and drug development in AML. Conference. 5th International Workshop on Acute Leukemias. San Diego, US.
2023. Controversies in AML. Conference. 5th International Workshop on Acute Leukemias. San Diego, US.
2023. Deciding between Sequential and Combination Treatment. Conference. EHA 2023 - Updates in Hematology. Frankfurt, DE.
2023. A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML). Conference. Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant. Chicago, US.
2023. Immune-based therapies in AML: The Next Frontier. Conference. Hikma Cancer Network: 5th Annual MENA Cancer Forum. Istanbul, TR.
2023. Personalizing Therapy in AML by Incorporating Targeted Therapies in Frontline and Relapsed/Refractory AML. Conference. Hikma Cancer Network: 5th Annual MENA Cancer Forum. Istanbul, TR.
2023. Treatment of Frontline and R/R FLT3 mutated AML. Conference. 10th SOHO Turkiye Meeting. Istanbul, TR.
2023. KITE-222, an autologous anti-CLL-1 CAR T-in AML. Conference. 10th Global Summit on Hematologis Malignancies. Whistler, CA.
2023. Ongoing Trials with Magrolimab (targeting CD47) in MDS and AML. Conference. 10th Global Summit on Hematologis Malignancies. Whistler, CA.
2023. Menin Inhibitors: A New targeted Therapy for Patients with AML. Conference. The Japanese Society of Medical Oncology Annual Meeting. Fukuoka, JP.
2023. How I treat AML in 2023: Learnings from Recent Research. Conference. The Japanese Society of Medical Oncology Annual Meeting. Fukuoka, JP.
2023. Macrophage (CD47/SiRPa) and NK-Cell Based Therapies in AML. Conference. Acute Leukemias XVIII. Munich, DE.
2023. Higher-risk MDS. Conference. Current Challenges in Hematology - 1st Edition. Rome, IT.
2023. Immunotherapy in AML and MDS. Conference. Current Challenges in Hematology - 1st Edition. Rome, IT.
2023. Treatment of resistant-refractory disease. Conference. Current Challenges in Hematology - 1st Edition. Rome, IT.
2022. Immune Based Approaches in AML and MDS. Conference. AML-ALL Focus 2022. London, GB.
2022. Mechanisms of Resistance and Novel Combinations with Venetoclax Based Therapies in aml. Conference. AML-ALL Focus 2022. London, GB.
2022. Emerging Targeting Antibodies in AML. Conference. SOHO Italy 4th Annual Conference. Rome, IT.
2022. KT-253: A Novel in MDM2 Degrader to Activate TP53. Conference. 1st Bermuda Summit on Hematologic Malignancies. Hamilton, BM.
2022. Ziftomenib (KO-539), JNJ-75276617, and other Menin Inhibitors in AML. Conference. 1st Bermuda Summit on Hematologic Malignancies. Hamilton, BM.
2022. Doublet and Triplet Combinations in AML. Conference. 14th International Workshop on Acute Leukemias. Nice, FR.
2022. Emerging NK cell-based therapies in AML. Conference. 14th International Workshop on Acute Leukemias. Nice, FR.
2017. Molecular and/or immune therapies in AML/MDS. Conference. Molecular and/or immune therapies in AML/MDS. Mumbai, IN.
2016. N/A. Conference. N/A. Copenhagen, DK.
2015. N/A. Conference. N/A. Vienna, AT.
2013. N/A. Conference. N/A. Mumbai, IN.

Less

Grant & Contract Support

Date:	2025 - 2029
Title:	Evaluation of LNS8801 in Combination with Venetoclax and Azacitadine for Acute Myeloid Leukemia
Funding Source:	FDA
Role:	Co-PI

Date:	2024 - 2028
Title:	Overcoming Therapeutic Resistance and Enhancing Treatment Response in Magrolimab-Based Therapy for Acute Myeloid Leukemia
Funding Source:	Department of the Army - USAMRAA
Role:	PI

Date:	2024 - 2027
Title:	Targeting of AML by CD123-Directed NK-Cell Engager/NK Cell Immune Therapy and Harnessing Apoptotic Machinery by BCL-2 Inhibition
Funding Source:	US Department of Defense
Role:	PI

Date:	2024 - 2029
Title:	Elucidating the Role of Ontogeny and Bone Marrow Micro Environment in TP53 Mutated Acute Myeloid Leukemia at Single Cell Resolution
Funding Source:	NIH
Role:	Co-I

Date:	2023 - 2026
Title:	Targeting Immune-checkpoint protein B7-H3 in Acute Myeloid Leukemia
Funding Source:	Department of Defense Health Program
Role:	Co-I
ID:	FP00017673 / Grant # 13723146

Date:	2023 - 2026
Title:	Arming NK Cells to Target B7-H3+ AML Cells
Funding Source:	Leukemia and Lymphoma Society
Role:	Collaborator
ID:	FP00018510/ Grant # TRP-23942-23

Date:	2023 - 2026
Title:	A PHASE I STUDY INVESTIGATING THE SAFETY & EFFICACY OF DANVATIRSEN AS MONOTHERAPY FOLLOWED BY COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MDS & AML
Funding Source:	NIH
Role:	PI
ID:	FP#17651

Date:	2023 - 2030
Title:	2022-0842: Phase I/II Open-Label Study to Assess Safety, Tolerability and Preliminary Efficacy of the CLEVER-1 Antibody Bexmarilimab in Combination with Standard of Care Therapy in Patients with Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia
Funding Source:	Faron Pharmaceuticals, Ltd
Role:	PI

Date:	2023 - 2030
Title:	2023-0105: A Phase I, Single-arm, Open Label, Dose Escalation, Multicenter Study of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Participants with Relapsed or Refractory Acute Myeloid Leukemia (R/R) AML
Funding Source:	Sanofi (Kiadis Pharma Netherlands B.V.)
Role:	PI

Date:	2023 - 2030
Title:	2022-0817: Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up
Funding Source:	Arcellx, Inc
Role:	PI

Date:	2023 - 2026
Title:	Focal radiotherapy in stimulate immune responses against systemic leukemias
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP230278

Date:	2022 - 2025
Title:	Identifying, Understanding, and Eradicating Measurable Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
Funding Source:	Break Through Cancer
Role:	Co-PI
ID:	FP00018527

Date:	2022 - 2029
Title:	2022-0036: A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy
Funding Source:	Astellas Pharma Global Development, Inc
Role:	PI

Date:	2022 - 2027
Title:	Antisense Inhibition of STAT3 in Therapy Resistant Myeloid Malignancies
Funding Source:	Albert Einstein College of Medicine
Role:	PI
ID:	FP00015019

Date:	2022 - 2027
Title:	Biology and efficacy of Menin Inhibitors in AML therapy
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	FP00015061

Date:	2022 - 2029
Title:	2022-0038: An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination with Azacitidine or with Azacitidine and Venetoclax for the Treatment of Subjects with Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Funding Source:	Shattuck Labs, Inc
Role:	PI

Date:	2022 - 2027
Title:	2021-0220: A Phase Ib, Multicenter Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma
Funding Source:	Novartis
Role:	PI

Date:	2022 - 2029
Title:	2021-0711: A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL)-rearrangement or Nucleophosmin 1 (NPM1) Mutation
Funding Source:	Sumitomo Dainippon Pharma Oncology, Inc
Role:	PI

Date:	2022 - 2024
Title:	Biology and efficacy of Menin Inhibitors in AML therapy
Funding Source:	MDA IRG
Role:	PI

Date:	2021 - 2028
Title:	2021-0790: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Funding Source:	Gilead Sciences, Inc
Role:	PI

Date:	2021 - 2026
Title:	2021-1181: A phase Ib/II Open Label Dose Confirmation, Proof of Concept Study of Siremadlin in Combination with Venetoclax plus Azacitidine in Unfit Adult AML Participants Who Responded Sub-Optimally to First line Venetoclax plus Azacitidine Treatment and in Participants with Newly Diagnosed
Funding Source:	Novartis
Role:	PI

Date:	2021 - 2024
Title:	Investigating Novel therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy: the INTERCEPT study
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-I
ID:	FP00009733_Res1

Date:	2021 - 2029
Title:	2021-1046: A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination with Antineoplastic Agents in Subjects with Acute Myeloid Leukemia and Myelodysplastic Syndromes
Funding Source:	Bristol-Myers Squibb
Role:	PI

Date:	2021 - 2026
Title:	Antisense Inhibition of STAT3 in Therapy Resistant Myeloid Malignancies
Funding Source:	Montefiore Medical Center
Role:	Co-PI
ID:	1R01CA262893-01

Date:	2021 - 2028
Title:	2021-0654: An Open-label Phase Ib Study of DSP107 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Funding Source:	KAHR Medical, Ltd
Role:	PI

Date:	2021 - 2028
Title:	2021-0007: A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Funding Source:	Kite Pharma, Inc
Role:	PI

Date:	2021
Title:	2021-0099: A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies
Funding Source:	Gilead Sciences, Inc
Role:	PI

Date:	2021 - 2028
Title:	2021-0186: A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician’s Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia
Funding Source:	Gilead Sciences, Inc
Role:	PI

Date:	2021 - Present
Title:	2020-0946: An Open-label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination with Azacitidine and Venetoclax or mini-HCVD for the Treatment of Patients with Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)
Funding Source:	Daiichi Sankyo Co., LTD
Role:	PI

Date:	2020 - 2027
Title:	An Open-label Phase IB/II Study of Magrolimab in Combination with Azacitidine and Venetoclax for the Treatment of Patients with Acute Myeloid Leukemia (AML)
Funding Source:	Forty Seven Inc
Role:	PI

Date:	2020 - 2021
Title:	2020-0597; A Phase 1b Study Assessing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 330 cIV in Combination with Pembrolizumab in Adult Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Funding Source:	Amgen, Inc
Role:	PI

Date:	2020 - 2027
Title:	2019-1089: A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Funding Source:	Newave Pharmaceutical, Inc
Role:	Investigator

Date:	2020 - 2021
Title:	Simultaneous targeting of mutant FLT3-pathways and anti-apoptic BCL-2 signaling in AML
Funding Source:	IRG MDACC
Role:	PI
ID:	RCTS#58081

Date:	2019 - 2026
Title:	Alan and Charlotte Waxman Fund Award
Funding Source:	Alan and Charlotte Waxman Fund at Schwab Charitable
Role:	Co-PI

Date:	2019 - 2022
Title:	2019-0362; A Phase 2/3, Open-label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Emapalumab in Adult Patients with Hemophagocytic Lymphohistiocytosis
Funding Source:	Sobi
Role:	PI

Date:	2019 - 2026
Title:	2019-0656: A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia
Funding Source:	ImmunoGen, Inc
Role:	Investigator

Date:	2019 - 2027
Title:	2019-0688: A Phase 1b, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezoliumab (Anti-PD-L1 Antibody) Administered in Combination with Hu5F9-G4 to Patients with Relapsed and/or Refractory Acute Myeloid Leukemia
Funding Source:	Genentech, Inc
Role:	Investigator
ID:	2019-0688: A Phase 1b, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezoliumab (Anti-PD-L1 Antibody) Administered in Combination with Hu5F9-G4 to Patients with Relapsed and/or Refractory Acute Myeloid Leukemia

Date:	2019 - 2026
Title:	2017-0795: A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Hematological Malignancies
Funding Source:	Forty Seven Inc
Role:	PI

Date:	2019 - 2026
Title:	2019-0100; A Phase Ib/II Study Evaluating The Safety And Efficacy Of Idasanutlin In Combination With Cytarabine And Daunorubicin In Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) And The Safety And Efficacy Of Idasanutlin In The Maintenance Of First AML Complete Remission
Funding Source:	F. Hoffman La Roche Ltd
Role:	PI

Date:	2019 - 2027
Title:	2018-0918; A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Funding Source:	Aptose Biosciences, Inc. and Hanmi Pharm Co, Ltd
Role:	PI

Date:	2019 - 2023
Title:	2018-1007; An International Phase Ib multicentre study to characterize the safety and tolerability of intravenously administered S64315, a selective Mcl-1 inhibitor, in combination with orally administered
Funding Source:	I.R.I.S
Role:	PI

Date:	2018 - 2023
Title:	2018-0608; A Phase Ib/II Study of Venetoclax in Combination with Quizartinib in FLT3-mutated Acute Myelogenous Leukemia (AML)
Funding Source:	Daiichi Sankyo Co
Role:	PI

Date:	2018 - 2022
Title:	2018-0675; A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Funding Source:	Abbvie
Role:	PI

Date:	2018 - 2023
Title:	2018-0467; A phase 3 randomized, double-blind trial to evaluate the efficacy of uproleselan administered with chemotherapy versus chemotherapy alone in patients with relapsed/refractory AML
Funding Source:	GlycoMimetics
Role:	PI

Date:	2018 - 2023
Title:	SPORE in Leukemia Project 5: Targeting Oxidative Phosphorylation in AML
Funding Source:	NIH/NCI
Role:	Co-I
ID:	P50 CA100632-16

Date:	2018 - 2022
Title:	iREACT: Immune Related Adverse Events Induced by Checkpoint Therapy: MDACC Efforts for Advanced Mechanistic, Clinical, and Translational Science
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI

Date:	2018 - Present
Title:	2018-0367; AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATION THE SAFETY AND TOLERABILITY OF DC119718S IN PATIENTS WITH RELAPSED OR REFRACORY ACUTE MYELOID LEUKEMIA (AML) OR DCLL9718S IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED AML UNSUITABLE FOR INTENSIVE INDUCTION CHEMOTHERAPY
Funding Source:	Genentech, Inc
Role:	PI

Date:	2018 - Present
Title:	2018-0278; A Phase 1 multicenter study of DS-3032 (MDM2 inhibitor) in combination with quizartinib in subjects with FLT3-ITD mutant AML that are relapsed/refractory, or newly diagnosed and unfit for intensive chemotherapy
Funding Source:	Daiichi Sankyo
Role:	PI

Date:	2018 - Present
Title:	2017-0900; Phase I, International, multicentre, open-label, non-randomised, non-comparative study of intravenously administered S64315, a Mcl-1 inhibitor, in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Funding Source:	I.R.I.S. - INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
Role:	PI

Date:	2017 - 2024
Title:	2017-0855; A phase 1, multicenter, open-label study of IMGN632 (CD123 ADC) in patients with relapsed/refractory CD123-positive AML and other CD123-positive hematologic malignancies
Funding Source:	ImmunoGen, Inc
Role:	PI
ID:	6025

Date:	2017 - 2020
Title:	MDACC-Pfizer Strategic Alliance to evaluate multiple immune checkpoint based therapies in solid tumors, leukemia, multiple myeloma
Funding Source:	Pfizer
Role:	Principal Investigator-MDACC

Date:	2017 - 2022
Title:	Over a period of up to 5 years, this intention will be fulfilled through annual payments to be applied as follows:
Funding Source:
Role:

Date:	2017 - 2020
Title:	2017-0337: An open-label phase IB multi-arm study of OX40 agonist monoclonal antibody (mAb), anti-4-1BB mAb, anti-PDL1 mAb, smoothened inhibitor, anti-CD33 mAb, and azacitidine as single-agents and/or combinations for the treatment of patients with relapsed or refractory AML
Funding Source:	Pfizer
Role:	PI

Date:	2017 - Present
Title:	2017-0259;A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia
Funding Source:	Nohla Therapeutics
Role:	PI

Date:	2017 - Present
Title:	2016-0227; Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose Granulocyte-Macrophage Colony Stimulating Factor, As Consolidation Treatment in Patients with Hematologic Malignancies
Funding Source:	KiromicPharma
Role:	PI

Date:	2017 - 2019
Title:	Preclinical Testing of Galectin-3C
Funding Source:	NIH STTR Fast-Track
Role:	Co-PI

Date:	2017 - 2020
Title:	Targeting Metabolic Vulnerability of AML LSC with Novel Inhibitor of Oxidative Phosphorylation
Funding Source:	NIH/NCI
Role:	Co-PI

Date:	2017 - 2019
Title:	Simultaneous targeting of mutant FLT3 pathways aond anti-apoptotic BCL-2 signaling in AML
Funding Source:	NIH R21
Role:	PI

Date:	2017 - 2019
Title:	2016-0782; An Open-Label Phase IB/II Study of Selinexor in combination with Pembrolizumab for the treatment of patients with Refractory/Relapsed Acute Myeloid Leukemia
Funding Source:	MDACC
Role:	PI

Date:	2017 - 2020
Title:	2016-0771; A Phase ib/II Study of Venetoclax (ABT-199) in Combination with Sorafenib in FLT3-mutated Acute Myelogenous Leukemia
Funding Source:	Abbvie
Role:	PI

Date:	2017 - Present
Title:	2016-1130; A Phase 1 study of DS-3201B in subjects with AML and ALL
Funding Source:	Daiichi Sankyo, Inc
Role:	PI

Date:	2016 - Present
Title:	2016-0444; An Open-label Phase Ib/II Study of Avelumab in Combination with 5-azacytidine (Vidaza) for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia
Funding Source:	Pfizer
Role:	PI

Date:	2016 - Present
Title:	2016-0233, A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination with Ruxolitinib in Subjects with Myelofibrosis
Funding Source:	Incyte
Role:	PI

Date:	2016 - 2021
Title:	Acute Myeloid Leukemia in the Immunosuppressed Microenvironment
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator

Date:	2016
Title:	Phase I/II Study of KV-001 Dendritic Cell Vaccine for Consolidation Therapy in Patients with Leukemias (AML,CLL,CML,ALL)
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI

Date:	2016 - 2019
Title:	Phase 1 Study of IACS-010759 in Subjects with relapsed or refractory AML
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-PI

Date:	2016 - 2017
Title:	Identification of novel immunotherapy targets for AML using computational genomics and mass spectrometry
Funding Source:	Ladies Leukemia League
Role:	PI

Date:	2016 - 2019
Title:	First-in-human trial of IACS-010759 in patients with AML
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-I
ID:	52852

Date:	2016 - Present
Title:	2015-1024; A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients with Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
Funding Source:	ImmunoGen
Role:	PI

Date:	2015
Title:	To evaluate the role of DAC-CIA based high intensity therapy followed by allogeneic SCT in patients below 65 years of age with primary refractory AML after high-dose cytarabine based induction
Funding Source:	HI-CSRP MDACC
Role:	Co-PI

Date:	2015 - 2018
Title:	2014-0975: Phase I/II Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
Funding Source:	Karyopharm Therapeutics Inc
Role:	PI
ID:	14420

Date:	2015 - 2017
Title:	Targeting PD1 and identifying novel immune checkpoint pathways in AML
Funding Source:	Leukemia SPORE Career Development Award
Role:	PI

Date:	2015 - 2018
Title:	2014-0862: An Open-label Phase I/II Study of Lirilumab (BMS-986015) in Combination with 5-azacytidine (vidaza) for the Treatment of Patients with Refractory/ Relapsed Acute Myeloid Leukemia
Funding Source:	Bristol-Myers Squibb
Role:	PI
ID:	39925

Date:	2015 - 2025
Title:	2014-0861: An Open-label Phase I/II Study of Nivolumab (BMS-936558) in Combination with 5-azacytidine (Vidaza) for the Treatment of Patients with Refractory/ Relapsed Acute Myeloid Leukemia
Funding Source:	Bristol-Myers Squibb
Role:	PI
ID:	39923

Date:	2014 - 2017
Title:	2014-0128: Open-Label, Phase I/II Study of Nilotinib (Tasigna) + MEK-162 (Arry-162) for Patients with Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia
Funding Source:	Novartis
Role:	PI
ID:	11487

Date:	2013 - 2018
Title:	Leukemia SPORE (Project 3: p53 activation as novel therapeutic strategy for acute myelogenous leukemia)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5 P50 CA100632-15

Date:	2013 - 2026
Title:	2013-0099: A Phase I/II Study of Vosaroxin and Decitabine in Older Patients with Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Funding Source:	Sunesis
Role:	PI
ID:	CS2013-37435

Date:	2013 - 2024
Title:	2012-0737: Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients with Myelofibrosis and Myelodysplastic/ Myeloproliferative Neoplasms
Funding Source:	InCyte Corporation
Role:	PI
ID:	6410

Title:	Evaluating the efficacy and safety of nilotinib in combination with MEK-inhibitor (MEK-162) for the treatment of patients with refractory and advanced phase chronic myeloid leukemia (CML)
Funding Source:	MDACC R. Lee Clark Fellows Award
Role:	PI
ID:	01

Selected Publications

Peer-Reviewed Articles

Willekens, C, Bazinet, A, Chraibi, S, Bataller Torralba, A, Decroocq, J, Arani, N, Carpentier, B, Rausch, C, Lebon, D, Maiti, A, Gauthier, N, Short, NJ, Bonnet, S, Sasaki, K, Khalife-Hachem, S, Swaminathan, M, Micol, JB, Pasquier, F, Marzac, C, Roos-Weil, D, Pascal, L, Daver, NG, Kadia, TM, Bouscary, D, Ravandi-Kashani, F, Pages, A, Kantarjian, HM, De Botton, S, DiNardo, C. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40246832.
Bataller Torralba, A, Sasaki, K, Urrutia, S, Montalban Bravo, G, Bazinet, A, Chien, KS, Hammond, DE, Bouligny, IM, Swaminathan, M, Issa, GC, Short, NJ, Daver, NG, DiNardo, C, Kadia, TM, Jabbour, EJ, Ravandi-Kashani, F, Roboz, G, Savona, MR, Griffiths, EA, McCloskey, J, Odenike, O, Oganesian, A, Keer, HN, Azab, M, Kantarjian, HM, Garcia-Manero, G. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40164584.
Fiskus, WC, Mill, CP, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Birdwell, C, Das, K, Hou, H, Davis, JA, Jain, A, Malovannaya, A, Kadia, TM, Daver, NG, Sasaki, K, Takahashi, K, Hammond, D, Reville, PK, Flores, L, Loghavi, S, Su, X, DiNardo, C, Bhalla, K. Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40089460.
DiNardo, C, Jen, WY, Montalban Bravo, G, Wang, X, Loghavi, S, Lavu, S, Short, NJ, Chien, KS, Issa, GC, Pemmaraju, N, Yilmaz, M, Andreeff, M, Borthakur, G, Kadia, TM, Daver, NG, Garcia-Manero, G, Mill, CP, Su, X, Fiskus, WC, Bhalla, K. Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1. Blood Neoplasia 2(4), 2025. e-Pub 2025. PMID: 40979071.
Bazinet, A, Loghavi, S, Wei, Y, Bataller Torralba, A, Sasaki, K, Arani, N, Darbaniyan, F, Chien, KS, Hammond, DE, Bouligny, IM, Kanagal Shamanna, R, Thongon, N, Tang, G, Urrutia, S, Kadia, TM, DiNardo, C, Daver, NG, Short, NJ, Issa, GC, Pemmaraju, N, Jabbour, EJ, Wang, S, Wang, W, Borthakur, G, Bueso-Ramos, CE, Ravandi-Kashani, F, Medeiros, LJ, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy. Leukemia 39(9):2256-2265, 2025. e-Pub 2025. PMID: 40691503.
DiNardo, C, Marvin-Peek, J, Loghavi, S, Takahashi, K, Issa, GC, Jen, WY, Daver, NG, Reville, PK, Short, NJ, Sasaki, K, Mullin, JK, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Abbas, HA, Hammond, DE, Haddad, FG, Bravo, GM, Chien, KS, Yilmaz, M, Kornblau, SM, Jabbour, EJ, Ravandi-Kashani, F, Kadia, TM, Garcia-Manero, G, Konopleva, M, Kantarjian, HM. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML. Journal of Clinical Oncology 43(24):2692-2699, 2025. e-Pub 2025. PMID: 40513054.
Arora, S, Jen, WY, Yilmaz, M, Deshmukh, I, Senapati, J, Loghavi, S, Issa, GC, Short, NJ, Kadia, TM, DiNardo, C, Borthakur, G, Jabbour, J, Pemmaraju, N, Andreeff, M, Takahashi, K, Bhalla, K, Popat, UR, Shpall, E, Oran, B, Abbas, HA, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, NG. Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations. Cancer 131(16), 2025. e-Pub 2025. PMID: 40782343.
Senapati, J, Kantarjian, HM, Kadia, TM, Kekedjian, J, Borthakur, G, Daver, NG, DiNardo, C, Jabbour, EJ, Bose, P, Short, NJ, Yilmaz, M, Jain, N, Pemmaraju, N, Abbas, HA, Issa, GC, Maiti, A, Bravo, GM, Deshmukh, I, Shpall, E, Kebriaei, P, Popat, UR, Loghavi, S, Thakral, B, Tang, G, Haddad, FG, Alvarado, Y, Manero, GG, Ravandi-Kashani, F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer 131(16), 2025. e-Pub 2025. PMID: 40772501.
Tefferi, A, Fathima, S, Abdelmagid, M, Alsugair, AA, Aperna, F, Rezasoltani, M, Yousuf, M, Natu, A, Csizmar, C, Gurney, M, Lasho, T, Finke, C, Kangal-Shamanna, R, Hammond, DE, Chien, KS, Bazinet, A, DiNardo, C, Kadia, TM, Mangaonkar, AA, Daver, NG, Pardanani, A, Borthakur, G, Zepeda-Mendoza, CJ, Reichard, KK, He, R, Loghavi, S, Passamonti, F, Ravandi-Kashani, F, Sasaki, K, Larson, DR, Garcia-Manero, G, Onida, F, Gangat, N, Montalban Bravo, G, Patnaik, MM. BLAST. Blood 146(7):874-886, 2025. e-Pub 2025. PMID: 40332442.
Kadia, TM, Jen, WY, Bataller Torralba, A, Bazinet, A, Borthakur, G, Jabbour, EJ, Qiao, W, Short, NJ, Takahashi, K, Issa, GC, DiNardo, C, Montalban Bravo, G, Pemmaraju, N, Tran, A, Bharathi, V, Loghavi, S, Alousi, AM, Popat, UR, Daver, N, Ravandi-Kashani, F, Kantarjian, HM. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia. American journal of hematology 100(8):1365-1373, 2025. e-Pub 2025. PMID: 40401707.
Zeidner, JF, Sallman, D, Recher, C, Daver, NG, Leung, AY, Hiwase, DK, Subklewe, M, Pabst, T, Montesinos, P, Larson, RA, Wilde, L, Enjeti, AK, Kawashima, I, Papayannidis, C, O'Nions, J, Johnson, L, Dong, M, Huang, J, Bagheri, T, Hacohen Kleiman, G, Lee, C, Vyas, P. Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia. Blood 146(5):590-600, 2025. e-Pub 2025. PMID: 40009500.
Daver, NG, Vyas, P, Huls, G, Döhner, H, Maury, S, Novák, J, Papayannidis, C, Martinez-Chamorro, C, Montesinos, P, Niroula, R, Fenaux, P, Esteve, J, Wu, SJ, De Voeght, A, Mayer, J, Valk, PJ, Johnson, L, Dong, M, Liu, K, Kuwahara, S, Caldwell, KJ, Guru Murthy, GS. The ENHANCE-3 study. Blood 146(5):601-611, 2025. e-Pub 2025. PMID: 40233321.
Zhang, W, Li, L, Muftuoglu, M, Basyal, M, Togashi, N, Iwanaga, K, Tanzawa, F, Numata, M, Bixby, D, Erba, HP, Podoltsev, N, Schiller, GJ, Kumar, P, Lesegretain, A, Isoyama, T, Seki, T, Daver, NG, Andreeff, M. Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias. Clinical Cancer Research 31(14):3033-3047, 2025. e-Pub 2025. PMID: 40327322.
Kontro, M, Stein, A, Pyörälä, M, Rimpiläinen, J, Siitonen, T, Ylitalo, A, Fjällskog, ML, Jalkanen, J, Aakko, S, Pawlitzky, I, Hollmén, M, Daver, NG. Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia. The Lancet Haematology 12(7):e516-e528, 2025. e-Pub 2025. PMID: 40449509.
Uryu, H, Saeki, K, Haeno, H, Kapadia, C, Furudate, D.M.D., Ph.D., K, Nangalia, J, Spencer Chapman, M, Zhao, L, Hsu, JI, Zhao, C, Chen, S, Tanaka, T, Li, Z, Ogata, S, Hanache, S, Yang, H, DiNardo, C, Daver, NG, Pemmaraju, N, Jain, N, Ravandi-Kashani, F, Zhang, J, Song, X, Thompson, EJ, Tang, H, Little, L, Gumbs, C, Orlowski, R, Qazilbash, MH, Bhalla, K, Colla, S, Kantarjian, HM, Kanagal Shamanna, R, Bueso-Ramos, CE, Nakada, D, Al-Atrash, G, Molldrem, JJ, Futreal, A, Shpall, E, Goodell, MA, Garcia-Manero, G, Takahashi, K. Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation. Nature Genetics 57(7):1695-1707, 2025. e-Pub 2025. PMID: 40596442.
Bataller Torralba, A, Goulart, H, Issa, GC, DiNardo, C, Daver, N, Kadia, TM, Bazinet, A, Bouligny, IM, Senapati, J, Haddad, FG, Borthakur, G, Sasaki, K, Short, NJ, Yilmaz, M, Montalban Bravo, G, Tang, G, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Jabbour, EJ. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia 39(7):1640-1649, 2025. e-Pub 2025. PMID: 40346311.
Reville, PK, Wang, B, Marvin-Peek, J, Yuan, B, Kuo, YA, Garza, AI, Root, J, Qiao, W, Arruda, A, Veletic, I, Liu, Y, Short, NJ, DiNardo, C, Kadia, TM, Daver, N, Lorenzi, PL, Sasaki, K, Kornblau, SM, Minden, MD, Ravandi-Kashani, F, Kantarjian, HM, Abbas, HA. Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes. Blood 145(25):3015-3029, 2025. e-Pub 2025. PMID: 40179376.
Daver, NG, Senapati, J, Kantarjian, HM, Wang, B, Reville, PK, Loghavi, S, Yilmaz, M, DiNardo, C, Kadia, TM, Yassouf, MY, Maiti, A, Arora, S, Montalban Bravo, G, Tang, G, Borthakur, G, Sasaki, K, Pemmaraju, N, Alvarez, J, Nogueras Gonzalez, G, Ning, J, Issa, GC, Konopleva, M, Andreeff, M, Ravandi-Kashani, F, Garcia-Manero, G, Abbas, HA. Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia. Clinical Cancer Research 31(12):2386-2398, 2025. e-Pub 2025. PMID: 40198272.
Lontos, K, Saliba, RM, Kanagal Shamanna, R, Ozcan, G, Ramdial, JL, Chen, GL, Kadia, TM, Short, NJ, Daver, N, Kantarjian, HM, Marin, D, Kebriaei, P, Popat, UR, Champlin, RE, Shpall, E, Oran, B. TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation. Blood Advances 9(11):2845-2854, 2025. e-Pub 2025. PMID: 39853269.
Braish, JS, Montalban Bravo, G, Ravandi-Kashani, F, Short, NJ, Kadia, TM, Ohanian, M, Chien, KS, Masarova, L, Sasaki, K, Yilmaz, M, Logahvi, S, Daver, NG, Borthakur, G, Jabbour, EJ, Schneider, H, Romero, LT, Kantarjian, HM, Garcia-Manero, G. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome. Leukemia Research 153, 2025. e-Pub 2025. PMID: 40252309.
Senapati, J, Loghavi, S, Garcia-Manero, G, Tang, G, Kadia, TM, Short, NJ, Abbas, HA, Arani, N, DiNardo, C, Borthakur, G, Pemmaraju, N, Oran, B, Shpall, E, Popat, UR, Champlin, RE, Pierce, S, Arora, S, Issa, GC, Yilmaz, M, Patel, KP, Takahashi, K, Montalban Bravo, G, Hammond, DE, Haddad, FG, Ravandi-Kashani, F, Kantarjian, HM, Daver, NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica 110(6):1304-1315, 2025. e-Pub 2025. PMID: 39665206.
Senapati, J, Loghavi, S, Marvin-Peek, J, Garcia-Manero, G, Kadia, TM, Borthakur, G, Daver, NG, Short, NJ, Jain, N, Issa, GC, Haddad, FG, Hammond, D, Chien, KS, Tang, G, Thakral, B, Montalban Bravo, G, Pemmaraju, N, Bazinet, A, Swaminathan, M, Pierce, S, Abbas, HA, Reville, PK, Popat, UR, Shpall, EJ, Champlin, RE, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia. American journal of hematology 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
Sasaki, K, Garcia-Manero, G, Nigo, M, Jabbour, EJ, Ravandi-Kashani, F, Wierda, WG, Jain, N, Takahashi, K, Montalban Bravo, G, Daver, NG, Thompson, PA, Pemmaraju, N, Kontoyiannis, DP, Sato, J, Karimaghaei, S, Soltysiak, KA, Raad, II, Kantarjian, HM, Carter, B. Artificial Intelligence Assessment of Chest Radiographs for COVID-19. Clinical Lymphoma, Myeloma and Leukemia 25(5):319-327, 2025. e-Pub 2025. PMID: 39710565.
Goulart, H, Kantarjian, HM, Borthakur, G, Daver, NG, DiNardo, C, Jabbour, EJ, Pemmaraju, N, Alvarado, Y, Atluri, H, Yilmaz, M, Haddad, FG, Marx, K, Rausch, C, Loghavi, S, Jain, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia. Cancer 131(8), 2025. e-Pub 2025. PMID: 40193193.
DiNardo, C, Jen, WY, Takahashi, K, Kadia, TM, Loghavi, S, Daver, NG, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, S, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, JA, Haddad, FG, Montalban Bravo, G, Chien, KS, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
Long, JP, Prakash, R, Edelkamp, P, Knafl, M, Lionel, AC, Nair, R, Ahmed, S, Strati, P, Malpica Castillo, LE, Al Zaki, A, Chien, KS, Chihara, D, Westin, JR, Khawaja, F, Nastoupil, L, Mulanovich, VE, Futreal, A, Woodman, SE, Daver, NG, Flowers, CR, Neelapu, SS, Manzano, JM, Iyer, SP. Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy. JAMA Network Open:e253455, 2025. e-Pub 2025. PMID: 40193078.
Borate, U, Pugh, K, Waller, A, Welkie, RL, Huang, Y, Bewersdorf, J, Stahl, M, Dezern, A, Platzbecker, U, Sekeres, MA, Wei, A, Buckstein, R, Roboz, G, Savona, MR, Loghavi, S, Hasserjian, RP, Fenaux, P, Sallman, D, Hourigan, CS, Della Porta, M, Nimer, SD, Little, R, Santini, V, Efficace, F, Taylor, J, Garcia-Manero, G, Odenike, O, Kim, TK, Halene, S, Komrokji, RS, Griffiths, EA, Greenberg, P, Xu, M, Xie, Z, Bejar, R, Sanz, G, Patnaik, MM, Figueroa, ME, Carraway, H, Abdel-Wahab, O, Starczynowski, DT, Padron, E, Boultwood, J, Gore, SD, Daver, NG, Churpek, JE, Majeti, R, Bennett, JM, List, A, Brunner, AM, Zeidan, AM. Reducing clinical trial eligibility barriers for patients with MDS. Blood 145(13):1369-1381, 2025. e-Pub 2025. PMID: 40146152.
Bazinet, A, Bataller Torralba, A, Kadia, TM, Daver, NG, Short, NJ, Yilmaz, M, Sasaki, K, DiNardo, C, Borthakur, G, Issa, GC, Bouligny, IM, Pierce, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia. Cancer 131(6), 2025. e-Pub 2025. PMID: 40097915.
Wei, Q, Hu, S, Loghavi, S, Toruner, GA, Ravandi-Kashani, F, Tang, Z, Li, S, Xu, J, Daver, NG, Medeiros, LJ, Tang, G. Chromoanagenesis Is Frequently Associated With Highly Complex Karyotypes, Extensive Clonal Heterogeneity, and Treatment Refractoriness in Acute Myeloid Leukemia. American journal of hematology 100(3):417-426, 2025. e-Pub 2025. PMID: 39871121.
Jen, WY, Sasaki, K, Ravandi-Kashani, F, Kadia, TM, Wang, S, Wang, W, Loghavi, S, Daver, NG, DiNardo, C, Issa, GC, Abbas, HA, Nasnas, C, Bataller Torralba, A, Urrutia, S, Karrar, OS, Pierce, S, Kantarjian, HM, Short, NJ. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy. Blood Advances 9(4):783-792, 2025. e-Pub 2025. PMID: 39631072.
Senapati, J, Kantarjian, HM, Haddad, FG, Short, NJ, Borthakur, G, Kanagal Shamanna, R, Tang, G, Jabbour, EJ, DiNardo, C, Daver, NG, Montalban Bravo, G, Shah, V, Alousi, AM, Shpall, E, Popat, UR, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia. American journal of hematology 100(2):249-259, 2025. e-Pub 2025. PMID: 39718824.
Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, NG, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
Kantarjian, H, Short, NJ, Haddad, FG, Jain, N, Huang, X, Montalban-Bravo, G, Kanagal-Shamanna, R, Kadia, TM, Daver, N, Chien, KS, Alvarado, Y, Garcia-Manero, G, Issa, GC, Garris, R, Nasnas, C, Nasr, L, Ravandi, F, Jabbour, EJ. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. Journal of Clinical Oncology 42(36):4246-4251, 2024. e-Pub 2024. PMID: 39028925.
Urrutia, S, Kantarjian, H, Ravandi-Kashani, F, Bueso-Ramos, CE, Kanagal-Shamanna, R, Jabbour, EJ, Montalban-Bravo, G, Short, NJ, Daver, NG, Borthakur, G, DiNardo, CD, Kadia, TM, Masarova, L, Bose, P, Pemmaraju, N, Garcia-Manero, G, Sasaki, K. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. Journal of Hematology and Oncology 17(1), 2024. e-Pub 2024. PMID: 39548557.
Wei, Q, Hu, S, Xu, J, Loghavi, S, Daver, NG, Toruner, GA, Wang, W, Medeiros, LJ, Tang, G. Detection of KMT2A Partial Tandem Duplication by Optical Genome Mapping in Myeloid Neoplasms. Cancers 16(24), 2024. e-Pub 2024. PMID: 39766092.
Urrutia, S, Kantarjian, H, Ravandi-Kashani, F, Bueso-Ramos, CE, Kanagal-Shamanna, R, Jabbour, EJ, Montalban-Bravo, G, Short, NJ, Daver, N, Borthakur, G, DiNardo, CD, Kadia, TM, Masarova, L, Bose, P, Pemmaraju, N, Garcia-Manero, G, Sasaki, K. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. Journal of Hematology and Oncology 17(1), 2024. e-Pub 2024. PMID: 39548557.
Haddad, FG, Sasaki, K, Senapati, J, Xiao, L, Park, GS, Abuasab, T, Venugopal, S, Rivera, D, Bazinet, A, Babakhanlou, R, Kim, K, Ong, F, Desikan, SP, Pemmaraju, N, Loghavi, S, Borthakur, G, DiNardo, C, Abbas, HA, Short, NJ, Daver, NG, Jabbour, EJ, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Outcomes of Patients with Newly Diagnosed AML and Hyperleukocytosis. JCO Oncology Practice 20(12):1637-1644, 2024. e-Pub 2024. PMID: 39013130.
McCall, DC, Alqahtani, S, Budak, M, Sheikh, IN, Fan, AE, Ramakrishnan, R, Nunez, CA, Roth, M, Garcia, M, Gibson, A, Daver, N, Garces, S, Short, NJ, Issa, GC, Ravandi-Kashani, F, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Cuglievan, B, Kadia, TM. Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients. Cancers 16(22), 2024. e-Pub 2024. PMID: 39594839.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver NG, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
Yeh, JC, Pasvolsky, O, Saliba, RM, Figgins, B, Wang, C, Fang, Z, Ahmed, S, Yilmaz, M, Daver, NG, Ravandi, F, DiNardo, CD, Short, NJ, Kadia, TM, Al-Atrash, G, Daher, M, Costa, DM, Popat, U, Champlin, R, Shpall, EJ, Oran, B. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(11):e819-e826, 2024. e-Pub 2024. PMID: 39183099.
Gener-Ricos, G, Bataller, A, Rodriguez-Sevilla, JJ, Chien, KS, Quesada, AE, Almanza-Huante, E, Hammond, DE, Sasaki, K, DiNardo, C, Kadia, TM, Daver, N, Borthakur, G, Issa, GC, Short, NJ, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer 130(20):3452-3462, 2024. e-Pub 2024. PMID: 38896064.
DiNardo, C, Verma, D, Baran, N, Bhagat, TD, Skwarska, A, Lodi, A, Saxena, K, Cai, T, Su, X, Guerra, VA, Poigaialwar, G, Kuruvilla, VM, Konoplev, S, Gordon-Mitchell, S, Pradhan, K, Alluri, S, Hackman, GL, Chaudhry, S, Collins, M, Sweeney, SR, Busquets, J, Rathore, AS, Deng, Q, Green, M, Grant, S, Demo, SD, Choudhary, GS, Sahu, S, Agarwal, B, Spodek, M, Thiruthuvanathan, V, Will, B, Steidl, U, Tippett, G, Burger, JA, Borthakur, G, Jabbour, EJ, Pemmaraju, N, Kadia, TM, Kornblau, SM, Daver, NG, Naqvi, K, Short, NJ, Garcia-Manero, G, Tiziani, S, Verma, A, Konopleva, M. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes. Nature Cancer 5(10):1515-1533, 2024. e-Pub 2024. PMID: 39300320.
Senapati, J, Kantarjian, HM, Bazinet, A, Reville, PK, Short, NJ, Daver, N, Borthakur, G, Bataller, A, Jabbour, EJ, DiNardo, C, Haddad, FG, Sasaki, K, Popat, UR, Oran, B, Alousi, AM, Loghavi, S, Shpall, E, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. e-Pub 2024. PMID: 38809547.
Loghavi, S, Wei, Q, Ravandi-Kashani, F, Quesada, AE, Routbort, MJ, Hu, S, Toruner, GA, Wang, S, Wang, W, Miranda, R, Li, S, Xu, J, DiNardo, C, Daver, N, Kadia, TM, Issa, GC, Kantarjian, HM, Medeiros, LJ, Tang, G. Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. American journal of hematology 99(10):1959-1968, 2024. e-Pub 2024. PMID: 39016111.
Montalban Bravo, G, Jabbour, EJ, Chien, KS, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Konopleva, M, Borthakur, G, Daver, N, Kanagal-Shammana, R, Loghavi, S, Qiao, W, Huang, X, Schneider, H, Meyer, M, Kantarjian, HM, Garcia-Manero, G. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leukemia Research 142, 2024. e-Pub 2024. PMID: 38744144.
Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee D, Hamidi H, Ott MG, Hong WJ, Andreeff M. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clin Lymphoma Myeloma Leuk 24(6):364-374, 2024. e-Pub 2024. PMID: 38378362.
Urrutia, S, Bose, P, Alvarado, Y, Borthakur, G, Ravandi-Kashani, F, Daver, NG, Pemmaraju, N, Jabbour, EJ, Takahashi, K, Kadia, TM, DiNardo, C, Kornblau, SM, Kanagal Shamanna, R, Huang, X, Bodden, K, Kantarjian, HM, Garcia-Manero, G. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML. Blood Neoplasia 1(2), 2024. e-Pub 2024.
Jen WY, Sasaki K, Loghavi S, Wang SA, Qiao W, Borthakur G, Ravandi F, Kadia TM, Issa GC, Short NJ, Yilmaz M, Daver NG, DiNardo CD. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression. Br J Haematol 204(6):2259-2263, 2024. e-Pub 2024. PMID: 38603594.
Daver NG Craddock C. Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome. J Clin Oncol 42(15):JCO2400006, 2024. e-Pub 2024. PMID: 38471058.
Short NJ, Daver NG, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol 42(13):JCO2301911, 2024. e-Pub 2024. PMID: 38277619.
Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, Al-Atrash G, Adeel M, Ramdial J, Marin D, Rondon G, Kebriaei P, Champlin R, Daver NG, Dinardo C, Short NJ, Shpall EJ, Oran B. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 24(5):e196-e204, 2024. e-Pub 2024. PMID: 38403505.
Montalban-Bravo G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chien K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver NG, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38(5):1178-1181, 2024. e-Pub 2024. PMID: 38418609.
Abuasab T, Mohamed S, Pemmaraju N, Kadia TM, Daver NG, DiNardo CD, Ravandi F, Qiao W, Montalban-Bravo G, Borthakur G. BRAF mutation in myeloid neoplasm: incidences and clinical outcomes. Leuk Lymphoma:1-6. e-Pub 2024. PMID: 38696743.
Tentori CA, Zhao LP, Tinterri B, Strange KE, Zoldan K, Dimopoulos K, Feng X, Riva E, Lim B, Simoni Y, Murthy V, Hayes MJ, Poloni A, Padron E, Cardoso BA, Cross M, Winter S, Santaolalla A, Patel BA, Groarke EM, Wiseman DH, Jones K, Jamieson L, Manogaran C, Daver NG, Gallur L, Ingram W, Ferrell PB, Sockel K, Dulphy N, Chapuis N, Kubasch AS, Olsnes AM, Kulasekararaj A, De Lavellade H, Kern W, Van Hemelrijck M, Bonnet D, Westers TM, Freeman S, Oelschlaegel U, Valcarcel D, Raddi MG, Grønbæk K, Fontenay M, Loghavi S, Santini V, Almeida AM, Irish JM, Sallman DA, Young NS, van de Loosdrecht AA, Adès L, Della Porta MG, Cargo C, Platzbecker U, Kordasti S, consortium I. Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium. Hemasphere 8(5):e64, 2024. e-Pub 2024. PMID: 38756352.
Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Ravandi F, Kantarjian H, Garcia-Manero G. Cytogenetic and molecular associations with outcomes in HR-MDS treated with hypomethylating agents plus venetoclax. Clin Cancer Res 30(7):1319-1326, 2024. e-Pub 2024. PMID: 38300723.
Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver NG, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. e-Pub 2024. PMID: 38591430.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver NG Garcia-Manero G, Ravandi F, Kadia T. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
Abuasab T, Borthakur G, Kanagal-Shamanna R, Masarova L, Patel K, Takahashi K, Bose P, Villarreal J, Pierce S, Kadia T, Garcia-Manero G, Short NJ, DiNardo C, Daver NG, Ravandi F, Kantarjian H, Verstovsek S, Yilmaz M. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications. Am J Hematol. e-Pub 2024. PMID: 38613831.
Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. e-Pub 2024. PMID: 38572554.
Birdwell, C, Fiskus, WC, Kadia, TM, Mill, CP, Sasaki, K, Daver, N, DiNardo, C, Pemmaraju, N, Borthakur, G, Davis, JA, Das, K, Sharma, S, Horrigan, SK, Ruan, X, Su, X, Khoury, J, Kantarjian, HM, Bhalla, K. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia 38(3):545-556, 2024. e-Pub 2024. PMID: 38086946.
Root, J, Desai, PN, Ly, C, Wang, B, Jelloul, FZ, Zhou, J, Mackay, S, Alfayez, M, Matthews, JA, Pierce, S, Reville, PK, Daver, N, Abbas, HA. Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy. Cancer Research Communications 4(3):671-681, 2024. e-Pub 2024. PMID: 38391202.
Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Todisco E, Sweet KL, Pemmaraju N, Lane AA, Torres-Miñana L, Thompson JE, Konopleva MY, Sloss CM, Watkins K, Bedse G, Du Y, Malcolm KE, Zweidler-McKay PA, Kantarjian HM. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol 25(3):388-399, 2024. e-Pub 2024. PMID: 38423051.
Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver NG, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. e-Pub 2024. PMID: 38452788.
Root JL, Desai PN, Ly C, Wang B, Jelloul FZ, Zhou J, Mackay S, Alfayez M, Matthews J, Pierce S, Reville PK, Daver NG, Abbas HA. Single-Cell CD4 and CD8 T Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy. Cancer Res Commun. e-Pub 2024. PMID: 38391202.
Fiskus W, Piel J, Collins MP, Hentemann M, Cuglievan B, Mill CP, Birdwell C, Das K, Davis JA, Hou H, Jain A, Malovannaya A, Kadia TM, Daver NG, Sasaki K, Takahashi K, Hammond D, Reville PK, Wang J, Loghavi S, Sen R, Ruan X, Su X, Flores L, DiNardo CD, Bhalla KN. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor. Blood. e-Pub 2024. PMID: 38437498.
Guo S, Mohan GS, Wang B, Li T, Daver NG, Zhao Y, Reville PK, Hao D, Abbas HA. Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia. J Immunother Cancer 12(2), 2024. e-Pub 2024. PMID: 38418394.
Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. e-Pub 2024. PMID: 38316133.
Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol. e-Pub 2024. PMID: 38361282.
Wang B, Reville PK, Yassouf MY, Jelloul FZ, Ly C, Desai PN, Wang Z, Borges P, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Garza AI, Nasnas C, Vaughn NR, Baran N, Deng Q, Matthews J, Gunaratne PH, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia MB, Cuglievan B, Hao D, Daver NG, Green MR, Konopleva M, Futreal A, Post SM, Abbas HA. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun 15(1):1821, 2024. e-Pub 2024. PMID: 38418901.
Yacoub A, Borate U, Rampal RK, Ali H, Wang ES, Gerds AT, Hobbs GS, Kremyanskaya M, Winton EF, O'Connell C, Goel S, Oh ST, Schiller GJ, McCloskey J, Palmer JM, Holmes H, Hager S, Assad A, Erickson-Viitanen S, Zhou F, Daver NG. Phase 2 study of add-on parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib: Final results. Blood Adv. e-Pub 2024. PMID: 38290135.
Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv 9(48):eadh1436, 2023. e-Pub 2023. PMID: 38019903.
Fiskus, WC, Mill, CP, Birdwell, C, Davis, JA, Das, K, Boettcher, S, Kadia, TM, DiNardo, C, Takahashi, K, Loghavi, S, Soth, MJ, Heffernan, TP, McGeehan, G, Ruan, X, Su, X, Vakoc, CR, Daver, N, Bhalla, K. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood cancer journal 13(1), 2023. e-Pub 2023. PMID: 37055414.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. e-Pub 2023. PMID: 38113472.
Rajakumaraswamy N, Gandhi M, Wei AH, Sallman DA, Daver NG, Mo S, Iqbal S, Karalliyadda R, Chen M, Wang Y, Vyas P. Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. e-Pub 2023. PMID: 38216397.
Subklewe M, Bücklein V, Sallman D, Daver NG. Novel immunotherapies in the treatment of AML: is there hope?. Hematology Am Soc Hematol Educ Program 2023(1):691-701, 2023. e-Pub 2023. PMID: 38066884.
Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce SA, Chien KS, Sasaki K, Kadia TM, Hammond D, Borthakur G, Patel KP, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
Kadia, TM, Ravandi-Kashani, F, Molica, M, Bataller, A, Borthakur, G, Daver, N, Jabbour, EJ, DiNardo, C, Pemmaraju, N, Jain, N, Ferrajoli, A, Ylimaz, M, Bose, P, Tidwell, R, Marx, KR, Rausch, CR, Kanagal Shamanna, R, Wang, S, Islam, R, Champlin, RE, Shpall, E, Konopleva, M, Garcia-Manero, G, Kantarjian, HM. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. American journal of hematology 98(11):1711-1720, 2023. e-Pub 2023. PMID: 37635400.
Senapati J, Fiskus WC, Daver NG, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res 29(21):4352-4360, 2023. e-Pub 2023. PMID: 37585491.
Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DA. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol 41(31):JCO2202604, 2023. e-Pub 2023. PMID: 37703506.
Altan M, Soto F, Zhong LL, Akhmedzhanov FO, Wilson NR, Zarifa A, Albittar AA, Yang V, Lewis J, Rinsurongkawong W, Jack Lee J, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Jennings K, Khawaja F, Faiz SA, Shannon VR, Shroff G, Godoy MCB, Daver NG, Gandhi S, Mendoza TR, Naing A, Daniel-MacDougall C, Heymach JV, Sheshadri A. Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. Oncologist 28(11):E1065-E1074, 2023. e-Pub 2023. PMID: 37156009.
Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver NG, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver NG, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol 203(4):581-592, 2023. e-Pub 2023. PMID: 37608562.
Sasaki K, Morita K, Kantarjian H, Garcia-Manero G, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Wierda W, Daver NG, Takahashi K, DiNardo C, Bravo GM, Issa GC, Pierce SA, Soltysiak KA, Tingen MS, Cortes JE. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. Clin Lymphoma Myeloma Leuk 23(11):e369-e378, 2023. e-Pub 2023. PMID: 37690903.
Tyagi A, Jaggupilli A, Ly S, Yuan B, El-Dana F, Hegde VL, Anand V, Kumar B, Puppala M, Yin Z, Wong STC, Mollard A, Vankayalapati H, Foulks JM, Warner SL, Daver NG, Borthakur G, Battula VL. TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. Leukemia. e-Pub 2023. PMID: 38007585.
Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver NG, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol 98(10):E281-E284, 2023. e-Pub 2023. PMID: 37515433.
Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver NG, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica 108(10):2626-2638, 2023. e-Pub 2023. PMID: 37078252.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. The role of therapy in the outcome of patients with myelofibrosis. Cancer 129(18):2828-2835, 2023. e-Pub 2023. PMID: 37243913.
Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver NG, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol 98(9):1383-1393, 2023. e-Pub 2023. PMID: 37334870.
Hammond D, Loghavi S, Wang SA, Konopleva MY, Kadia TM, Daver NG, Ohanian M, Issa GC, Alvarado Y, Short NJ, Sasaki K, Pemmaraju N, Montalban-Bravo G, Lachowiez CA, Maiti A, Garcia-Manero G, Jabbour EJ, Borthakur G, Ravandi F, Takahashi K, Pierce SR, Kantarjian HM, DiNardo CD. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J 13(1):148, 2023. e-Pub 2023. PMID: 37735426.
Daver NG, Iqbal S, Huang J, Renard C, Lin J, Pan Y, Williamson M, Ramsingh G. Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion. Am J Hematol 98(8):1176-1184, 2023. e-Pub 2023. PMID: 37139921.
Yilmaz M, Daver NG. Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia. Lancet Haematol 10(8):e559-e561, 2023. e-Pub 2023. PMID: 37532412.
Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver NG, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv 7(14):3573-3581, 2023. e-Pub 2023. PMID: 37104058.
Bazinet A, Kadia TM, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen JL, Patel KP, DiNardo CD, Daver NG, Alvarado Y, Haddad FG, Pierce SR, Nogueras Gonzalez GM, Maiti A, Sasaki K, Yilmaz M, Thompson PA, Wierda WG, Garcia-Manero G, Andreeff M, Jabbour EJ, Konopleva MY, Huang X, Kantarjian HM, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. Blood Cancer Discov 4(4):276-293, 2023. e-Pub 2023. PMID: 37102976.
Fan H, Wang F, Zeng A, Murison A, Tomczak K, Hao D, Jelloul FZ, Wang B, Barrodia P, Liang S, Chen K, Wang L, Zhao Z, Rai K, Jain AK, Dick J, Daver NG, Futreal A, Abbas HA. Single-cell chromatin accessibility profiling of acute myeloid leukemia reveals heterogeneous lineage composition upon therapy-resistance. Commun Biol 6(1):765, 2023. e-Pub 2023. PMID: 37479893.
Desai PN, Wang B, Fonseca A, Borges P, Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, Baran N, Post SM, Deng Q, Sun H, Harmanci AO, Burks JK, Gomez JA, DiNardo CD, Daver NG, Alatrash G, Konopleva M, Green MR, Antunes DA, Futreal A, Hao D, Abbas HA. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol Res 11(7):1011-1028, 2023. e-Pub 2023. PMID: 37163233.
Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver NG, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer 129(12):1856-1865, 2023. e-Pub 2023. PMID: 36892949.
Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski D, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore S, List AF, Kutchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa M, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). Blood Adv 7(12):2709-2714, 2023. e-Pub 2023. PMID: 36260702.
DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver NG Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 7(11):2378-2387, 2023. e-Pub 2023. PMID: 35973199.
Desai PN, Wang B, Fonseca A, Borges P, Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, Baran N, Post SM, Deng Q, Sun H, Harmanci AO, Burks JK, Gomez JA, DiNardo CD, Daver NG, Alatrash G, Konopleva M, Green MR, Antunes DA, Futreal A, Hao D, Abbas HA. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol Res:OF1-OF18. e-Pub 2023. PMID: 37285177.
Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver NG, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver NG, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia 37(6):1336-1348, 2023. e-Pub 2023. PMID: 36977823.
Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver NG, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver NG, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. e-Pub 2023. PMID: 37196217.
Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol 41(15):JCO2201794, 2023. e-Pub 2023. PMID: 36888930.
Lee SE, Wang F, Grefe M, Trujillo-Ocampo A, Ruiz-Vasquez W, Takahashi K, Abbas HA, Borges P, Antunes DA, Al-Atrash G, Daver NG, Molldrem JJ, Futreal A, Garcia-Manero G, Im JS. Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. Clin Cancer Res 29(10):OF1-OF14, 2023. e-Pub 2023. PMID: 36988276.
Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver NG, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. Blood Adv 7(10):1958-1966, 2023. e-Pub 2023. PMID: 36287248.
Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Adès L, Borate U, Bowen DT, Buckstein RJ, Brunner AM, Carraway HE, Daver NG, Díez-Campelo M, de Witte TM, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Iastrebner MC, Komrokji RS, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz GF, Scheinberg P, Stauder R, Van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes. Blood 141(17):2047-2061, 2023. e-Pub 2023. PMID: 36724453.
Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, DDaver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer 129(7):1017-1029, 2023. e-Pub 2023. PMID: 36715486.
Trabal, AM, Gibson, A, He, J, McCall, DC, Roth, M, Nunez, CA, Garcia, MB, Buzbee, M, Toepfer, L, Bidikian, A, Daver, N, Kadia, TM, Short, NJ, Issa, GC, Ravandi-Kashani, F, DiNardo, C, Montalban Bravo, G, Garces, S, Marcogliese, A, Paek, H, Dreyer, Z, Brackett, J, Redell, MS, Yi, JS, Garcia-Manero, G, Konopleva, M, Stevens, A, Cuglievan, B. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients. Cancers 15(7), 2023. e-Pub 2023. PMID: 37046645.
Siddiqui M, Konoplev S, Issa G, Kantarjian H, Daver NG, Ravandi F, Kadia T, Tang G, Wang SA, Thakral B, Medeiros LJ, Pozdnyakova O, Pierce S, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Garcia-Manero G, Hasserjian RP. Biologic Features and Clinical Outcomes in Newly Diagnosed Myelodysplastic Syndrome with KMT2A rearrangements. Am J Hematol 98(4):E91-E94, 2023. e-Pub 2023. PMID: 36661399.
Abbas HA, Sun H, Pierce S, Kanagal-Shamanna R, Li Z, Yilmaz M, Borthakur G, DiPippo AJ, Jabbour E, Konopleva M, Short NJ, DiNardo C, Daver NG Ravandi F, Kadia TM. Validation of Acute Leukemia French Association ALFA1200 model in older patients with AML treated with intensive chemotherapy. Blood Adv 7(5):828-831, 2023. e-Pub 2023. PMID: 35405739.
Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica. e-Pub 2023. PMID: 36951163.
Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver NG Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol 98(3):E53-E56, 2023. e-Pub 2023. PMID: 36565294.
Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver NG. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2023. PMID: 36322818.
Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial. Blood 141(11):1265-1276, 2023. e-Pub 2023. PMID: 36265087.
Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, Daver NG, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. Blood 141(6):567-578, 2023. e-Pub 2023. PMID: 36399715.
Hasegawa K, Wei AH, Garcia-Manero G, Daver NG, Rajakumaraswamy N, Iqbal S, Chan RJ, Hu H, Tse P, Yan J, Zoratti MJ, Xie F, Sallman DA. Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. Clin Lymphoma Myeloma Leuk 23(2):127-137, 2023. e-Pub 2023. PMID: 36428152.
Zeng Z, Maiti A, Herbrich S, Cai T, Cavazos A, Manzella T, Ma H, Hayes K, Matthews J, DiNardo CD, Daver NG, Konopleva MY. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia. Cancer 129(4):531-540, 2023. e-Pub 2023. PMID: 36477735.
Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. e-Pub 2023. PMID: 36458426.
Shallis RM, Daver NG, Altman JK, Hasserjian RP, Kantarjian HM, Platzbecker U, Santini V, Wei AH, Sallman DA, Zeidan AM. TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. Cancer 129(2):175-180, 2023. e-Pub 2023. PMID: 36397669.
Figueroa M, Ma H, Alfayez M, Morales-Mantilla DE, Wang F, Lu Y, Estecio M, King KY, Kleinerman ES, Moghaddam SJ, Daver NG, Andreeff M, Konopleva MY, DiNardo CD, Chandra J. Cigarette smoke exposure accelerates AML progression in FLT3-ITD models. Blood Adv 7(21):6624-6629, 2023. e-Pub 2023. PMID: 37486624.
Morse JW, Rios M, Ye J, Rios A, Zhang CC, Daver NG, DiNardo CD, Zhang N, An Z. Antibody Therapies for the Treatment of Acute Myeloid Leukemia: Exploring Current and Emerging Therapeutic Targets. Expert Opin Investig Drugs 32(2):107-125, 2023. e-Pub 2023. PMID: 36762937.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver NG, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24-e34, 2023. e-Pub 2023. PMID: 36402146.
Yap TA, Daver NG, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
Aminu M, Daver NG Godoy MCB, Shroff G, Wu C, Torre-Sada LF, Goizueta A, Shannon VR, Faiz SA, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim ST, Kontoyiannis DP, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Front Immunol 14:1249511, 2023. e-Pub 2023. PMID: 37841255.
Daver NG, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol 40(35):4048-4059, 2022. e-Pub 2022. PMID: 35849791.
Maiti A, Daver NG. Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions. J Clin Oncol 40(34):3994-3997, 2022. e-Pub 2022. PMID: 36070541.
Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver NG, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol 97(12):1560-1567, 2022. e-Pub 2022. PMID: 36087091.
Aminu M, Yadav D, Hong L, Young E, Edelkamp P, Saad M, Salehjahromi M, Chen P, Sujit SJ, Chen MM, Sabloff B, Gladish G, de Groot PM, Godoy MCB, Cascone T, Vokes NI, Zhang J, Brock KK, Daver NG, Woodman SE, Tawbi HA, Sheshadri A, Lee JJ, Jaffray D, Team D, Wu CC, Chung C, Wu J. Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19. Cancers (Basel) 15(1), 2022. e-Pub 2022. PMID: 36612278.
Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver NG, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma 63(13):3105-3116, 2022. e-Pub 2022. PMID: 36089905.
Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 36(12):2939-2946, 2022. e-Pub 2022. PMID: 36266326.
Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver NG, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol 97(12):1599-1606, 2022. e-Pub 2022. PMID: 36117258.
Wei Y, Zheng H, Lockyer PP, Darbaniyan F, Li Z, Kanagal-Shamanna R, Soltysiak KA, Yang H, Ganan-Gomez I, Montalban-Bravo G, Chien KS, Do KA, Daver NG Garcia-Manero G. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 63(13):3154-3164, 2022. e-Pub 2022. PMID: 36059252.
Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabbour EJ, Takahashi K, Ohanian M, Daver NG, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol 97(11):1427-1434, 2022. e-Pub 2022. PMID: 36053747.
Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver NG, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol 97(11):E408-E411, 2022. e-Pub 2022. PMID: 36054774.
Daver NG, Jonas BA, Medeiros BC, Patil U, Yan M. Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia. Leuk Lymphoma 63(11):2711-2714, 2022. e-Pub 2022. PMID: 35834732.
Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):3848-3857, 2022. e-Pub 2022. PMID: 35704787.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver NG, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
Fiskus W, Daver NG, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia 36(11):2729-2733, 2022. e-Pub 2022. PMID: 36151141.
Venugopal S, Borthakur G, Daver NG, DiNardo CD, Pemmaraju N, Short NJ, Abbas HA, Garcia-Manero G, Konopleva MY, Ravandi F, Kadia TM. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. Blood Adv 6(19):5546-5549, 2022. e-Pub 2022. PMID: 35201293.
Daver, NG, Montesinos, P, Aribi, A, Martinelli, G, Altman, JK, Wang, ES, Roboz, G, Burke, PW, Gaidano, G, Walter, RB, Thomas, X, Jeyakumar, D, DeAngelo, DJ, Erba, HP, Todisco, E, Begna, K, Advani, A, Gastaud, L, De La Fuente, A, Curti, A, Mendez, LM, Vyas, P, Boissel, N, Vey, N, Recher, C, Longval, T, Platzbecker, U, Kapp-Schwörer, S, Schliemann, C, Konopleva, M, Torres, L, Sallman, D, Marcucci, G, Marconi, G, Kantarjian, HM, Sloss, CM, Malcolm, KE, Zweidler-McKay, PA, Sweet, KL. AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. Clinical Lymphoma, Myeloma and Leukemia 22:S231-S232, 2022. e-Pub 2022. PMID: 36163801.
Daver, NG, Wei, A, Stein, EM, DeAngelo, DJ, Pathak, D, Xu, Y, Grzesiak, S, Venditti, A. AML-143 Trial in Progress. Clinical Lymphoma, Myeloma and Leukemia 22:S217, 2022. e-Pub 2022. PMID: 36163772.
Abuasab, T, Alvarado, Y, Issa, GC, Islam, R, James, N, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Pemmaraju, N, Montalban Bravo, G, Pierce, S, DiNardo, C, Kadia, TM, Daver, NG, Konopleva, M, Garcia-Manero, G, Ravandi-Kashani, F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia 22:S237, 2022. e-Pub 2022. PMID: 36163813.
Sallman, D, Al Malki, MM, Asch, A, Wang, ES, Jurcic, J, Bradley, T, Flinn, IW, Pollyea, DA, Kambhampati, S, Tanaka, T, Zeidner, JF, Garcia-Manero, G, Jeyakumar, D, Gu, L, Tan, A, Chao, MP, O'Hear, C, Lal, I, Vyas, P, Daver, NG. MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS). Clinical Lymphoma, Myeloma and Leukemia 22:S314-S315, 2022. e-Pub 2022. PMID: 36163963.
Ong, F, Kadia, TM, Short, NJ, Yilmaz, M, Alvarado, Y, Sasaki, K, Pierce, S, Garcia-Manero, G, DiNardo, C, Borthakur, G, Konopleva, M, Daver, N, Kantarjian, HM, Ravandi-Kashani, F. AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34). Clinical Lymphoma, Myeloma and Leukemia 22:S258, 2022. e-Pub 2022. PMID: 36163855.
Bazinet, A, Kantarjian, HM, Borthakur, G, Yilmaz, M, Bose, P, Jabbour, EJ, Alvarado, Y, Chien, KS, Pemmaraju, N, Takahashi, K, Short, NJ, Daver, NG, Issa, GC, Jain, N, Bull-Linderman, D, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Sasaki, K, Ravandi-Kashani, F, Kadia, TM. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
Venugopal, S, Kantarjian, HM, Maiti, A, Short, NJ, Montalban Bravo, G, Alvarado, Y, Chien, KS, Kanagal Shamanna, R, Pemmaraju, N, Daver, NG, Kadia, TM, Borthakur, G, Jabbour, EJ, Garcia-Manero, G. MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma, Myeloma and Leukemia 22:S321, 2022. e-Pub 2022. PMID: 36163977.
Vyas, P, Daver, NG, Chao, MP, Xing, G, Renard, C, Ramsingh, G, Sallman, D. AML-399 A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia 22:S247, 2022. e-Pub 2022. PMID: 36163834.
Lachowiez, C, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, TM, Masarova, L, Takahashi, K, Tippett, G, Garcia, JS, Bose, P, Jabbour, EJ, Ravandi-Kashani, F, Daver, NG, Garcia-Manero, G, Vyas, P, Kantarjian, HM, Konopleva, M, DiNardo, C. AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia 22:S240-S241, 2022. e-Pub 2022. PMID: 36163821.
Abuasab, T, Mohamed, SF, Biostatistics, HH, Biostatistics, XW, Sasaki, K, Yilmaz, M, Kadia, TM, DiNardo, C, Daver, N, Pemmaraju, N, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G, Takahashi, K. AML-387 Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD). Clinical Lymphoma, Myeloma and Leukemia 22:S243, 2022. e-Pub 2022. PMID: 36163827.
Daver, NG, Vyas, P, Kambhampati, S, Al Malki, MM, Larson, RA, Asch, A, Mannis, GN, Chai-Ho, W, Tanaka, T, Bradley, T, Jeyakumar, D, Wang, ES, Xing, G, Chao, MP, Ramsingh, G, Renard, C, Lal, I, Zeidner, JF, Sallman, D. AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia 22:S253-S254, 2022. e-Pub 2022. PMID: 36163845.
Daver, NG, Affinito, J, Cai, H, Dobrowolska, H, Eguchi, K, Stoudemire, J, Watanabe, A, Hitron, M. AML-391 Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients With Acute Leukemia With and Without Mixed-Lineage Leukemia (MLL)– Rearrangement or Nucleophosmin 1 (NPM1) Mutation. Clinical Lymphoma, Myeloma and Leukemia 22:S244, 2022. e-Pub 2022. PMID: 36163829.
Bidikian, A, Kantarjian, HM, Dabaja, BS, Ravandi-Kashani, F, Jabbour, EJ, DiNardo, C, Borthakur, G, Daver, NG, Garcia-Manero, G, Kadia, TM, Sasaki, K, Issa, GC. AML-285 Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration. Clinical Lymphoma, Myeloma and Leukemia 22:S233-S234, 2022. e-Pub 2022. PMID: 36163805.
Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, Nguyen AT, Miller PG, McConkey ME, Quevedo Barrios VA, Furudate K, Zhang L, Kanagal-Shamanna R, Zhang J, Little L, Gumbs C, Daver NG, DiNardo CD, Kadia T, Ravandi F, Kantarjian H, Garcia-Manero G, Futreal PA, Ebert BL, Takahashi K. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood 140(16):1753-1763, 2022. e-Pub 2022. PMID: 35512188.
Yacoub A, Borate U, Rampal R, Ali H, Wang E, Gerds A, Hobbs G, Kremyanskaya M, Winton E, O'Connell C, Goel S, Oh S, Schiller G, Assad A, Erickson-Viitanen S, Zhou F, Daver NG. MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S324, 2022. e-Pub 2022. PMID: 36163982.
Kim K, Bazinet A, Loghavi S, Konopleva M, Bhalla K, Daver NG, Khoury JD, Kadia T, Wilson NR, Curry JL, Heberton M, Miller D, Pierce S, Borthakur G, Pemmaraju N. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. Leuk Res 119:106884, 2022. e-Pub 2022. PMID: 35691130.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver NG, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
Tashakori M, Kadia TM, Loghavi S, Daver NG, Kanagal-Shamanna R, Pierce SR, Sui D, Wei P, Khodakarami F, Tang Z, Routbort M, Bivins C, Jabbour EJ, Medeiros LJ, Bhalla KN, Kantarjian HM, Ravandi F, Khoury JD. TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia. Blood 140(1):58-72, 2022. e-Pub 2022. PMID: 35390143.
Sheshadri A, Goizueta AA, Shannon VR, London D, Garcia-Manero G, Kantarjian HM, Ravandi-Kashani F, Kadia TM, Konopleva MY, DiNardo CD, Pierce S, Zarifa A, Albittar AA, Zhong LL, Akhmedzhanov FO, Arain MH, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza TR, Godoy MCB, Shroff G, Kim ST, Faiz SA, Kontoyiannis DP, Khawaja F, Jennings K, Daver NG. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer 128(14):2736-2745, 2022. e-Pub 2022. PMID: 35452134.
Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver NG, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol 97(7):856-864, 2022. e-Pub 2022. PMID: 35357036.
Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver NG, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol 97(7):885-894, 2022. e-Pub 2022. PMID: 35413152.
Tashakori M, Wang W, Kadia TM, Daver NG, Montalban-Bravo G, Loghavi S, Wang SA, Medeiros LJ, Ravandi F, Khoury JD. Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy. Leuk Res 118:106860, 2022. e-Pub 2022. PMID: 35636055.
Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver NG, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 6(13):4006-4014, 2022. e-Pub 2022. PMID: 35533262.
Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver NG, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol 97(7):865-876, 2022. e-Pub 2022. PMID: 35384048.
Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, Chan-Seng-Yue M, Voisin V, van Galen P, Tierens A, Cheok M, Preudhomme C, Dombret H, Daver NG, Futreal PA, Minden MD, Kennedy JA, Wang JCY, Dick JE. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med 28(6):1212-1223, 2022. e-Pub 2022. PMID: 35618837.
Nelson BE, Ejezie CL, Stephen BA, Nardo M, Campbell E, Gong J, Hong DS, Fu S, Yap TA, Murphy MB, Piha-Paul S, Daver NG, Rojas-Hernandez CM, Naing A. Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. J Hematol 11(3):113-120, 2022. e-Pub 2022. PMID: 35837373.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver NG, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. e-Pub 2022. PMID: 35483396.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver NG. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver NG, DiNardo C, Alvarado Y, Aldrich J, Borthakur G. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol 97(5):574-582, 2022. e-Pub 2022. PMID: 35150150.
Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver NG, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv 6(10):3027-3035, 2022. e-Pub 2022. PMID: 35061885.
Spallone A, Alotaibi AS, Jiang Y, Daver NG, Kontoyiannis DP. Infectious Complications Among Patients With AML Treated With Immune Checkpoint Inhibitors. Clin Lymphoma Myeloma Leuk 22(5):305-310, 2022. e-Pub 2022. PMID: 34810120.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer 128(8):1658-1665, 2022. e-Pub 2022. PMID: 35077575.
Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver NG. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma:1-10. e-Pub 2022. PMID: 35442137.
Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver NG, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma 63(3):1-4, 2022. e-Pub 2022. PMID: 34668451.
Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol 97(3):329-337, 2022. e-Pub 2022. PMID: 34981570.
Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, Barth D, Fraga M, Bixby DL, Zeidan AM, Yilmaz M, Desai P, Mannis G, Deutsch YE, Abaza Y, Dinner S, Frankfurt O, Litzow M, Al-Kali A, Foran JM, Sproat LZ, Jovanovic B, Daver NG, Perl AE, Altman JK. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol 97(3):322-328, 2022. e-Pub 2022. PMID: 34981560.
Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver NG, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2. Blood 139(6):907-921, 2022. e-Pub 2022. PMID: 34601571.
Zoref-Lorenz A, Murakami J, Hofstetter L, Iyer S, Alotaibi AS, Mohamed SF, Miller PG, Guber E, Weinstein S, Yacobovich J, Nikiforow S, Ebert BL, Lane A, Pasvolsky O, Raanani P, Nagler A, Berliner N, Daver NG, Ellis M, Jordan MB. An improved index for diagnosis and mortality prediction in malignancy associated hemophagocytic lymphohistiocytosis. Blood 139(7):1098-1110, 2022. e-Pub 2022. PMID: 34780598.
Maiti A, Daver NG. A nonstick marrow may help to fry leukemia. Blood 139(8):1119-1121, 2022. e-Pub 2022. PMID: 35201330.
Fiskus W, Manshouri T, Birdwell C, Mill CP, Masarova L, Bose P, Kadia TM, Daver NG, DiNardo CD, Borthakur G, Khoury JD, Verstovsek S, Bhalla KN. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J 12(1):23, 2022. e-Pub 2022. PMID: 35102145.
Venugopal S, Takahashi K, Daver NG, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 12(1):10, 2022. e-Pub 2022. PMID: 35078972.
Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver NG, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol 15(1):12, 2022. e-Pub 2022. PMID: 35093134.
Fiskus W, Boettcher S, Daver NG, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J 12(1):5, 2022. e-Pub 2022. PMID: 35017466.
Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol 97(1):68-78, 2022. e-Pub 2022. PMID: 34716921.
Franklin S, Aitken SL, Shi Y, Sahasrabhojane PV, Robinson S, Peterson CB, Daver NG, Ajami NA, Kontoyiannis DP, Shelburne SA, Galloway-Peña J. Oral and Stool Microbiome Coalescence and Its Association With Antibiotic Exposure in Acute Leukemia Patients. Front Cell Infect Microbiol 12:848580, 2022. e-Pub 2022. PMID: 35433514.
Wurster S, Albert ND, Bharadwaj U, Kasembeli MM, Tarrand JJ, Daver NG, Kontoyiannis DP. Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis. Front Immunol 13:838344, 2022. e-Pub 2022. PMID: 35251033.
Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver NG Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. Acta Haematol 145(5):529-536, 2022. e-Pub 2022. PMID: 35717939.
Haddad F, Zeidan AM, Daver NG. Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia. Cancer J 28(1):43-50, 2022. e-Pub 2022. PMID: 35072373.
Abou Dalle I, Kantarjian H, Daver NG, Masarova L, Pemmaraju N, Bose P, Garcia-Manero G, Verstovsek S. Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol 100(12):2957-2960, 2021. e-Pub 2021. PMID: 34350483.
Young PE, Kanagal-Shamanna R, Hu S, Tang G, Thakral B, Daver NG, Issa GC, Medeiros LJ, Konoplev S. Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation - First case series from a single institution. Leuk Res 111:106685, 2021. e-Pub 2021. PMID: 34438119.
McCall D, Roth M, Mahadeo KM, Toepfer L, Nunez C, Short NJ, Daver NG, Kadia TM, DiNardo C, Yi JS, Cuglievan B. Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv 5(23):5215-5219, 2021. e-Pub 2021. PMID: 34592761.
Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma 62(14):3501-3505, 2021. e-Pub 2021. PMID: 34474640.
Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia T, Garcia-Manero G, Garris R, O'Brien S, Jabbour E. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv 5(23):5415-5419, 2021. e-Pub 2021. PMID: 34525185.
Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver NG, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma 62(14):1-9, 2021. e-Pub 2021. PMID: 34380367.
Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver NG, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol 96(11):1420-1428, 2021. e-Pub 2021. PMID: 34351647.
Tanaka T, Morita K, Loghavi S, Wang F, Furudate K, Sasaki Y, Little L, Gumbs C, Matthews J, Daver NG, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal PA, Takahashi K. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood 138(18):1733-1739, 2021. e-Pub 2021. PMID: 34115096.
Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer 127(22):4213-4220, 2021. e-Pub 2021. PMID: 34343352.
Abbas HA, Alaniz Z, Mackay S, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Konopleva M, Andreeff M, Daver NG. Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. Blood Adv 5(22):4569-4574, 2021. e-Pub 2021. PMID: 34555853.
Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol 195(3):378-387, 2021. e-Pub 2021. PMID: 34340254.
Wei SC, Mancuso JJ, Daver NG, Allison JP. Checkpoint Blockade + Chemotherapy: the Right Combination for AML?. Blood Cancer Discov 2(6):551-554, 2021. e-Pub 2021. PMID: 35015675.
Maiti A, Daver NG. Lowering mTORC1 Drives CAR T-Cells Home in Acute Myeloid Leukemia. Clin Cancer Res 27(21):5739-5741, 2021. e-Pub 2021. PMID: 34470774.
Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver NG, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 35(11):3282-3286, 2021. e-Pub 2021. PMID: 33833386.
Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer 127(20):3772-3781, 2021. e-Pub 2021. PMID: 34255353.
Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver NG, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun 12(1):6071, 2021. e-Pub 2021. PMID: 34663807.
Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver NG, Pierce S, Jabbour E, Kadia T, DiNardo C, Garcia-Manero G, Qazilbash M, Konopleva M, Kantarjian H. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood 138(15):1373-1377, 2021. e-Pub 2021. PMID: 34098573.
Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver NG, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer 127(19):3541-3551, 2021. e-Pub 2021. PMID: 34182597.
Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver NG. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer 127(20):3761-3771, 2021. e-Pub 2021. PMID: 34171128.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver NG, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):2768-2778, 2021. e-Pub 2021. PMID: 34043428.
Wang J, Ma J, Cai C, Daver NG, Ning J. A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules. Stat Med 40(21):4629-4639, 2021. e-Pub 2021. PMID: 34101217.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver NG, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
S Mehta R, Torres Cabala CA, DiNardo CD, Daver NG, Dabaja B, Rezvani K, Champlin RE, Shpall E, Duvic M. Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. Am J Hematol 96(9):E350-E353, 2021. e-Pub 2021. PMID: 34096089.
Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver NG, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J 11(9):162, 2021. e-Pub 2021. PMID: 34588432.
Jain N, Maiti A, Ravandi F, Konopleva M, Daver NG, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia. Am J Hematol 96(8):1000-1007, 2021. e-Pub 2021. PMID: 33991360.
Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver NG, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 96(8):914-924, 2021. e-Pub 2021. PMID: 33901324.
Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver NG, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 127(15):2648-2656, 2021. e-Pub 2021. PMID: 33793964.
Yilmaz M, Daver NG, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in CR1 improves outcomes in patients with newly diagnosed AML with very low FLT3 allelic burden. Am J Hematol 96(8):E275-E279, 2021. e-Pub 2021. PMID: 33891709.
Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver NG, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver NG, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552-e561, 2021. e-Pub 2021. PMID: 34329576.
Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. e-Pub 2021. PMID: 34424319.
Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver NG, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer 127(15):2641-2647, 2021. e-Pub 2021. PMID: 33823073.
Herbrich S, Baran N, Cai T, Weng C, Aitken MJL, Post SM, Henderson J, Shi C, Richard-Carpentier G, Sauvageau G, Baggerly K, Al-Atrash G, Davis RE, Daver NG, Zha D, Konopleva M. Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34326171.
Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver NG, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, Genomic, and Transcriptomic Differences between Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS). Am J Hematol 96(7):E246-E249, 2021. e-Pub 2021. PMID: 33811786.
Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver NG, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica 106(7):1988-1990, 2021. e-Pub 2021. PMID: 31296578.
Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver NG, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An Effective Chemotherapy-Free Regimen of Ponatinib plus Venetoclax for Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Am J Hematol 96(7):E229-E232, 2021. e-Pub 2021. PMID: 33780038.
Zeng Z, Ly C, Daver NG, Cortes J, Kantarjian HM, Andreeff M, Konopleva M. High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells. Ann Hematol 100(6):1485-1496, 2021. e-Pub 2021. PMID: 33787984.
Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver NG, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver NG, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol 14(1):94, 2021. e-Pub 2021. PMID: 34130720.
Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NG, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. e-Pub 2021. PMID: 33740268.
Abou Dalle I, Kantarjian HM, Ravandi F, Daver NG, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer 127(11):1894-1900, 2021. e-Pub 2021. PMID: 33449377.
Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and Venetoclax for IDH1/2-mutated Acute Myeloid Leukemia. Am J Hematol 96(5):E154-E157, 2021. e-Pub 2021. PMID: 33580980.
Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver NG, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35(5):1494-1499, 2021. e-Pub 2021. PMID: 33846541.
Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver NG, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver NG, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. Clin Infect Dis 72(10):1755-1763, 2021. e-Pub 2021. PMID: 32236406.
Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver NG, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. e-Pub 2021. PMID: 33597098.
Daver NG, Salhotra A, Brandwein JM, Podoltsev NA, Pollyea DA, Jurcic JG, Assouline S, Yee K, Li M, Pourmohamad T, Samineni D, Sumiyoshi T, Vaze A, Dere RC, Ma C, Cooper J. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. Am J Hematol 96(5):E175-E179, 2021. e-Pub 2021. PMID: 33617672.
Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk 21(5):318-327.e6, 2021. e-Pub 2021. PMID: 33551345.
Haddad F, Daver NG. Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab. J Immunother Precis Oncol 4(2):67-71, 2021. e-Pub 2021. PMID: 35663535.
Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver NG, Kadia TM, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv 5(8):2156-2164, 2021. e-Pub 2021. PMID: 33885751.
Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver NG, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. e-Pub 2021. PMID: 33885753.
Wei AH, Daver NG. Taking aim at IDH in fitter patients with AML. Blood 137(13):1706-1707, 2021. e-Pub 2021. PMID: 33792680.
Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver NG, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J 11(3):60, 2021. e-Pub 2021. PMID: 33731681.
Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver NG, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol 192(6):1054-1063, 2021. e-Pub 2021. PMID: 33618432.
Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver NG, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia 35(3):691-700, 2021. e-Pub 2021. PMID: 32561839.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2021. PMID: 33264443.
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2021. PMID: 33681815.
Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver NG, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J 11(3):52, 2021. e-Pub 2021. PMID: 33677472.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver NG. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2021. PMID: 33119202.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver NG, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. Am J Hematol 96(2):E50-E53, 2021. e-Pub 2021. PMID: 33156969.
Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver NG Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer 9(2), 2021. e-Pub 2021. PMID: 33637601.
Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver NG, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The Leukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes. Am J Hematol 96(2):241-250, 2021. e-Pub 2021. PMID: 33180322.
Abbas HA, Mohanty V, Wang R, Huang Y, Liang S, Wang F, Zhang J, Qiu Y, Hu CW, Qutub AA, Dail M, Bolen CR, Daver NG, Konopleva M, Futreal A, Chen K, Wang L, Kornblau SM. Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes. Front Oncol 11:705627, 2021. e-Pub 2021. PMID: 34422660.
Isidori A, Daver NG, Curti A. Editorial: The Biological Landscape of Immunotherapy in AML. Front Oncol 11:671252, 2021. e-Pub 2021. PMID: 33937085.
Haddad F, Daver NG. An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. Adv Exp Med Biol 1342:273-295, 2021. e-Pub 2021. PMID: 34972969.
Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver NG, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3). Am J Hematol 95(12):E326-E329, 2020. e-Pub 2020. PMID: 32886803.
Short NJ, Rafei H, Daver NG, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv 4(24):6117-6126, 2020. e-Pub 2020. PMID: 33351107.
Chifotides HT, Masarova L, Alfayez M, Daver NG, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv 4(21):5336-5342, 2020. e-Pub 2020. PMID: 33112940.
Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver NG, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver NG, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol 95(11):1296-1303, 2020. e-Pub 2020. PMID: 32697348.
Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver NG, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia. Am J Hematol 95(11):1288-1295, 2020. e-Pub 2020. PMID: 32681739.
Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver NG, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4(22):5681-5689, 2020. e-Pub 2020. PMID: 33211826.
Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver NG, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations. Am J Hematol 95(11):E313-E315, 2020. e-Pub 2020. PMID: 32804409.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, Daver NG, Ravandi F, Pemmaraju N. Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol 191(1):e10-e13, 2020. e-Pub 2020. PMID: 32686139.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Wierda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
Saxena K, DiNardo C, Daver NG, Konopleva M. Harnessing Apoptosis in AML. Clin Lymphoma Myeloma Leuk 20 Suppl 1:S61-S64, 2020. e-Pub 2020. PMID: 32862872.
Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel KP, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver NG. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol 95(9):E225-E228, 2020. e-Pub 2020. PMID: 32356320.
Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver NG, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma:1-8. e-Pub 2020. PMID: 32755333.
Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. e-Pub 2020. PMID: 32589978.
Thakral B, Daver NG, Tang Z, Patel KP, Ok CY, Loghavi S, Khoury JD, Alotaibi AS, Konopleva M, Yilmaz M, Medeiros LJ. Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leuk Lymphoma:1-4. e-Pub 2020. PMID: 32696696.
Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. e-Pub 2020. PMID: 32697338.
Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver NG, Burger J, DiNardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Am J Hematol 95(7):734-739, 2020. e-Pub 2020. PMID: 32170867.
Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver NG, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of Acute Myeloid Leukemia with Myelodysplasia Related Changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612-622, 2020. e-Pub 2020. PMID: 32112433.
Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver NG, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2020. PMID: 32792304.
Galloway-Peña JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, Daver NG, Alfayez M, Boddu PC, Khan MAW, Wargo JA, Do KA, Jenq RR, Kontoyiannis DP, Shelburne SA. Gut Microbiome Signatures are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clin Infect Dis 71(1):63-71, 2020. e-Pub 2020. PMID: 31436833.
Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver NG, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47, 2020. e-Pub 2020. PMID: 32366832.
Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver NG. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer 126(10):2193-2205, 2020. e-Pub 2020. PMID: 32125707.
Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver NG, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J 10(5):48, 2020. e-Pub 2020. PMID: 32366841.
Lachowiez CA, Loghavi S, Kadia TM, Daver NG, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. e-Pub 2020. PMID: 32251497.
Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv 4(8):1690-1699, 2020. e-Pub 2020. PMID: 32330243.
Daver NG. A bispecific approach to improving CAR T cells in AML. Blood 135(10):703-704, 2020. e-Pub 2020. PMID: 32135017.
Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. e-Pub 2020. PMID: 32099037.
Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver NG, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4(3):482-495, 2020. e-Pub 2020. PMID: 32027746.
Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver NG, Konopleva M, Champlin RE. Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation?. Blood 135(6):449-452, 2020. e-Pub 2020. PMID: 31826244.
Pankow JD, Richard-Carpentier G, Daver NG, Glass WF, Kala J. Unique case of ANCA-negative pauci-immune necrotizing glomerulonephritis with diffuse alveolar hemorrhage, potentially associated with midostaurin. CEN Case Rep. e-Pub 2020. PMID: 31955389.
Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver NG. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol 11:590494, 2020. e-Pub 2020. PMID: 33552049.
Daver NG, Price A, Benton CB, Patel K, Zhang W, Konopleva M, Pemmaraju N, Takahashi K, Andreeff M, Borthakur G. First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations. Front Oncol 10:1538, 2020. e-Pub 2020. PMID: 32984009.
Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver NG, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2020. PMID: 33585199.
Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, Thakral B, Pemmaraju N, Issa GC, Konopleva M, Short NJ, Patel K, Tang G, Ravandi F, Daver NG. Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. Front Oncol 10:588876, 2020. e-Pub 2020. PMID: 33194747.
Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol 143(6):1-7, 2020. e-Pub 2020. PMID: 32289808.
Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver NG, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver NG, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer 125(21):3755-3766, 2019. e-Pub 2019. PMID: 31310323.
Ye MT, Wang Y, Wang SA, Pemmaraju N, Daver NG, Verstovsek S, Zhang Y, Zuo Z, Medeiros LJ, You MJ. Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leuk Lymphoma:1-4. e-Pub 2019. PMID: 31750750.
Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol 20(11):1544-1555, 2019. e-Pub 2019. PMID: 31563517.
Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver NG. Emerging drug profile: CPX-351 (vyxeos) in AML. Leuk Lymphoma:1-10. e-Pub 2019. PMID: 31547736.
Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver NG, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer 125(18):3219-3224, 2019. e-Pub 2019. PMID: 31150121.
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver NG, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol 94(9):984-991, 2019. e-Pub 2019. PMID: 31237017.
Ravandi F, Assi R, Daver NG, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480-e488, 2019. e-Pub 2019. PMID: 31400961.
Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver NG, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 125(15):2579-2586, 2019. e-Pub 2019. PMID: 30985931.
Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1-8, 2019. e-Pub 2019. PMID: 30632841.
Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver NG, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive Chemotherapy (IC) is More Effective than Hypomethylating Agents (HMA) for the Treatment of Younger Patients with Myelodysplastic Syndrome (MDS) and Elevated Bone Marrow Blasts. Am J Hematol 94(7):E188-E190, 2019. e-Pub 2019. PMID: 30977182.
Yilmaz M, Daver NG. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia. Drugs 79(11):1177-1186, 2019. e-Pub 2019. PMID: 31222627.
Daver NG, Stein E. AML: The future is now or was it yesterday?. Best Pract Res Clin Haematol 32(2):115, 2019. e-Pub 2019. PMID: 31203992.
Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma:1-4. e-Pub 2019. PMID: 31246142.
Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. e-Pub 2019. PMID: 31076409.
Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver NG, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol 109(5):545-552, 2019. e-Pub 2019. PMID: 30830579.
Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125(9):1470-1481, 2019. e-Pub 2019. PMID: 30500073.
Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver NG, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leuk Lymphoma:1-9. e-Pub 2019. PMID: 31125272.
Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer 125(10):1665-1673, 2019. e-Pub 2019. PMID: 30668890.
Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Bottecelli Koller P, Jacamo R, Burks JK, DiNardo C, Daver NG, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. e-Pub 2019. PMID: 31123034.
Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer 125(7):1091-1100, 2019. e-Pub 2019. PMID: 30521114.
Angelova E, Audette C, Kovtun Y, Daver NG, Wang SA, Pierce S, Konoplev SN, Khogeer H, Jorgensen JL, Konopleva M, Zweidler-McKay PA, Medeiros LJ, Kantarjian HM, Jabbour EJ, Khoury JD. CD123 expression patterns and selective targeting with a CD123-specific antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica 104(4):749-755, 2019. e-Pub 2019. PMID: 30361418.
Daver NG, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. Cancer Discov 9(3):370-383, 2019. e-Pub 2019. PMID: 30409776.
Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver NG, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol 37(1):96-102, 2019. e-Pub 2019. PMID: 30153704.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver NG, Ohanian M, DiNardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2019. PMID: 30545576.
Shroff GS, Truong MT, Carter BW, Benveniste MF, Kanagal-Shamanna R, Rauch G, Viswanathan C, Boddu PC, Daver NG, Wu CC. Leukemic Involvement in the Thorax. Radiographics 39(1):44-61, 2019. e-Pub 2019. PMID: 30620703.
Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver NG, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol 12(1):1, 2019. e-Pub 2019. PMID: 30606227.
Daver NG. The Emerging Profile of Immunotherapy Approaches in the Treatment of AML. Oncology (Williston Park) 33(1):28-32, 2019. e-Pub 2019. PMID: 30731016.
Abbas HA, Alfayez M, Kadia T, Ravandi-Kashani F, Daver NG. Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. Cancer Manag Res 11:8817-8828, 2019. e-Pub 2019. PMID: 31632141.
Alfayez M, Ivan D, Pemmaraju N, Daver NG, DiNardo CD. Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 30957058.
Jabbour E, Short NJ, Ravandi F, Huang X, Daver NG, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5(12):e618-e627, 2018. e-Pub 2018. PMID: 30501869.
Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2018. PMID: 30635233.
Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). Blood 132(19):2100-2103, 2018. e-Pub 2018. PMID: 30242087.
Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, DiNardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124(21):4192-4201, 2018. e-Pub 2018. PMID: 30307606.
Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver NG, Tashakori M, Kadia T, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD. P53 Protein Overexpression in De Novo Acute Myeloid Leukemia Patients with Normal Diploid Karyotype Correlates with FLT3 Internal Tandem Duplication and Worse Relapse-Free Survival. Am J Hematol 93(11):1376-1383, 2018. e-Pub 2018. PMID: 30117185.
Zhang W, Ly C, Ishizawa J, Mu H, Ruvolo V, Shacham S, Daver NG, Andreeff M. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103(10):1642-1653, 2018. e-Pub 2018. PMID: 29773601.
Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver NG. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
Yalniz FF, Daver NG, Rezvani K, Kornblau S, Ohanian M, Borthakur G, DiNardo CD, Konopleva M, Burger J, Gasior Y, Pierce S, Kantarjian H, Garcia-Manero G. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 18(10):658-663.e2, 2018. e-Pub 2018. PMID: 30001986.
Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver NG, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia (AML). Am J Hematol 93(9):1136-1141, 2018. e-Pub 2018. PMID: 30028037.
Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver NG, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma 59(9):1-4, 2018. e-Pub 2018. PMID: 29338567.
Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver NG, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 5(9):e411-e421, 2018. e-Pub 2018. PMID: 30115541.
Lyle L, Daver NG. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway. Am J Manag Care 24(16 Suppl):S356-S365, 2018. e-Pub 2018. PMID: 30132679.
Wiese M, Daver NG. Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. Am J Manag Care 24(16 Suppl):S347-S355, 2018. e-Pub 2018. PMID: 30132678.
Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver NG, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol 182(3):442-444, 2018. e-Pub 2018. PMID: 28616864.
Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver NG. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma 59(7):1-5, 2018. e-Pub 2018. PMID: 29119847.
Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N, Zeng Z, McQueen T, Daver NG, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M. Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865(7):959-969, 2018. e-Pub 2018. PMID: 29655803.
Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver NG, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med 24(7):1036-1046, 2018. e-Pub 2018. PMID: 29892070.
Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver NG, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124(13):2758-2765, 2018. e-Pub 2018. PMID: 29660836.
Boddu P, Oviedo SP, Rausch CR, Yam C, Daver NG, Kantarjian H, Kadia TM. PET-CT in AML-related hemophagocytic lymphohistiocytosis. Leuk Lymphoma 59(6):1-4, 2018. e-Pub 2018. PMID: 28958191.
Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver NG, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 24(6):1232-1236, 2018. e-Pub 2018. PMID: 28918304.
Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver NG, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36(18):JCO2017776757, 2018. e-Pub 2018. PMID: 29702001.
Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver NG, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59(6):1-11, 2018. e-Pub 2018. PMID: 28972430.
Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer 124(12):2534-2540, 2018. e-Pub 2018. PMID: 29645075.
Chyla B, Daver NG, Doyle K, McKeegan E, Huang X, Ruvolo V, Wang Z, Chen K, Souers A, Leverson J, Potluri J, Boghaert E, Bhathena A, Konopleva M, Popovic R. Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia. Am J Hematol. e-Pub 2018. PMID: 29770480.
Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver NG, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15(4):218, 2018. e-Pub 2018. PMID: 29434334.
Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2018. PMID: 28718728.
Boddu P, Kantarjian H, Garcia-Manero G, Ravandi F, Jabbour E, Borthakur G, Daver NG, Pemmaraju N, Pierce S, Cortes J, Kadia TM. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leuk Lymphoma 59(4):1-4, 2018. e-Pub 2018. PMID: 28838278.
Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver NG. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 59(4):1-13, 2018. e-Pub 2018. PMID: 28679300.
Assi R, Kantarjian H, Ravandi F, Daver NG. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol 25(2):136-145, 2018. e-Pub 2018. PMID: 29206680.
Masarova L, Alhuraiji A, Bose P, Daver NG, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol 100(3):257-263, 2018. e-Pub 2018. PMID: 29226426.
DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver NG, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical Experience with the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies. Am J Hematol 93(3):401-407, 2018. e-Pub 2018. PMID: 29218851.
Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver NG, Cortes J, O'Brien S, Kantarjian H, Topp MS. Outcome of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia after Blinatumomab Failure: No Change in the Level of CD19 Expression. Am J Hematol 93(3):371-374, 2018. e-Pub 2018. PMID: 29178361.
Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver NG, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124(6):1160-1168, 2018. e-Pub 2018. PMID: 29266206.
Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver NG, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Borthakur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, DiNardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver NG. A Phase II Trial of Ruxolitinib in Combination with Azacytidine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms. Am J Hematol 93(2):277-285, 2018. e-Pub 2018. PMID: 29134664.
Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget 9(11):9714-9727, 2018. e-Pub 2018. PMID: 29515765.
Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver NG, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2018. PMID: 29047158.
Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, Daver NG, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, Hao Y, Lowder JN, Azab M, Issa JJ. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer 124(2):325-334, 2018. e-Pub 2018. PMID: 29211308.
Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver NG, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93(1):84-90, 2018. e-Pub 2018. PMID: 29027261.
Masarova L, Kantarjian H, Ravandi F, Sharma P, Garcia-Manero G, Daver NG. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. Adv Exp Med Biol 995:97-116, 2018. e-Pub 2018. PMID: 30539507.
Wang W, Routbort MJ, Tang Z, Ok CY, Patel KP, Daver N, Garcia-Manero G, Medeiros LJ, Wang SA. Characterization of TP53 Mutations in Low-Grade Myelodysplastic Syndromes and Myelodysplastic Syndromes with a Non-Complex Karyotype. Eur J Haematol 99(6):536-543, 2017. e-Pub 2017. PMID: 28926144.
Jain N, Lu X, Daver NG, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Concurrent diagnosis of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica 102(12):e514-e517, 2017. e-Pub 2017. PMID: 28860345.
Daver NG Kontoyiannis DP. Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis. Lancet Oncol 18(12):1571-1573, 2017. e-Pub 2017. PMID: 29208429.
Assi R, Kantarjian H, Short NJ, Daver NG, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk 17(12):897-901, 2017. e-Pub 2017. PMID: 28927784.
Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver NG, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience. Am J Hematol 92(12):1295-1302, 2017. e-Pub 2017. PMID: 28850699.
Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer 123(22):4430-4439, 2017. e-Pub 2017. PMID: 28708931.
Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer 123(22):4391-4402, 2017. e-Pub 2017. PMID: 28743165.
Masarova L, Verstovsek S, Kantarjian H, Daver NG. Immunotherapy based approaches in myelofibrosis. Expert Rev Hematol 10(10):903-914, 2017. e-Pub 2017. PMID: 28799436.
Daver NG, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. Haematologica 102(10):1709-1717, 2017. e-Pub 2017. PMID: 28729302.
Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C, Grizzi F, Patrinicola F, Kast WM, Nguyen DD, Rahman RL, Daver NG, Ruvolo P, Post SM, Bresalier RS, Chiriva-Internati M. Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. Oncotarget 8(43):74378-74390, 2017. e-Pub 2017. PMID: 29088794.
Ragon BK, Daver NG, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, Oran B, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Minimal Residual Disease Eradication with Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia. Am J Hematol 92(9):845-850, 2017. e-Pub 2017. PMID: 28494506.
Daver NG, Kantarjian H. FLT3 inhibition in acute myeloid leukaemia. Lancet Oncol 18(8):988-989, 2017. e-Pub 2017. PMID: 28759368.
Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver NG, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv 1(19):1546-1550, 2017. e-Pub 2017. PMID: 29296796.
Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 59:110-116, 2017. e-Pub 2017. PMID: 28601551.
Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver NG, Cortes J, Kantarjian H, Verstovsek S. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 130(9):1125-1131, 2017. e-Pub 2017. PMID: 28674026.
Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver NG, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv 1(17):1312-1323, 2017. e-Pub 2017. PMID: 29296774.
Shah AR, Muzzafar T, Assi R, Schellingerhout D, Estrov Z, Tamamyan G, Kantarjian H, Daver NG. Hemophagocytic lymphohistiocytosis in adults: An under recognized entity. BBA Clin 7:36-40, 2017. e-Pub 2017. PMID: 28070498.
Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res 57:85-88, 2017. e-Pub 2017. PMID: 28324773.
Hust MA, Blechacz BRA, Bonilla DL, Daver NG, Rojas-Hernandez CM. Adult cancer-related hemophagocytic lymphohistiocytosis - a challenging diagnosis: a case report. J Med Case Rep 11(1):172, 2017. e-Pub 2017. PMID: 28651636.
Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver NG, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. Greater than one TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129(18):2584-2587, 2017. e-Pub 2017. PMID: 28246192.
Jabbour E, Daver NG, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. e-Pub 2017. PMID: 28556489.
Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver NG, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation. Am J Hematol 92(4):331-337, 2017. e-Pub 2017. PMID: 28052408.
Naqvi K, Daver NG, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma 58(4):1-6, 2017. e-Pub 2017. PMID: 27494751.
Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, DiNardo C, Daver NG, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents. Am J Hematol 92(4):351-358, 2017. e-Pub 2017. PMID: 28076892.
Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol 92(3):238-243, 2017. e-Pub 2017. PMID: 28006851.
Assi R, Verstovsek S, Daver N. 'Janus kinase-ing' up the treatment of primary myelofibrosis: building better combination strategies. Curr Opin Hematol 24(2):115-124, 2017. e-Pub 2017. PMID: 28072602.
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver NG, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129(10):1275-1283, 2017. e-Pub 2017. PMID: 28003274.
Jabbour E, Faderl S, Sasaki K, Kadia T, Daver NG, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer 123(4):629-637, 2017. e-Pub 2017. PMID: 27741352.
Galloway-Peña JR, Smith DP, Sahasrabhojane P, Wadsworth WD, Fellman BM, Ajami NJ, Shpall EJ, Daver NG, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. Genome Med 9(1):21, 2017. e-Pub 2017. PMID: 28245856.
Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver NG, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer 123(3):426-435, 2017. e-Pub 2017. PMID: 27657543.
Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver NG, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer 123(3):459-467, 2017. e-Pub 2017. PMID: 27696391.
Daver NG, Kantarjian H. Malignancy-associated haemophagocytic lymphohistiocytosis in adults. Lancet Oncol 18(2):169-171, 2017. e-Pub 2017. PMID: 28214404.
Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia. Am J Hematol 92(2):155-160, 2017. e-Pub 2017. PMID: 27874212.
Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver NG. Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias. Am J Hematol 92(1):7-11, 2017. e-Pub 2017. PMID: 27673440.
Masarova L, Kantarjian H, Garcia-Manero G, Ravandi F, Sharma P, Daver NG. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Adv Exp Med Biol 995:73-95, 2017. e-Pub 2017. PMID: 28321813.
Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer 122(23):3650-3656, 2016. e-Pub 2016. PMID: 27479888.
Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver NG, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk 16(11):616-624, 2016. e-Pub 2016. PMID: 27601000.
Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver NG, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer 122(21):3336-3343, 2016. e-Pub 2016. PMID: 27509035.
Daver NG, Konopleva M. Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL. Blood 128(10):1316-7, 2016. e-Pub 2016. PMID: 27609539.
Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer 122(18):2857-66, 2016. e-Pub 2016. PMID: 27244347.
Khan M, Sarfraz M, Daver NG. Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition. Future Oncol. e-Pub 2016. PMID: 27676208.
Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver NG, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - A propensity score analysis. Haematologica 101(8):e324-7, 2016. e-Pub 2016. PMID: 27175025.
Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented berlin-frankfurt-münster (ABFM), in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL), and comparison to the hyper-CVAD regimen. Am J Hematol 91(8):819-23, 2016. e-Pub 2016. PMID: 27178680.
Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. e-Pub 2016. PMID: 27463065.
Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer 122(14):2186-96, 2016. e-Pub 2016. PMID: 27142181.
Daver NG, Ravandi F. Enhancing cytotoxicity of immunotoxins in AML. Blood 127(23):2787-8, 2016. e-Pub 2016. PMID: 27282944.
Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver NG, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol 91(4):385-9, 2016. e-Pub 2016. PMID: 26800008.
Vitale C, Jabbour E, Lu X, Yabe M, Kanagal Shamanna R, Daver NG, Pemmaraju N, Bueso-Ramos CE, Takahashi K. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. Am J Hematol 91(4):E274-6, 2016. e-Pub 2016. PMID: 26798971.
Ouyang J, Goswami M, Peng J, Zuo Z, Daver NG, Borthakur G, Tang G, Medeiros LJ, Jorgensen JL, Ravandi F, Wang SA. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. Am J Clin Pathol 145(6):769-77, 2016. e-Pub 2016. PMID: 27298396.
Jain P, Tang G, Huh YO, Yin CC, Zuo Z, Pemmaraju N, Estrov Z, Daver NG. Philadelphia - positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation. Am J Hematol 91(6):647-8, 2016. e-Pub 2016. PMID: 26799924.
Daver NG, Cortes J, Kantarjian H, Ravandi F. Acute myeloid leukemia: advancing clinical trials and promising therapeutics. Expert Rev Hematol 9(5):433-45, 2016. e-Pub 2016. PMID: 26910051.
Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver NG, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 127(10):1269-75, 2016. e-Pub 2016. PMID: 26729897.
Jain P, Tang G, Konoplev SN, Kanagal-Shamanna R, Wang SA, Pemmaraju N, Daver NG, Estrov Z. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations. Am J Hematol 91(3):354-5, 2016. e-Pub 2016. PMID: 26437693.
Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver NG, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget 7(12):14172-87, 2016. e-Pub 2016. PMID: 26871476.
Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver NG, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk 16(3):152-62, 2016. e-Pub 2016. PMID: 26796981.
Daver NG, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 30(2):268-73, 2016. e-Pub 2016. PMID: 26365212.
Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver NG, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer 122(2):238-48, 2016. e-Pub 2016. PMID: 26479889.
Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver NG, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res 39(12):1367-74, 2015. e-Pub 2015. PMID: 26547258.
Daver NG, Konopleva M. Sorafenib and novel multikinase inhibitors in AML. Lancet Oncol 16(16):1582-3, 2015. e-Pub 2015. PMID: 26549588.
Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver NG, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol 90(11):1065-70, 2015. e-Pub 2015. PMID: 26299958.
Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver NG, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 16(15):1547-55, 2015. e-Pub 2015. PMID: 26432046.
Nazha A, Khoury JD, Rampal RK, Daver NG. Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications. Oncologist 20(10):1154-60, 2015. e-Pub 2015. PMID: 26304912.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver NG, Verstovsek S. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res 39(9):950-6, 2015. e-Pub 2015. PMID: 26183878.
Issa JP, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver NG, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol 16(9):1099-110, 2015. e-Pub 2015. PMID: 26296954.
Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, Daver NG, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes J. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol 2(9):e376-e383, 2015. e-Pub 2015. PMID: 26436130.
Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver NG, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol 90(9):769-73, 2015. e-Pub 2015. PMID: 26017166.
Daver NG, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. Haematologica 100(8):1058-63, 2015. e-Pub 2015. PMID: 26088933.
Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver NG, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol 170(4):590-3, 2015. e-Pub 2015. PMID: 25716073.
Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver NG, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 100(7):927-34, 2015. e-Pub 2015. PMID: 25682597.
Gowin K, Verstovsek S, Daver NG, Pemmaraju N, Valdez R, Kosiorek H, Dueck A, Mesa R. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. Leuk Res 39(7):684-8, 2015. e-Pub 2015. PMID: 25922307.
DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver NG, Routbort M, Patel KP, Brandt M, Pierce S, Kantarjian H, Garcia-Manero G. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. e-Pub 2015. PMID: 26228814.
Daver NG, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res 21(12):2704-14, 2015. e-Pub 2015. PMID: 25724525.
Ouyang J, Goswami M, Tang G, Peng J, Ravandi F, Daver NG, Routbort M, Konoplev S, Lin P, Medeiros LJ, Jorgensen JL, Wang SA. The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. Am J Hematol 90(6):504-10, 2015. e-Pub 2015. PMID: 25732229.
Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver NG, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J. Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(6):358-63, 2015. e-Pub 2015. PMID: 25630528.
Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, Daver NG, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce S, Cortes J, Ravandi F. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leuk Lymphoma 56(5):1-4, 2015. e-Pub 2015. PMID: 25120050.
Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver NG, Jain P, Pierce S, Kantarjian H, Cortes JE. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2(5):e186-93, 2015. e-Pub 2015. PMID: 26688093.
Daver NG, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Haematologica 100(5):653-61, 2015. e-Pub 2015. PMID: 25682595.
Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver NG, Woodman K. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol 122(2):391-8, 2015. e-Pub 2015. PMID: 25666482.
Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver NG, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol 90(4):276-81, 2015. e-Pub 2015. PMID: 25530214.
Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver NG, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research Consortium. Cancer 121(6):876-82, 2015. e-Pub 2015. PMID: 25410759.
Daver NG, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol 168(5):646-53, 2015. e-Pub 2015. PMID: 25312977.
Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver NG, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15(2):110-4, 2015. e-Pub 2015. PMID: 25107338.
Daver NG, Verstovsek S. Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. Leuk Lymphoma 56(2):279-80, 2015. e-Pub 2015. PMID: 24913500.
Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver NG, Kadia T, Teng A, Kantarjian H. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma 56(2):390-4, 2015. e-Pub 2015. PMID: 24844364.
Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver NG, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol 90(2):120-4, 2015. e-Pub 2015. PMID: 25368968.
DiNardo CD, Daver NG, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol 2(1):e12-20, 2015. e-Pub 2015. PMID: 26687423.
Daver NG, Cortes J. The changing face of acute myeloid leukemia therapeutics in the elderly population. South Asian J Cancer 4(1):1-2, 2015. e-Pub 2015. PMID: 25839008.
Pemmaraju N, Sasaki K, Johnson D, Daver NG, Afshar-Kharghan V, Chen M, Ahmed S, Colen RR, Kwon M, Huh Y, Borthakur G. Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. Front Oncol 5:29, 2015. e-Pub 2015. PMID: 25717439.
Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer 120(23):3660-8, 2014. e-Pub 2014. PMID: 25042398.
Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver NG, Cortes J, Kantarjian H, Verstovsek S. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res 38(10):1212-6, 2014. e-Pub 2014. PMID: 25217891.
Quintás-Cardama A, Daver NG, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 14(5):401-10, 2014. e-Pub 2014. PMID: 24875590.
Daver NG, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res 38(9):1126-9, 2014. e-Pub 2014. PMID: 25047979.
Shah DR, Daver NG, Borthakur G, Hirsch-Ginsberg C, Oo TH. Pernicious anemia with spuriously normal vitamin B12 level might be misdiagnosed as myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk 14(4):e141-3, 2014. e-Pub 2014. PMID: 24630920.
Geethakumari PR, Hoffmann MS, Pemmaraju N, Hu S, Jorgensen JL, O'Brien S, Daver NG. Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge. Clin Lymphoma Myeloma Leuk 14(4):e115-8, 2014. e-Pub 2014. PMID: 24589157.
Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver NG, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma 55(6):1337-44, 2014. e-Pub 2014. PMID: 24004182.
Daver NG, Naqvi K, Jabbour E, Kadia T, DiNardo C, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol 89(5):509-16, 2014. e-Pub 2014. PMID: 24458781.
DiNardo CD, Daver NG, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia 28(4):958-61, 2014. e-Pub 2014. PMID: 24492324.
Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver NG, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk 14(2):163-71, 2014. e-Pub 2014. PMID: 24461514.
Ghanem H, Garcia-Manero G, Faderl S, Ravandi F, Cortes J, Katragadda L, O'Brien S, Daver NG, Pierce S, Kadia T, Kantarjian H, Jabbour E. Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Ther Adv Hematol 5(2):29-34, 2014. e-Pub 2014. PMID: 24688752.
Jabbour E, Daver NG, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol 89(4):395-8, 2014. e-Pub 2014. PMID: 24375514.
Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver NG, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28(4):973-5, 2014. e-Pub 2014. PMID: 24157581.
Sasaki K, Pemmaraju N, Westin JR, Wang WL, Khoury JD, Podoloff DA, Moon B, Daver NG, Borthakur G. A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine. Front Oncol 4:297, 2014. e-Pub 2014. PMID: 25401088.
Pemmaraju N, Chang E, Daver NG, Patel K, Jorgensen J, Sabloff B, Verstovsek S, Borthakur G. Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature. Front Oncol 4:130, 2014. e-Pub 2014. PMID: 24918086.
Daver NG, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res 37(11):1440-4, 2013. e-Pub 2013. PMID: 23890523.
Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver NG, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia. Am J Hematol 88(11):961-6, 2013. e-Pub 2013. PMID: 23877926.
Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver NG, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 27(10):2081-3, 2013. e-Pub 2013. PMID: 23774633.
Daver NG, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. A phase II Open-label Study of the Intravenous Administration of Homoharringtonine in the treatment of Myelodysplastic syndrome. Eur J Cancer Care (Engl) 22(5):605-11, 2013. e-Pub 2013. PMID: 23701251.
Strati P, Daver NG, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S276-81, 2013. e-Pub 2013. PMID: 23969309.
Daver NG, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk 13(4):435-40, 2013. e-Pub 2013. PMID: 23763915.
Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver NG, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23):4655-62, 2013. e-Pub 2013. PMID: 23613521.
Daver NG, O'Brien S. Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia - A Focus on Emerging Monoclonal Antibodies. Curr Hematol Malig Rep 8(2):123-31, 2013. e-Pub 2013. PMID: 23539383.
Bhamidipati PK, Jabbour E, Konoplev S, Estrov Z, Cortes J, Daver NG. Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine. Clin Lymphoma Myeloma Leuk 13(3):342-6, 2013. e-Pub 2013. PMID: 23246163.
Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver NG, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia 27(4):836-42, 2013. e-Pub 2013. PMID: 23135353.
Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver NG, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol 88(3):198-200, 2013. e-Pub 2013. PMID: 23345254.
Daver NG, Nazha A, Kantarjian HM, Haltom R, Ravandi F. Treatment of hairy cell leukemia during pregnancy: Are purine analogues and rituximab viable therapeutic options. Clin Lymphoma Myeloma Leuk 13(1):86-9, 2013. e-Pub 2013. PMID: 22981963.
Borthakur G, Rosenblum MG, Talpaz M, Daver NG, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 Study of Anti-CD33 Immunotoxin HUM-195/rGEL in Patients with Advanced Myeloid Malignancies. Haematologica 98(2):217-21, 2013. e-Pub 2013. PMID: 22875630.
Daver NG, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 88(1):56-9, 2013. e-Pub 2013. PMID: 23115106.
Lee HJ, Daver NG, Kantarjian HM, Verstovsek S, Ravandi F. The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia. Clin Cancer Res 19(2):327-35, 2013. e-Pub 2013. PMID: 23209034.
Nazha A, Cortes J, Faderl S, Pierce S, Daver NG, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating mutations of the FMS-like tyrosine kinase-3 internaltandem duplication (FLT3-ITD) at complete response and relapsein patients with acute myeloid leukemia. Haematologica 97(8):1242-5, 2012. e-Pub 2012. PMID: 22532519.
Shastri A, Daver NG, Hayes TG. Primary gastric chorioadenocarcinoma: a needle in a haystack. Rare Tumors 3(2):e19, 2011. e-Pub 2011. PMID: 21769318.
Tanaka MF, Daver NG, Rice L. Romiplostim: Therapeutic Value in Chronic Immune Thrombocytopenic Purpura. Clinical Medical Insights: Therapeutics(2):499-511, 2010. e-Pub 2010.
Livorsi DJ, Daver NG, Atmar RL, Shelburne SA, White AC, Musher DM. Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect 57(2):128-31, 2008. e-Pub 2008. PMID: 18562009.
Daver NG, Shelburne SA, Atmar RL, Giordano TP, Stager CE, Reitman CA, White AC. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. The Journal of Infection 54(6):539-44, 2007. e-Pub 2007. PMID: 17198732.
del la Garza Y, Graviss EA, Daver NG, Gambarin KJ, Shandera WX, Schantz PM, White AC. Epidemiology of neurocysticercosis in Houston, Texas. American Journal Tropical Medicine and Hygiene 73(4):766-70, 2005. e-Pub 2005. PMID: 16222023.
Daver GB, Bakhshi GD, Patil A, Ellur S, Jain M, Daver N. Bifid liver in a patient with diaphragmatic hernia. Indian J Gastroenterol 24(1):27-8, 2005. e-Pub 2005. PMID: 15778526.
Joshi SR, Butala N, Patwardhan MR, Daver NG, Kelkar D. Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy. J Assoc Physicians India 52(1):597- 598, 2004. e-Pub 2004. PMID: 15645995.
Shastri A, Daver NG, Hayes T. A rare case of Gastric Chorio - adenocarcinoma. Rare tumors 2011.
Bhamidipati P, Jabbour E, Konoplev S, Estrov Z, Cortes JE, Daver NG. EBV Induced CD30 Positive Diffuse Large B-Cell Lymphoma in a Mixed Phenotypic Leukemia patient treated with Clofarabine. Clinical Lymphoma, Myeloma & Leukemia.
Chen Y, Kantarjian H, Pierce S, Faderl S, O' Brien S, Qian W, Abruzzo L, De Lima M, Kebriaaei P, Jabbour E, Daver NG, Kadia T, Garcia-Manero G, Cortes JE, Ravandi F. Prognostic Significance of 11q23 Cytogenetic Abnormalities in Adult Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation. Blood.

Invited Articles

Daver NG, Cortes J. Molecular targeted therapy in Acute Myeloid Leukemia. Hematology 17 Suppl 1:S59-62, 2012. e-Pub 2012. PMID: 22507781.

Review Articles

Senapati, J, Kadia, TM, Daver, NG, DiNardo, C, Borthakur, G, Ravandi-Kashani, F, Kantarjian, HM. Therapeutic horizon of acute myeloid leukemia. Cancer 131(7), 2025. e-Pub 2025. PMID: 40105906.
Wei, A, Loo, S, Daver, NG. How I treat patients with AML using azacitidine and venetoclax. Blood 145(12):1237-1250, 2025. e-Pub 2025. PMID: 39316723.
Goulart, H, Kantarjian, HM, Pemmaraju, N, Daver, NG, DiNardo, C, Rausch, CR, Ravandi-Kashani, F, Kadia, TM. Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia. Blood cancer discovery 6(1):23-37, 2025. e-Pub 2025. PMID: 39565177.
Kantarjian, HM, DiNardo, C, Kadia, TM, Daver, NG, Altman, JK, Stein, EM, Jabbour, EJ, Schiffer, CA, Lang, A, Ravandi-Kashani, F. Acute myeloid leukemia management and research in 2025. Ca-A Cancer Journal for Clinicians 75(1):46-67, 2025. e-Pub 2025. PMID: 39656142.
Aakash, F, Gisriel, SD, Zeidan, AM, Bennett, JM, Bejar, R, Bewersdorf, J, Borate, U, Boultwood, J, Brunner, AM, Buckstein, R, Carraway, H, Churpek, JE, Daver, NG, Dezern, A, Efficace, F, Fenaux, P, Figueroa, ME, Garcia-Manero, G, Gore, SD, Greenberg, PL, Griffiths, EA, Halene, S, Hourigan, CS, Kim, TK, Kim, N, Komrokji, RS, Kutchroo, V, List, A, Little, R, Majeti, R, Nazha, A, Nimer, SD, Odenike, O, Padron, E, Patnaik, MM, Platzbecker, U, Della Porta, M, Roboz, G, Sallman, D, Santini, V, Sanz, G, Savona, MR, Sekeres, MA, Stahl, M, Starczynowski, DT, Steensma, DP, Taylor, J, Abdel-Wahab, O, Wei, A, Xie, Z, Xu, M, Hasserjian, RP, Loghavi, S. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Modern Pathology 37(12), 2024. e-Pub 2024. PMID: 39322118.
Kantarjian, H, Borthakur, G, Daver, N, DiNardo, CD, Issa, GC, Jabbour, EJ, Kadia, TM, Sasaki, K, Short, NJ, Yilmaz, M, Ravandi, F. Current status and research directions in acute myeloid leukemia. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39300079.
Shahzad, M, Amin, MK, Daver, NG, Shah, MV, Hiwase, DK, Arber, DA, Kharfan-Dabaja, MA, Badar, T. What have we learned about TP53-mutated acute myeloid leukemia?. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39562552.
Shahzad, M, Amin, MK, Daver, N, Shah, MV, Hiwase, DK, Arber, DA, Kharfan-Dabaja, MA, Badar, T. What have we learned about TP53-mutated acute myeloid leukemia?. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39562552.
Komrokji, RS, Lanino, L, Ball, S, Bewersdorf, J, Marchetti, M, Maggioni, G, Travaglino, E, Al Ali, NH, Fenaux, P, Platzbecker, U, Santini, V, Díez-Campelo, M, Singh, A, Jain, AG, Aguirre, LE, Tinsley-Vance, SM, Schwabkey, Z, Chan, OY, Xie, Z, Brunner, AM, Kuykendall, A, Bennett, JM, Buckstein, R, Bejar, R, Carraway, H, Dezern, A, Griffiths, EA, Halene, S, Hasserjian, RP, Lancet, JE, List, A, Loghavi, S, Odenike, O, Padron, E, Patnaik, MM, Roboz, G, Stahl, M, Sekeres, MA, Steensma, DP, Savona, MR, Taylor, J, Xu, M, Sweet, KL, Sallman, D, Nimer, SD, Hourigan, CS, Wei, A, Garcia-Manero, G, Daver, NG, Wang, S. Data-driven, harmonised classification system for myelodysplastic syndromes. The Lancet Haematology 11(11):e862-e872, 2024. e-Pub 2024. PMID: 39393368.
Cuglievan, B, Kantarjian, HM, Rubnitz, JE, Cooper, T, Zwaan, CM, Pollard, J, DiNardo, C, Kadia, TM, Guest, E, Short, NJ, McCall, DC, Daver, NG, Nunez, CA, Haddad, FG, Garcia, MB, Bhalla, K, Maiti, A, Catueno, S, Fiskus, WC, Carter, BZ, Gibson, A, Roth, M, Khazal, SJ, Tewari, P, Abbas, HA, Bourgeois, W, Andreeff, M, Shukla, N, Truong, D, Connors, JS, Ludwig, JA, Stutterheim, J, Salzer, E, Juul-Dam, KL, Sasaki, K, Mahadeo, KM, Tasian, SK, Borthakur, G, Dickson, S, Jain, N, Jabbour, EJ, Meshinchi, S, Garcia-Manero, G, Ravandi, F, Stein, EM, Kolb, EA, Issa, GC. Menin inhibitors in pediatric acute leukemia. Leukemia 38(10):2073-2084, 2024. e-Pub 2024. PMID: 39179671.
Jen WY, Kantarjian H, Kadia TM, DiNardo CD, Issa GC, Short NJ, Yilmaz M, Borthakur G, Ravandi F, Daver NG. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease. Br J Haematol 205(1):30-47, 2024. e-Pub 2024. PMID: 38724457.
Stahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev 62:101128, 2023. e-Pub 2023. PMID: 37704469.
Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J, Garces S, Quesada AE, Roth M, Garcia M, McCall D, Gibson A, Ragoonanan D, Petropoulos D, Tewari P, Nunez C, Mahadeo KM, Tasian SK, Lamble AJ, Pawlowska A, Hammond D, Maiti A, Haddad FG, Senapati J, Daver NG, Gangat N, Konopleva M, Meshinchi S, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 37(9):1767-1778, 2023. e-Pub 2023. PMID: 37452102.
Shallis RM, Daver NG, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žucenka A, Zeidan AM. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. Lancet Haematol 10(9):e767-e776, 2023. e-Pub 2023. PMID: 37572683.
Bewersdorf JP, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, Porta MGD, DeZern AE, Fenaux P, Figueroa ME, Gore SD, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim TK, Komrokji R, Kuchroo VK, List AF, Loghavi S, Majeti R, Odenike O, Patnaik MM, Platzbecker U, Roboz GJ, Sallman DA, Santini V, Sanz G, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Xu ML, Savona MR, Wei AH, Zeidan AM. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Rev 60:101072, 2023. e-Pub 2023. PMID: 36934059.
Daver NG, Iqbal S, Renard C, Chan RJ, Hasegawa K, Hu H, Tse P, Yan J, Zoratti MJ, Xie F, Ramsingh G. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. J Hematol Oncol 16(1):19, 2023. e-Pub 2023. PMID: 36879351.
Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, Garcia-Manero G, Craddock C, Sallman DA, Kantarjian HM. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov 12(11):2516-2529, 2022. e-Pub 2022. PMID: 36218325.
El Hussein S, Daver NG, Liu JL, Kornblau S, Fang H, Konoplev S, Kantarjian H, Khoury JD. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. Clin Lymphoma Myeloma Leuk 22(6):e386-e391, 2022. e-Pub 2022. PMID: 34980577.
Desikan SP, Daver NG, DiNardo C, Kadia T, Konopleva M, Ravandi F. Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer J 12(6):91, 2022. e-Pub 2022. PMID: 35680852.
Saxena K, DiNardo C, Daver NG, Konopleva M. Harnessing Apoptosis in AML. Clin Lymphoma Myeloma Leuk 22(3):133-139, 2022. e-Pub 2022. PMID: 34602371.
Senapati J, Daver NG, Pemmaraju N. Antibody-Drug Conjugates in Myeloid Leukemias. Cancer J 28(6):454-461, 2022. e-Pub 2022. PMID: 36383908.
Kantarjian H, Short NJ, DiNardo C, Stein EM, Daver NG, Perl AE, Wang ES, Wei A, Tallman M. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematol 8(12):e922-e933, 2021. e-Pub 2021. PMID: 34687602.
Daver N, Alotaibi AS, Bücklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia 35(7):1843-1863, 2021. e-Pub 2021. PMID: 33953290.
Daver NG, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J 11(5):104, 2021. e-Pub 2021. PMID: 34045454.
Daver NG. Immune checkpoint inhibitors in acute myeloid leukemia. Best Pract Res Clin Haematol 34(1):101247, 2021. e-Pub 2021. PMID: 33762102.
Kantarjian H, Kadia T, DiNardo C, Daver NG, Borthakur G, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F. Acute myeloid leukemia: current progress and future directions. Blood Cancer J 11(2):41, 2021. e-Pub 2021. PMID: 33619261.
Venugopal S, Daver NG, Ravandi F. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia. Curr Hematol Malig Rep 16(1):89-96, 2021. e-Pub 2021. PMID: 33630233.
Cerchione C, Romano A, Daver NG, DiNardo C, Jabbour EJ, Konopleva M, Ravandi-Kashani F, Kadia T, Martelli MP, Isidori A, Martinelli G, Kantarjian H. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. Front Oncol 11:639387, 2021. e-Pub 2021. PMID: 33898313.
Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver NG, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol 144(2):1-13, 2021. e-Pub 2021. PMID: 32392559.
Isidori A, Cerchione C, Daver NG, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Romano A, Loscocco F, Visani G, Martinelli G, Kantarjian H, Curti A. Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Front Oncol 11:656218, 2021. e-Pub 2021. PMID: 34041025.
Pasvolsky O, Daher M, Alatrash G, Marin D, Daver NG, Ravandi F, Rezvani K, Shpall E, Kebriaei P. CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. Front Oncol 11:800110, 2021. e-Pub 2021. PMID: 35083154.
Koshy AG, Daver NG, Fathi AT. A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition. Best Pract Res Clin Haematol 33(4):101220, 2020. e-Pub 2020. PMID: 33279176.
Konopleva M, Martinelli G, Daver NG, Papayannidis C, Wei A, Higgins B, Ott M, Mascarenhas J, Andreeff M. MDM2 inhibition: an important step forward in cancer therapy. Leukemia 34(11):2858-2874, 2020. e-Pub 2020. PMID: 32651541.
Daver NG, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J 10(10):107, 2020. e-Pub 2020. PMID: 33127875.
Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, Daver NG. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discov. e-Pub 2020. PMID: 32014868.
Samra B, Konopleva M, Isidori A, Daver NG, DiNardo C. Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. Front Oncol 10:562558, 2020. e-Pub 2020. PMID: 33251134.
Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol 94(7):803-811, 2019. e-Pub 2019. PMID: 30945331.
Daver NG, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33(2):299-312, 2019. e-Pub 2019. PMID: 30651634.
Oran B, Daver NG. Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword. Biol Blood Marrow Transplant 25(1):e1-e2, 2019. e-Pub 2019. PMID: 30500441.
Short NJ, Kantarjian H, Ravandi F, Daver NG. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol 10:2040620719827310, 2019. e-Pub 2019. PMID: 30800259.
Daver NG, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J, Kantarjian H. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 32(5):1094-1105, 2018. e-Pub 2018. PMID: 29487386.
Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver NG, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47-62, 2018. e-Pub 2018. PMID: 28925994.
Daver NG, McClain K, Allen CE, Parikh SA, Otrock Z, Rojas-Hernandez C, Blechacz B, Wang S, Minkov M, Jordan MB, La Rosée P, Kantarjian HM. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer 123(17):3229-3240, 2017. e-Pub 2017. PMID: 28621800.
Otrock ZK, Daver NG, Kantarjian HM, Eby CS. Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis. Clin Lymphoma Myeloma Leuk 17S:S105-S110, 2017. e-Pub 2017. PMID: 28760295.
Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, Daver NG, Ohanian M, Kantarjian H, Konopleva M. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol 110:20-34, 2017. e-Pub 2017. PMID: 28109402.
Alatrash G, Daver NG, Mittendorf EA. Targeting Immune Checkpoints in Hematologic Malignancies. Pharmacol Rev 68(4):1014-1025, 2016. e-Pub 2016. PMID: 27664133.
Nazha A, Khoury JD, Verstovsek S, Daver NG. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?. Crit Rev Oncol Hematol 105:112-7, 2016. e-Pub 2016. PMID: 27401783.
Daver NG, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian H. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood 125(21):3236-45, 2015. e-Pub 2015. PMID: 25795921.

Abstracts

Daver NG, Montesinos P, Aribi A, Marconi G, Altman JK, Wang E, Roboz G, Burke P, Gaidano G, Walter R, Thomas X, Jeyakumar, D DeAngelo D, Erba H, Todisco E, Begna K, Advani A, Gastaud L, De La Fuente A, Curti A, Mendez L, Vyas P, Boissel N, Vey N, Recher C, Longval T, Platzbecker U, Kapp-Schwoerer S, Schliemann C, Konopleva M, Torres L, Sallman D, Marcucci G, Pemmaraju N, Martinelli G, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Sweet K. Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). American Society of Hematology Annual Meeting, 2022. e-Pub 2022.
Daver NG. Let’s Talk: Community Perspectives on Acute Myeloid Leukemia and Myelodysplastic Syndrome. American Society of Hematology Annual Meeting, 2022. e-Pub 2022.
Daver NG, Senapati J, Maiti A, Loghavi S, Kadia T, DiNardo CD, Pemmaraju N, Jabbour E, Montalban-Bravo G, Tang G, Sasaki K, Borthakur G, Yilmaz M, Alvarez J, Pierce S, Nogueras González G, Ning J, Issa G, Andreeff M, Abbas H, Ravandi F, Garcia-Manero G, Kantarjian H. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. American Society of Hematology Annual Meeting, 2022. e-Pub 2022.
Popat UR, Bassett R, Thall PF, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver NG, Ravandi F, Shpall EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Blood 138(Supp. 1), 2021. e-Pub 2021.
Daver NG, Aribi A, Montesinos P, Roboz GJ, Wang ES, Walter RB, JeyakumarD, DeAngelo DJ, Erba HP, Advani A, Burke PW, Martinelli G, Gastaud L, Thomas X, Altman JK, Mendez LM, de la Fuente A, Todisco E, Gaidano G, Curti A, Boissel N, Recher C, Schliemann C, Sloss CM, WangJ, Malcolm KE, Zweidler-McKay PA, Sweet K. A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Pemmaraju N, Marconi G, Todisco E, Montesinos P, Lane AA, Sweet K, Wang ES, Deconinck E, Rizzieri DA, Walter RB, Aribi A, Lebon D, Levy MY, Mazzarella L, Martinelli G, Gigli F, Erba HP, Acuña-Cruz E, Konopleva M, Kantarjian H, Sloss CM, Wang J, Malcolm KE, Zweidler-McKay PAZ, DeAngelo DJ, Daver NG. A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 138(Supp. 1), 2021. e-Pub 2021.
Daver NG, Konopleva M, Maiti A, Kadia TM, DiNardo CD, Loghavi S, Pemmaraju N, Jabbour E, Montalban-Bravo G, Tang G, Sasaki K, Borthakur G, Yilmaz M, Alvarez J, Golez M, Pierce SA, González GMN, Ning J, Abbas HA, Ravandi F, Garcia-Manero G, Kantarjian H. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. Blood 138(Supp. 1), 2021. e-Pub 2021.
Venugopal S, Issa GC, Konopleva M, DiNardo CD, Borthakur G, Jabbour EJ, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce SA, Takahashi K, Tang G, Loghavi S, Andreeff M, Bhalla KN, Garcia-Manero G, Ravandi F, Kantarjian H, Daver NG. NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). Blood 138(Supp. 1), 2021. e-Pub 2021.
Skwarska A, Moujalled DM, Panis PF, Patel S, Zhang Q, Herbrich S, Kurvilla V, Baran N, Pomilio G, Halilovic E, Mistry P, Ruvolo V, Ruvolo PP, Derréal A, Banquet S, Niemira M, Kretowski A, Daver NG, Andreeff M, Wei AH, Konopleva M. Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and In Vivo. Blood 138(Supp. 1), 2021. e-Pub 2021.
Nishida Y, Ishizawa J, Ayoub E, Patsilevas T, Ostermann L, Montoya RH, Muftuoglu M, Ruvolo V, Mak PY, Tao W, Carter BZ, Kojima K, Daver NG, Lesegretain A, Seki T, Shacham S, Konopleva M, Andreeff M. Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML. Blood 138(Supp. 1), 2021. e-Pub 2021.
Short NJ, Kantarjian H, Ravandi F, Huang X, Jain N, Kadia TM, Khoury JD, Jorgensen JL, Wang SA, Alvarado Y, Burger JA, Daver NG, Borthakur G, DiNardo CD, Konopleva M, Pemmaraju NP, Garcia-Manero G, Wierda WG, Kornblau SM, Jacob J, Kwari M, Rausch CR, Loiselle C, Milton A, Rivera J, Garris R, O'Brien SM, Jabbour EJ. Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Yilmaz M, Muftuoglu M, Kantarjian H, DiNardo CD, Kadia TM, Konopleva M, Borthakur G, Pemmaraju N, Short NJ, Alvarado Y, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike AM, Loghavi S, Patel K, Tang G, Matthews JA, Kornblau SM, Jabbour EJ, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver NG. Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. Blood 138(Supp. 1), 2021. e-Pub 2021.
Rivera D, Kadia TM, Montalban-Bravo G, Faderl S, Sasaki K, Short NJ, Daver NG, DiNardo CD, Masarova L, Ferrajoli A, Jabbour EJ, Borthakur G, Al Azzawi H, Konopleva M, Garcia-Manero G, Andreeff M, Kantarjian H, Ravandi F, Alvarado Y. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood 138(Supp. 1), 2021. e-Pub 2021.
Fiskus WC, Mill CP, Birdwell C, Davis JA, Salazar A, Philip K, Kadia TM, DiNardo CD, Takahashi K, McGeehan GM, Daver NG, Bhalla KN. Preclinically Effective Menin Inhibitor SNDX-50469 and SNDX-5613-Based Combinations Against MLL1-Rearranged (MLL-r) or NPM1-Mutant AML Models. Blood 138(Supp. 1), 2021. e-Pub 2021.
Mohamed SF, Abuasba T, Chien KS, Montalban-Bravo G, Darbaniyan F, Pierce SA, Soltysiak KA, Haddad F, DMcCall D, Cuglievan B, Jabbour EJ, Daver NG, Kadia TM, Pemmaraju N, Kantarjian H, Garcia-Manero G. Characteristics and Outcomes of Adolescent and Young Adult (AYA) Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML): A Single-Center Retrospective Analysis. Blood 138(Supp. 1), 2021. e-Pub 2021.
Trabal A, Gibson A, McCall D, Mahadeo KM, Toepfer L, Roth ME, Buzbee M, Kadia TM, Garces S, Konopleva M, DiNardo CD, Daver NG, Short NJ, Issa GC, Ravandi F, Nunez C, Khazal SJ, Paek H, Brackett J, Garcia-Manero G, Kantarjian H, Marcogliese AN, Dreyer Z, Redell MS, Yi JS, Stevens AM, Cuglievan B. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Collaboration. Blood 138(Supp. 1), 2021. e-Pub 2021.
Venugopal S, Jabbour EJ, Pemmaraju N, Montalban-Bravo G, Chien KS, Daver NG, Jain J, Burger JA, Alvarado Y, Maiti A, DiNardo CD, Borthakur G, Malla R, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Phase II Study of Lower-Intensity Frontline Therapy for Newly Diagnosed Patients with AML Who Are Unfit or Otherwise Not Eligible for Frontline Clinical Trials. Blood 138(Supp. 1), 2021. e-Pub 2021.
Becker MN, Howson A, Quill TA, Daver NG, Stein EM. Practice Gaps and Barriers in Optimal Care Among Healthcare Providers Treating Patients with Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): Results of a Two-Phase Qualitative/Quantitative Study. Blood 138(Supp. 1), 2021. e-Pub 2021.
Chang KH, Basyal M, Alaniz Z, Honma D, Tsutsumi S, Dos Santos CE, Daver NG, Andreeff M. Targeting EZH1/2 to Restore Chemosensitivity in Dormant Myeloid Leukemia Stem Cells. Blood 138(Supp. 1), 2021. e-Pub 2021.
Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Borthakur G, Jabbour EJ, Daver NG, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Kwari M, Kantarjian H, Short NJ. A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation. Blood 138(Supp. 1), 2021. e-Pub 2021.
Reville PK, Kantarjian H, Borthakur G, Pemmaraju N, DiNardo CD, Sasaki K, Daver NG, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Bhalla KN, Jabbour EJ, Ferrajoli A, Takahashi K, Rausch CR, Malla M, Marek K, Brandt M, Popat UR, Andreeff M, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 138(Supp. 1), 2021. e-Pub 2021.
Jain N, Jabbour EJ, Konopleva M, Pemmaraju N, Thompson PA, Short NJ, Kadia TM, Borthakur G, Daver NG, DiNardo CD, Aldoss I, Cook R, Ravandi F, Kantarjian H. A Phase 1 Trial of Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory CD22+ B-Cell Acute Lymphoblastic Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Vyas P, Daver NG, Chao M, Xing G, Renard C, Ramsingh G, Wei AH, Sallman DA. A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Venugopal S, Jabbour EJ, Pemmaraju N, Montalban-Bravo G, Chien KS, Daver NG, Jain N, Burger JA, Alvarado Y, Maiti A, DiNardo CD, Borthakur G, Malla R, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Phase II Study of Lower-Intensity Frontline Therapy for Newly Diagnosed Patients with AML Who Are Unfit or Otherwise Not Eligible for Frontline Clinical Trials. Blood 138(Supp. 1), 2021. e-Pub 2021.
Daver NG, Perl AE, Maly J, Levis M, Ritchie E, Litzow MR, McCloskey J, Smith CC, Schiller GJ, Bradley T, Tiu RV, Naqvi K, Dail M, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Pemmaraju N, Marconi G, Todisco E, Montesinos P, Lane AA, Sweet K, Wang ES, Deconinck E, Rizzieri DA, Walter RB, Aribi A, Lebon D, Levy MY, Mazzarella L, Martinelli G, Gigli G, Erba HP, Acuña-Cruz E, Konopleva M, Kantarjian H, Sloss CM, Wang J, Malcolm KE, Zweidler-McKay PA, DeAngelo DJ, Daver NG. A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 138(Supp. 1), 2021. e-Pub 2021.
Abuasab T, Kantarjian H, Garcia-Manero G, Montalban-Bravo G, Alvarado Y, Yilmaz M, Pemmaraju N, Chien KS, Mohamed SF, Daver NG, Kornblau SM, Burger JA, Jain N, Islam R, Courtney D DiNardo CD, Borthakur G, Ravandi F, Kadia TM. Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML). Blood 138(Supp. 1), 2021. e-Pub 2021.
Venugopal S, Chien KS, Hammond D, Kanagal-Shamanna R, Sasaki K, Kadia TM, DiNardo CD, Konopleva M, Daver N, Ravandi F, Pemmaraju N, Short NJ, Issa GC, Takahashi K, Estrov ZE, Pierce SA, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents. Blood 138(Supp. 1), 2021. e-Pub 2021.
Desikan SP, Ravandi F, Naveen Pemmaraju N, Konopleva M, Loghavi S, Borthakur G, Jabbour EJ, Daver NG, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Kwari M, Kantarjian H, Short NJ. A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation. Blood 138(Supp. 1), 2021. e-Pub 2021.
Jia Y, Zhang Q, Weng C, Ramage CL, Nishida Y, Chao M, Maute RL, Herbrich S, Zhang W, Andreeff M, Daver NG, Konopleva M. Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML Pre-Clinical Models. Blood 138(Supp. 1), 2021. e-Pub 2021.
Bazinet A, Jabbour EJ, Kantarjian H, Chien KS, DiNardo CD, Ohanian M, Daver NG, Kanagal-Shamanna R, Kadia TM, Takahashi K, Masarova L, Short NJ, Alvarado Y, Thompson PA, Montalban-Bravo G, Yilmaz M, Ravandi F, Kornblau SM, Pemmaraju N, Schneider H, Mirabella B, Naqvi K, Garcia-Manero G. A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 138(Supp. 1), 2021. e-Pub 2021.
Muftuoglu M, Li L, Basyal M, Liang S, Ball CJ, Chen K, Kumar P, Lesegretain A, Daver NG, Andreeff M. Single-Cell Proteomics Identifies Leukemia Landscape Associated with Clinical Outcomes in R/R AML Treated with MDM2i (Milademetan) and FLT3i (Quizartinib): Putative Role of CD68 and Diversity Index. Blood 138(Supp. 1), 2021. e-Pub 2021.
Venugopal S, Kantarjian H, Maiti A, Short NJ, Montalban-Bravo G, Alvarado Y, Chien KS, Kanagal-Shamanna R, Pemmaraju N, Daver NG, Kadia TM, Borthakur G, Jabbour EJ, Garcia-Manero G. A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment‐Naïve High‐Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 138(Supp. 1), 2021. e-Pub 2021.
Kim K, Kantarjian H, Borthakur G, Takahashi K, Short NJ, DiNardo CD, Jabbour EJ, Chien KS, Daver N, Pemmaraju N, Jain N, Adewale L, Montalban-Bravo G, Wierda WG, Verstovsek S, Konopleva M, Ravandi F, Kadia TM. A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 138(Supp. 1), 2021. e-Pub 2021.
Haddad F, Kantarjian H, Short NJ, Konopleva M, Jain N, Ravandi F, Daver NG, Alvarado Y, Takahashi K, Garcia-Manero G, Velasquez M, Garris R, Jabbour EJ. A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Daver N, Konopleva M, Maiti A, Kadia TM, DiNardo CD, Loghavi S, Pemmaraju N, Jabbour EJ, Montalban-Bravo G, Tang G, Sasaki K, Borthakur G, Yilmaz M, Alvarez J, Golez M, Pierce SA, González GMN, Ning J, Abbas HA, Ravandi F, Garcia-Manero G, Kantarjian H. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. Blood 138(Supp. 1), 2021. e-Pub 2021.
Hammond D, Kadia TM, DiNardo CD, Konopleva M, Short NJ, Daver NG, Ravandi F, Pemmaraju N, Jabbour EJ, Chien KS, Pierce SA, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Daver NG, Affinito J, Cai H, Dobrowolska H, Dow E, Eguchi K, Song G, Stoudemire J, Watanbe A, Komarnitsky P. Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia ( MLL )-Rearrangement or Nucleophosmin 1 ( NPM1 ) Mutation. Blood 138(Supp. 1), 2021. e-Pub 2021.
Maiti A, DiNardo CD, Daver NG, Kadia TM, Borthakur G, Short NJ, Pemmaraju N, Ohanian M, Alvarado Y, Takahashi K, Pierce SA, Patel KP, Jabbour EJ, Garcia-Manero G, Ravandi F, Kantarjian H, Konopleva M. Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax. Blood 138(Supp. 1), 2021. e-Pub 2021.
Davis JA, Fiskus WC, Daver N, Mill CP, Birdwell C, Salazar A, Philip K, Kadia TM, DiNardo CD, Leoni M, Burrows F, Bhalla KN. Clinical-Stage Menin Inhibitor KO-539 Is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A-r and NPM1-Mutant AML Models. Blood 138(Supp. 1), 2021. e-Pub 2021.
Lachowiez C, DiNardo CD, Morita K, Furudate K, Wang F, Tanaka T, Wang SA, Kadia TM, Daver NG, Short NJ, Khoury JD, Patel K, Medeiros LJ, Konopleva M, Ravandi F, Takahashi K, Loghavi S. Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML. Blood 138(Supp. 1), 2021. e-Pub 2021.
Mohamed SF, Assi R, Ning J, Xiao L, Jabbour EJ, Pemmaraju N, Kadia TM, Jain N, DiNardo CD, Yilmaz M, Maiti A, Issa GC, Short NJ, Bose P, Masarova L, Garcia-Manero G, Ravandi F, Konopleva M, Kantarjian H, Daver N. Characteristics and Outcomes of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Single-Center, Prospective Analysis. Blood 138(Supp. 1), 2021. e-Pub 2021.
Daver NG, Lee KH, Jung CW, Yoon SS, Arellano ML, Yoon J, Lee N, Kim H, Lee J, Jonas BA, Baek S. First in Human (FIH) FLT3 and SYK Inhibitor HM43239 Shows Single Agent Activity in Patients (pts) with Relapsed or Refractory (R/R) FLT3 Mutated and Wild-Type Acute Myeloid Leukemia (AML). Blood 138(Supp. 1), 2021. e-Pub 2021.
Curtis Lachowiez C, DiNardo CD, Morita K, Furudate K, Wang F, Tanaka T, Wang SA, Kadia TM, Daver NG, Short NJ, Khoury JD, Patel K, Medeiros LJ, Konopleva M, Ravandi F, Takahashi K, Loghavi S. Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML. Blood 138(Supp. 1), 2021. e-Pub 2021.
Pemmaraju N, Bhalla KN, Daver NG, Wilson NR, Fiskus WC, Ravandi F, Garcia-Manero G, Kadia TM, DiNardo CD, Jabbour EJ, Burger JA, Short NJ, Alvarado Y, Jain N, Masarova L, Verstovsek S, Issa GC, Qiao W, Khoury JD, Pierce SA, Miller D, Konopleva M, Kantarjian H, Borthakur G. Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood 138(Supp. 1), 2021. e-Pub 2021.
Daver NG Aribi A, Montesinos P, Roboz GJ, Wang ES, Walter RB, Jeyakumar D, DeAngelo DJ, Erba HP, Advani A, Burke PW, Martinelli G, Gastaud L, Thomas X, Altman JK, Mendez LM, de la Fuente A, Todisco E, Gaidano G, Curti A, Boissel N, Recher C, Schliemann C, Konopleva M, Sallman DA, Torres L, Marcucci G, Kantarjian H, Sloss CM, Malcolm KE, Zweidler-McKay PA, Sweet K. Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Short NJ, DiNardo CD, Daver NG, Nguyen D, Yilmaz M, Kadia TM, Garcia-Manero G, Issa GC, Huang X, Qiao W, Sasaki K, Montalban-Bravo G, Chien KS, Borthakur G, Delumpa R, Milton A, Pierce SA, Jabbour EJ, Konopleva M, Kantarjian H, Ravandi F. A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. Blood 138(Supp. 1), 2021. e-Pub 2021.
Daver NG, Aribi A, Montesinos P, Roboz GJ, Wang ES, Walter RB, Jeyakumar D, DeAngelo DJ, Erba HP, Advani A, Burke PW, Martinelli G, Gastaud L, Thomas X, Altman JK, Mendez LM, de la Fuente A, Todisco E, Gaidano G, Curti A, Boissel N, Recher C, Schliemann C, Konopleva M, Sallman DA, Torres L, Marcucci G, Kantarjian H, Sloss CM, Malcolm KE, Zweidler-McKay PA, Sweet K. Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Maiti A, DiNardo CD, Rausch CR, Pemmaraju N, Garcia-Manero G, Ohanian M, Daver NG, Issa GC, Borthakur G, Ravandi F, Alvarado Y, Kadia TM, Short NJ, Jabbour EJ, Montalban-Bravo G, Jain N, Kornblau SM, Masarova L, Wierda WG, Sasaki K, Takahashi K, Yilmaz M, Burger JA, Estrov ZE, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson PA, Montalbano K, Vaughan K, Bivins CA, Pierce SA, Qiao W, Ning J, Welch J, Kantarjian H, Konopleva M. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. Blood 138(Supp. 1), 2021. e-Pub 2021.
Haddad F, Kantarjian H, Short NJ, Sasaki K, Ravandi F, Kebriaei P, Huang X, Jain N, Konopleva M, Garcia-Manero G, Champlin RE, Kadia TM, Takahashi K, Daver NG, Khoury JD, Jorgensen JL, Wang SA, Jacob J, Garris R, O'Brien SM, Jabbour EJ. Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Reville PK, Kantarjian H, Borthakur G, Pemmaraju N, DiNardo CD, Sasaki K, Daver N, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Bhalla KN, Jabbour EJ, Ferrajoli A, Takahashi K, Rausch CR, Malla R, Marek K, Brandt M, Popat UR, Andreeff M, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 138(Supp. 1), 2021. e-Pub 2021.
Kadia TM, Pemmaraju N, Yilmaz M, Daver NG, Li L, Lyu M, Huang M, Zeng K, Cook R, Parmar S, Mukherjee S, Sadeghi T, DiNardo CD, Issa GC, Jabbour EJ, Borthakur G, Jain N, Verstovsek S. Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Improves Transfusion Requirement in Bone Marrow Failure Syndromes. Blood 138(Supp. 1), 2021. e-Pub 2021.
Lachowiez C, DiNardo CD, Takahashi K, Loghavi S, Xiao LC, Kadia TM, Daver NG, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa GC, Maiti A, Alvarado Y, Pemmaraju N, Montalban-Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau SM, Ravandi F, Jabbour EJ, Konopleva M, Kantarjian H. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Desikan SPP, Montalban-Bravo G, Ohanian M, Daver NG, Yilmaz M, Konopleva M, Kadia TM, Venugopal S, Schneider H, Chien KS, Kanagal-Shamanna R, Kantarjian H, Garcia-Manero G. A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS). Blood 138(Supp. 1), 2021. e-Pub 2021.
Haddad F, Kantarjian H, Short NJ, Konopleva M, Jain N, Ravandi F, Daver NG, Alvarado Y, Takahashi K, Garcia-Manero G, Velasquez M, Garris R, Jabbour EJ. A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Yilmaz M, Muftuoglu M, Kantarjian H, DiNardo CD, Kadia TM, Konopleva M, Borthakur G, Pemmaraju N, Short NJ, Alvarado Y, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike AM, Loghavi S, Patel K, Tang G, Matthews JA, Kornblau SM, Jabbour EJ, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver NG. Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. Blood 138(Supp. 1), 2021. e-Pub 2021.
Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour EJ, Alvarado Y, Chien KS, Pemmaraju N, Takahashi K, Short NJ, Issa GC, Jain N, Ferrajoli A, Burger JA, Linderman DB, Daver NG, DiNardo CD, Konopleva M, Garcia-Manero G, Sasaki K, Ravandi F, Kadia TM. A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission. Blood 138(Supp. 1), 2021. e-Pub 2021.
Pemmaraju N, Martinelli G, Todisco E, Lane AA, Acuña-Cruz E, Deconinck E, Wang ES, Sweet K, Rizzieri DA, Marconi G, Mazzarella L, DeAngelo DJ, Montesinos P, Gigli F, Erba HP, Konopleva M, Kantarjian H, Walter RB, Aribi A, Lebon D, Levy MY, Sloss CM, Malcolm KE, Zweidler-McKay PA, Daver NG. Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 138(Supp. 1), 2021. e-Pub 2021.
Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver NG, Kadia TM, DiNardo CD, Jabbour EJ, Pierce SA, Villarreal J, Qazilbash MH, Konopleva M, Kantarjian H. Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy. Blood 138(Supp. 1), 2021. e-Pub 2021.
Desikan SP, Kantarjian H, DiNardo CD, Borthakur G, Daver NG, Pemmaraju N, Alvarado Y, Burger JA, Linderman DB, Pierce SA, Ravandi F, Garcia-Manero G, Kadia TM. A Phase I/II Study of Sapacitabine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Daver NG, Affinito J, Cai H, Dobrowolska H, Dow E, Eguchi K, Song G, Stoudemire J, Watanbe A, Komarnitsky P. Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia ( MLL )-Rearrangement or Nucleophosmin 1 ( NPM1 ) Mutation. Blood 138(Supp. 1), 2021. e-Pub 2021.
Daver NG, Vyas P, Chao M, Xing G, Renard C, Ramsingh G, Sallman DA, Wei AH. A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53 -Mutant Acute Myeloid Leukemia. Blood 138(Supp. 1), 2021. e-Pub 2021.
Short NJ, Montalban-Bravo G, Alvarado Y, Konopleva M, Jabbour EJ, Garcia-Manero G, Yilmaz M, Jain N, Borthakur G, DiNardo CD, Daver NG, Issa GC, Ohanian M, Pemmaraju N, Sasaki K, Maiti A, Chien KS, Ravandi F, Kadia TM, Andreeff M, Muftuoglu M, Delumpa R, Bose P, Pierce SA, Waller L, Banks G, Kantarjian H, Cortes JE. Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. Blood 138(Supp. 1), 2021. e-Pub 2021.
Venugopal S, Kantarjian H, Maiti A, Short NJ, Montalban-Bravo G, Alvarado Y, Chien KS, Kanagal-Shamanna R, Pemmaraju N, Daver NG, M Kadia T, Borthakur G, Jabbour EJ, Garcia-Manero G. A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment‐Naïve High‐Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 138(Supp. 1), 2021. e-Pub 2021.
Oran B, Garcia-Manero G, Saliba RM, Alatrash G, Jabbour EJ, Popat U, Ravandi F, Kadia TM, Cortes JE, Alousi AM, Konopleva MY, DiNardo CD, Rezvani K, Alfayez M, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, and Daver NG. Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. Blood 132(483), 2018. e-Pub 2018.
Daver NG, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Kadia TM, Konopleva MY, Jabbour EJ, DiNardo CD, Assi R, Pierce SA, Alvarado Y, Estrov ZE, Pemmaraju N, Takahashi K, Ning J, Nogueras González GM, Kornblau SM, Alfayez M, Matthews J, Flores W, Blando J, Allison JP, Sharma P, M Kantarjian AH. Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. Blood 132(906), 2018. e-Pub 2018.
Alfayez M, Kantarjian HM, Ravandi F, Konopleva MY, Garcia-Manero G, Kadia TM, Jabbour EJ, Borthakur G, DiNardo CD, Estrov ZE, Pemmaraju N, Pierce SA, Yilmaz ME, Short NJ, Takahashi K, Assi R, Andreeff M, Cortes JE, and Daver NG. Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. Blood 132(663), 2018. e-Pub 2018.
Daver NG, Pollyea DA, Garcia JS, Jonas BA, Yee KW, Fenaux P, Assouline S, Vey N, Olin R, Roboz GJ, Tafuri A, Visani G, Kirschbrown W, Green C, Ma C, Dail M, Wang J, Ott MG, Mobasher M, Phuong P, Hong W, Konopleva MY, Andreeff AM. Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. Blood 132(767), 2018. e-Pub 2018.
Daver NG, Kremyanskaya M, O'Connell C, Dao K, Oh ST, Gerds AT, Verstovsek S, Erickson-Viitanen S, Zhou F, Assad A, Yacoub AA. A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis. Blood 132(353), 2018. e-Pub 2018.
Masarova L, Verstovsek S, Cortes JE, Pemmaraju N, Bose P, Ohanian MN, Zhou L, Pierce SA, Gergis R, Borthakur G, Estrov ZE, Garcia-Manero G, Kantarjian HM, and Daver NG. Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis. Blood 132(352), 2018. e-Pub 2018.
Daver NG, Erba HP, Papadantonakis N, DeAngelo DJ, Wang ES, Konopleva MY, Sloss CM, Culm-Merdek K, Zweidler-McKay PA, M Kantarjian AH. A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies. Blood 132(27), 2018. e-Pub 2018.
Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Mareno G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis. Haematologica 101(8):e324-e327, 2016. e-Pub 2016.
Daver N, Ravandi F. Enhancing cytotoxicity of immunotoxins in AML. Blood 127(23):2787-2788, 2016. e-Pub 2016.
Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Shamanna RK, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O’Brien S, Cortes J. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127(10):1269-1275, 2016. e-Pub 2016.
Issa GC, Kantarjian HM, Jabbour E, Borthakur G, Verstovsek S, Pierce S, Wierda W, Ferrajoli A, Garcia-Manero G, Kadia T, Daver N, Pemmaraju N, Ravandi F, DelaSala SE, Cortes JE. Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia. Blood 126(23):823, 2015. e-Pub 2015.
Kadia T, Cortes JE, Jabbour E, Daver N, Pemmaraju N, Ravandi F, Jain N, Verstovsek S, DiNardo C, Alvarado Y, Ferrajoli A, Burger JA, Garcia-Manero G, Ohanian M, Konopleva M, Estrov Z, Wierda W, Brandt M, Fitch T, Borthakur G, Kantarjian H. Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). Blood 126(23):2541, 2015. e-Pub 2015.
Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Pemmaraju N, Vaughan K, Pierce S, Konopleva M, Kadia T, DiNardo C, Borthakur G, Cortes JE, Craig AR, Ravandi F. Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood 126(23):461, 2015. e-Pub 2015.
Short NJ, Garcia-Manero G, Bravo GM, Sasaki K, Sekeres MA, Komrokji RS, Steensma D, DeZern AE, Roboz G, Kadia T, Borthakur G, DiNardo C, Miller D, Estrov Z, Pemmaraji N, Daver N, Verstovsek S, Kantarjian H, Jabbour E. Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate- 1 Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium. Blood 126(23):94, 2015. e-Pub 2015.
Short NJ, Kantarjian H, Jabbour E, O'Brien S, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia T, Daver N, Borthakur G, Cortes JE, Ravandi F. Persistance of Cytogenetic Abnormalities at Complete Remission Is No Prognostic for Relapse-Free or Overall Survival in Adult Patients with Acute Lymphoblastic Leukemia. Blood 126(23):1416, 2015. e-Pub 2015.
Pemmaraju N, Kantarjian HM, Cortes JE, Duvic M, Khoury JD, Patel K, Daver N, O'Brien S, Pierce S, Garcia-Manero G, Jabbour E, Jain N, Faderl S, Thomas D, Frankel AE, Qazilbash MH, Konopleva M. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characterists and Patient Outcomes. Blood 126(23):3746, 2015. e-Pub 2015.
Ragon BK, Daver N, Garcia-Manero G, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Fusion Transcript Reduction in Core Binding Factor Acute Myeloid Leukemia: Maintenance Strategy with Hypomethylating Agents. Blood 126(23):2604, 2015. e-Pub 2015.
Chahoud J, Kantarjian HM, Garcia-Manero G, Sasaki K, Kadia T, Cortes JE, Khouri MR, Ravandi F, Dahl J, Ferrajoli A, Jacob J, Pemmaraju N, Daver N, Garris R, Jabbour E. Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin. Blood 126(23):1298, 2015. e-Pub 2015.
Navada SC, Silverman LR, Hearn KP, Odchimar-Reissig R, Demakos EP, Alvarado Y, Daver N, DiNardo C, Konopleva M, Borthakur G, Pemmaraju N, Kadia T, Fenaux P, Fruchtman S, Azarnia N, Garcia-Manero G. A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS). Blood 126(23):910, 2015. e-Pub 2015.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Daver N, Verstovsek S. Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients with Myeloproliferative Neoplasm in Blastic Phase/Acute Myeloid Leukemia (MPN-AML), Accelerated Phase (MPN-AP), and DIPSS-Plus High Risk Primary Myelofibrosis (PMF). Blood 124(21):3186, 2015. e-Pub 2015.
Sasaki K, Koller PB, Kantarjian HM, Thomas DA, Khouri MR, Garcia-Manero G, Garris R, Cortes JE, Schroeder H, Chahoud J, Kadia T, Ravandi F, Verstovsek S, Daver N, Jain N, Konopleva M, O'Brien S, Jabbour E. Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood 126(23):1295, 2015. e-Pub 2015.
Zhang W, Ishizawa J, Mu H, Daver N, Ruvolo V, Andreff M. Combinatorial Targeting of XPO1 and FLT3-ITD Exerts Synergistic Anti-Tumor Effects in FLT3-Mutated Acute Myeloid Leukemias. Blood 126(23):1266, 2015. e-Pub 2015.
Takahashi K, Kantarjian HM, Patel K, Bueso-Ramos CE, Kadia T, Jabbour E, DiNardo C, Daver N, Pierce S, Futreal A, Garcia-Manero G. TP53 Mutated MDS Patients Respond Equally to Hypomethylating Agents but Have Significantly Shorter Response Duration Compared to Patients with Wild Type TP53. Blood 126(23):1681, 2015. e-Pub 2015.
Han L, Zhang Q, Shi C, Leverson J, Dail M, Phillips DC, Chen J, Jin SS, Jacamo RO, Daver N, Jabbour EJ, Kantarjian HM, Andreeff M, Sampath D, Konopleva M. Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models. Blood 126(23):2544, 2015. e-Pub 2015.
Jain PL, Sasaki K, Kantarjian H, Ravandi F, Cortes JE, Garcia-Manero G, Bose P, Daver N, Kadia T, Verstovsek S, Konopleva M, Jain N, Montalban GB, Pierce S, Jabbour E. Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure. Blood 126(23):3718, 2015. e-Pub 2015.
Ravandi F, Cortes JE, Garcia-Manero G, Estey E, Borthakur G, Jabbour EJ, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, Kornblau SM, Kadia T, Daver N, DiNardo C, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, Kantarjian H. Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoci Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin. Blood 126(23):3776, 2015. e-Pub 2015.
Koller PB, Sasaki K, Ravandi F, Garcia-Manero G, O'Brien S, Cortes JE, Kadia T, Borthakur G, Pemmaraju N, Daver N, Chahoud J, Pike A, Brandt M, Pierce S, Kantarjian HM, Jabbour E. Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial. Blood 126(23):2508, 2015. e-Pub 2015.
Takahashi K, Wang F, Sahil S, Zhang J, Gumbs C, Issa GC, Benton CB, Pierce S, Jabbour E, Daver N, Kadia T, DiNardo C, Kantarjian HM, Futreal A, Garcia-Manero G. Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS. Blood 126(23):1663, 2015. e-Pub 2015.
DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Wei Y, Wierda WG, Bueso-Ramos CE, Patel KP, Cortes JE, Ravandi F, Kantarjian H, Garcia-Manero G. A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood 124(21):164, 2015. e-Pub 2015.
Daver N, Garcia-Manero G, Cortes JE, Zhou L, Pierce S, Pemmaraju N, Jabbour E, DiNardo C, Kadia T, Borthakur G, Ravandi F, Konopleva M, Wynn F, Derbur SV, Estrov Z, Kantarjian H, Verstovsek S. 5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloprliferative Neoplasms (MDS/MPNs). Blood 126(23):823, 2015. e-Pub 2015.
Akosile M, Pierce S, Brandt M, Verstovsek S, Borthakur G, Kantarjian H, Ravandi F, Wierda W, Garcia-Manero G, Daver N, Kadia T, Burger JA, Pemmaraju N, Jabbour E, Cortes JE. Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI). Blood 126(23):1587, 2015. e-Pub 2015.
Kantarjian H, Jabbour E, Garcia-Manero G, Kadia T, DiNardo C, Daver N, Borthakur G, Jain N, Waukau J, Kwari M, Anderson BD, Lizuka K, Jin C, Plunkett W. Results of a Phase I/II Study of DFP- 10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia. Blood 126(23):3804, 2015. e-Pub 2015.
Pantetta JC, Baker SD, Kantarjian H, Stewart C, Pond B, Macaraeg M, Makinde T, Vali S, Daver N, Ramachandran A, Collins R, Cortes JE. Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML. Blood 126(23):3695, 2015. e-Pub 2015.
Kadia T, Cortes JE, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour EJ, Bhalla KN, Konopleva M, Daver N, DiNardo C, Bose P, Patel KP, Pierce S, Kantarjian HM. Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia. Blood 126(23):564, 2015. e-Pub 2015.
Montalban-Bravo G, Garcia-Manero G, Short NJ, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Kadia T, Borthakur G, DiNardo C, Miller D, Estrov Z, Pemmaraju N, Daver N, Konopleva M, Cortes JE, Kantarjian HM, Jabbour E. Impact of Cytogenetic Abnormalties and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS). Blood 126(23):2877, 2015. e-Pub 2015.
Tamamyan G, Borthakur G, Cortes JE, Ravandi F, Jabbour E, Daver N, Pemmaraju N, Ohanian M, Kolomansky A, Todisco G, Shi C, Pierce S, Peng S, Konopleva M, Kantarjian H, Kadia T. Prognostic Score for Adults with Acute Myeloid Leukemia in First Complete Remission. Blood 126(23):3850, 2015. e-Pub 2015.
Ravandi F, Jeffrey JL, Jabbour EJ, Borthakur G, Kadia T, Faderl S, Pierce S, Brandt M, Wang SA, Konoplev S, Daver N, Pemmaraju N, Garcia-Manero G, Andreeff M, Konopleva M, Cortes JE, Kantarjian HM. Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is a Strong Predictor of Outcome in Younger Patients with Acute Myeloid Leukemia. Blood 126(23):2579, 2015. e-Pub 2015.
Abaza Y, Kantarjian HM, Borthakur G, Daver N, Ravandi F, Chihara D, Verstovsek S, Burger JA, Estrov Z, Ohanian M, Jabbour E, Cortes JE. An Open-label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML). Blood 126(23):1589, 2015. e-Pub 2015.
Montalban-Bravo G, Kantarjian HM, Jain PL, Garcia-Manero G, Ravandi F, Cortes JE, Daver N, Takahashi K, Jain N, Verstovsek S, Kadia T, Pierce S, Jabbour E. Outcome of Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (ALL) and Isolated Central Nervous System (CNS) Relapse. Blood 126(23):2503, 2015. e-Pub 2015.
Birendra KC, Kantarjian HM, Garcia-Manero G, Daver N, Borthakur G, Konopleva M, Andreeff M, Chihara D, Kadia T, Bose P, Estrov Z, Pemmaraju N, Ravandi F, Cortes JE. Prognostic Significance of Somatic Mutations in Treatment of AML in Salvage Setting: A Retrospective Analysis. Blood 126(23):1313, 2015. e-Pub 2015.
Jain P, Kantarjian HM, Jabbour E, Estrov Z, Borthakur G, Pemmaraju N, Kadia T, Daver N, Ravandi F, Verstovsek S, O'Brien S, Cortes JE. Outcomes of Patients with Chronic Phase CML Who Discontinued Ponatinib in the Frontline Setting. Blood 126(23):1580, 2015. e-Pub 2015.
Masarova L, Daver N, Pemmaraju N, Bose P, Pierce S, Manshouri T, Cortes JE, Kantarjian HM, Verstovsek S. Do Patients with Post-Essential Thrombocythemia and Post-Polycythemia Vera Differ from Patients with Primary Myelofibrosis. Blood 126(23):4069, 2015. e-Pub 2015.
Daver NG, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, DiNardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 2015. e-Pub 2015. PMID: 26365212.
Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in Combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica 100(8):1058-1063, 2015. e-Pub 2015.
Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II Study of the Hypoxia-Activated Prodrg PR104 In Refractory/Relapsed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. Haematologica 100(7):927-934, 2015. e-Pub 2015.
Daver N. First-in-human study of FLX925, an orally administered FLT3/CDK4/CDK6 inhibitor, in subjects with relapsed or refractory acute myeloid leukemia (AML). 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
Daver N, Kantarjian HM, Pierce S, Brandt M, Dinardo CD, Pemmaraju N, Vaughan K, Garcia-Manero G, Jabbour E, Borthakur G, Kadia TM, Cortes JE, Craig A, Ravandi F. Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 100(5):623-661, 2015. e-Pub 2015.
Gowin KL, Verstovsek S, Daver N, Pemmaraju N, Valdez R, Kosiorek H, Dueck AC, Mesa RA. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
Sasaki K, Kantarjian HM, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Jain P, Pierce S, Rios MB, Cortes JE. Propensity score analysis: Frontline therapy with high-dose (HD) imatinib vs. 2nd generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in chronic phase. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
Badar T, Luthra R, Kantarjian HM, Jabbour E, Borthakur G, Daver NG, Huang X, Singh R, Alvarez B, Morrison T, Cortes JE. New tool for monitoring molecular response in chronic myeloid leukemia. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
Kantarjian HM, Jabbour E, Garcia-Manero G, Kadia TM, Dinardo CD, Daver N, Borthakur G, Jain N, Waukau J, Kwari M, Anderson BD, Iizuka K, Jin C, Plunkett W. First report of a phase I/II study of DFP-10917, a nucleoside analog, given by continuous infusion (CI) in patients (pts) with relapsed or refractory acute leukemia. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
Chae YK, Dimou A, Takahashi K, Benton CB, Jabbour E, Ravandi F, Borthakur G, Cortes JE, Kadia TM, Thomas DA, Wierda WG, Daver N, Dinardo CD, Kantarjian HM, Garcia-Manero G. Effect of vorinostat use on survival in patients with acute myeloid leukemia (AML) with FLT3 ITD mutations. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
Daver N, De Lima MJ, Kantarjian H, Ravandi F, Bilen MA, Pierce S, Khouri IF, Dorkhom SJ, Giralt S, Garcia-Manero G, Nazha A, Mathisen M, Pemmaraju N, Cortes JE, Faderl S, Jabbour E. Allogenic stem cell transplant (ASCT) as initial salvage for patients (pts) with acute myeloid leukemia (AML) refractory to high-dose cytarabine-based induction chemotherapy. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
Daver N, Konopleva M, Kohrt HE, Fridman JS, Johnson D, Jaen JC, Kantarjian HM, Cortes JE. First-in-human stuty of FLX925, an orally administered FLT3/CDK4/DCK6 inhibitor, in subjects with relapsed or refractory acute myeloid leukemia (AML). 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
Daver N, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian H. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood 125(21):3236-3245, 2015. e-Pub 2015.
George B, Jabbour E, Cabrero M, Jain N, Daver N, Ravandi F, Borthakur G, Bohannan Z, Cortes JE, Keating MJ, O'Brien S, Kantarjian HM, Garcia-Manero G. Retrospective Analysis of Survival in Patients with Acute Erythroid Leukemia (AML-6) Treated with Conventional Chemotherapy Versus Hypomethylating Agents. Blood 124(21):2278, 2014. e-Pub 2014.
Daver N, Cortes JE, Jabbour E, Pemmaraju N, Jain N, Estrov Z, Kornblau SM, Burger JA, Kantarjian HM, Newberry KJ, Verstovsek S. Ruxolitinib and Lenalidomide As a Combination Therapy for Patients with Myelofibrosis. Blood 124(21):1831, 2014. e-Pub 2014.
Patel K, Routbort M, Noguera-Gonzalez G, Kantarjian HM, Jabbour E, Borthakur G, DiNardo CD, Estrov Z, Daver N, Wierda W, Jain N, O'Brien S, Konopleva M, Cortes JE, Pemmaraju N, Alvarado Y, Bueso-Ramos CE, Luthra R, Singh R, Pierce S, Medirios L, Bohannan Z, Huang X, Garcia-Manero G. Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes. Blood 124(21):4658, 2014. e-Pub 2014.
Sasaki K, Jabbour E, Pemmaraju N, Daver N, Kadia TM, DiNardo CD, Pierce S, Borthakur G, Kantarjian HM, Garci-Manero G. Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes). Blood 124(21):1922, 2014. e-Pub 2014.
Jain P, Kantarjian HM, Jabbour E, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau SM, Ravandi F, O'Brien S, Cortes JE. Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood 124(21):4535, 2014. e-Pub 2014.
Cabrero M, Jabbour E, Daver N, Borthakur G, DiNardo CD, Cortes JE, Bohannan Z, Sukholutsky V, Ravandi F, Pierce S, Kadia T, Pemmaraju N, Kantarjian HM, Garcia-Manero G. Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up. Blood 124(21):4664, 2014. e-Pub 2014.
Garcia-Manero G, Huang X, Cabrero M, DiNardo CD, Pemmaraju N, Daver N, Borthakur G, Wierda WG, Kadia T, Alvarado Y, Cortes JE, Jain N, Ravandi F, Jabbour E, Brandt M, Sneed T, Sukholutsky V, Pierce S, Bohannan Z, Kantarjian HM. A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities. Blood 124(21):3277, 2014. e-Pub 2014.
Navado SC, Garcia-Manero G, Wilhelm F, Hearn K, Odchimar-Reissig R, Demakos EP, Alvarado Y, Daver N, DiNardo CD, Konopleva M, Borthakur G, Azarnia N, Silverman LR. A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Blood 124(21):3252, 2014. e-Pub 2014.
Jabbour E, Sasaki K, Daver N, Pemmaraju N, DiNardo CD, Kadia T, Miller D, Sukholutsky V, Huang X, Borthakur G, Estrov Z, Kantarjian HM, Garcia-Manero G. Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low-or Intermediate-1 Risk Myelodysplastic Syndrome (MDS). Blood 124(21):4640, 2014. e-Pub 2014.
Pemmaraju N, Kantarjian HM, O'Brien S, Borthakur G, Ravandi F, Verstovsek S, Daver N. Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). Blood 124(21):4565, 2014. e-Pub 2014.
Cabrero M, Garcia-Manero G, Sasaki K, Daver N, Borthakur G, DiNardo CD, Cortes JE, Bohannan Z, Sukholutsky V, Ravandi F, Pierce S, Kadia TM, Pemmaraju N, Oran B, Champlin RE, Kantarjian H, Jabbour E. Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. Blood 124(21):4666, 2014. e-Pub 2014.
DiNardo CD, Aung FM, Martinez F, Daver N, Kadia T, Jain N, Jabbour E, Pemmaraju N, Reddy VM, Garcia-Manero G, Cortes J, Ravandi F, Kantarjian HM, Lichtiger B, Freireich EJ. A Phase II Feasibility Study of Prophylactic White Cell Transfusions for the Preventio of Infection in AML Patients Undergoing Induction Therapy. Blood 124(21):1564, 2014. e-Pub 2014.
Gowin KL, Dueck AC, Verstovsek S, Daver N, Pemmaraju N, Valdez R, Mesa RA. The Clinical Phenotype of Patients with Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis Whom Only Manifest WHO Grade 1 Fibrosis. Blood 124(21):3208, 2014. e-Pub 2014.
Daver N, Kantarjian HM, Garcia-Manero G, Pemmaraju N, Kadia TM, DiNardo CD, Jain N, Borthakur G, Jabbour E, Konopleva M, Cortes JE, Craig A, Ravandi F. Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood 124(21):385, 2014. e-Pub 2014.
Jabbour E, Sasaki K, Daver N, Pemmaraju N, Jain N, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Faderl SH, O'Brien S, Cortes J, Kantarjian H, Garcia-Manero G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. Blood 124(21):534, 2014. e-Pub 2014.
Jabbour E, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, SeZern AE, Gail RJ, Daver N, Pemmaraju N, Kadia T, DiNardo CD, Wang X, Nogueras-Gonzalez G, Borthakur G, Estov Z, Kantarjian HM, Garcia-Manero G. Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium. Blood 124(21):4641, 2014. e-Pub 2014.
Badar T, Thompson PA, George B, Daver N, Borthakur G, Cortes JE, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour E, Ravandi F, Kantarjian H, Patel KP, Luthra R, Sukholutsky V, Garcia-Manero G. Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications. Blood 124(21):4631, 2014. e-Pub 2014.
Randhawa JK, Jabbar KJ, Kadia T, Borthakur G, Pemmaraju N, Daver N, Kantarjian HM, Cortes JE, Hearn K, Bueso-Ramos CI, Garcia-Manero G. Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low - or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-kB Activation. Blood 124(21):1930, 2014. e-Pub 2014.
Matre P, Shariati M, Velez J, Qi Y, Konoplev S, Su X, DiNardo CD, Daver N, Majeti R, Andreeff M, Chan SM, Konopleva M. Efficacy of Novel Glutaminase Inhibitor CB-839 in Acute Myeloid Leukemia. Blood 124(21):3763, 2014. e-Pub 2014.
Kadia T, Borthakur G, Ferrajoli A, Daver N, Jabbour E, Pemmaraju N, Verstovsek S, Burger JA, Wierda WG, Konopleva M, DiNardo CD, Jain N, Brandt M, Tuttle C, Wang X, Ravandi F, Garcia-Manero G, Cortes JE, Kantarjian HM. Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). Blood 124(21):3671, 2014. e-Pub 2014.
Hu CW, Qutub AA, Qiu Y, Yoo SY, Zhang N, Daver N, Ohanian M, Coombes K, Kornblau SM. Adhesion Signaling States in AML. Blood 124(21):2386, 2014. e-Pub 2014.
Borthakur G, Kantarjian HM, O'Brien S, Garcia-Manero G, Jabbour E, Daver N, Kadia T, Gborogen R, Konopleva M, Andreeff M, Ravandi F. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood 124(21):388, 2014. e-Pub 2014.
Randhawa JK, Kantarjian HM, Borthakur G, Thompson PA, Konopleva M, Daver N, Pemmaraju N, Jabbour E, Kadia TM, Estrov Z, Ramachandran A, Paradela J, Andreef M, Levis M, Ravandi F, Cortes JE. Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations. Blood 124(21):389, 2014. e-Pub 2014.
Daver N, Kantarjian HM, O'Brien S, Jabbour E, Pierce S, Lim M, Borthakur G, Pemmaraju N, Konopleva M, DiNardo CD, Ravandi F, Garcia-Manero G, Cortes JE. Frequency and Impact of Molecular Response's with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)- Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). Blood 124(21):3156, 2014. e-Pub 2014.
Badar T, Kantarjian HM, O'Brien S, Garcia-Manero G, Jabbour E, Garris R, Pemmaraju N, Daver N, Ravandi F, Cortes J, Thomas DA. Clinical Outcome of De Novo Adult Acute Lymphoblastic Leukemia (ALL) with 11q23/Mixed Lineage Leukemia (MLL) Gene Rearrangements. Blood 124(21):5342, 2014. e-Pub 2014.
Thomas DA, O'Brien S, Rytting M, Ravandi F, Jabbour E, Ferrajoli A, Estrov Z, Garcia-Manero G, Burger JA, Wierda W, Konopleva M, Andreeff M, Kornblau SM, Verstovsek S, Borthakur G, Kadia T, Garris R, Pemmaraju N, Daver N, Jain N, Cortes J, Kantarjian HM. Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL). Blood 124(21):940, 2014. e-Pub 2014.
Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Pierce SR, Kantarjian HM, Cortes JE. Chronic Myeloid Leukemia in Chronic Phase: Survival in the Era of Tyrosine Kinase Inhibitors Is Similar to That of the General Population in All Age Groups. Blood 124(21):1801, 2014. e-Pub 2014.
Thompson PA, Keating MJ, Hinojosa C, Smith SC, Daver N, Jain N, Burger JA, Estrov Z, O'Brien S, Wierda WG, Kantarjian HM, Ferrajoli A. Lenalidomide and Rituximab in Combination As Initial Treatement of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study. Blood 124(21):1988, 2014. e-Pub 2014.
Duque AD, Cabrero M, Ravandi F, Pemmaraju N, Borthakur G, Kantarjian HM, Cortes JE, Kadia TM, Daver N, Jabbour E, Garcia-Manero G, Sasaki K. Long-Term Outcome of Chronic Myelomonocytic Leukema (CMML) Patients Treated with Hypomethylating Agents (HMA: A Single-Institution Experience. Blood 124(21):1924, 2014. e-Pub 2014.
Badar T, Kantarjian HM, Borthakur G, Garcia-Manero G, Andreef M, Konopleva M, Kadia TM, Daver N, Wierda WG, Ravandi F, Cortes JE. Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade. Blood 124(21):949, 2014. e-Pub 2014.
Jain N, Ravandi F, Garcia-Manero G, Borthakur G, Kadia T, Jabbour E, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Pike A, Bivins C, Pierce S, O'Brien S, Cortes JE, Kantarjian HM. Phase I-II Study of Sequential Therapy with Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) regimen) in Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood 124(21):5283, 2014. e-Pub 2014.
Garcia-Manero G, Ritchie EK, Walsh K, Savona M, Kropf P, O'Connell C, Tibes R, Daver N, Jabbour E, Lunin S, Rosenblat TL, Yee K, Stock W, Griffiths EA, Mace JR, Podoltsev NA, Berdeja JG, Issa J, Chung W, Naim S, Taverna P, Hao Y, Azab M, Kantarjian HM, Roboz GJ. First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 124(21):529, 2014. e-Pub 2014.
Kadia TM, Cortes JE, Borthakur G, Garcia-Manero G, Jabbour E, Ferrajoli A, Verstovsek S, Ravandi F, Pemmaraju N, Daver NG, Konopleva M, Wang X, Kantarjian HM. Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML. 2014 ASCO Annual Meeting, 2014. e-Pub 2014.
Pemmaraju N, Thomas DA, Kantarjian HM, Cortes JE, Khoury J, Manning JT, Medeiros L, O'Brien SM, Daver NG, Pierce S, Garcia-Manero G, Jabbour E, Jain N, Qazilbash MH, Faderl S, Frankel AE, Konopleva M. Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes. 2014 ASCO Annual Meeting, 2014. e-Pub 2014.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Daver NG, Verstovsek S. Decitabine therapy for myeloproliferative neoplasm in accelerated (MPN-AP) or blastic (acute myeloid leukemia; MPN-AML) phase. 2014 ASCO Annual Meeting, 2014. e-Pub 2014.
Andreeff M, Borthakur G, Zeng Z, Kelly MA, Wang R, McQueen TJ, Qiu Y, Mak D, Burger JA, Daver NG, Pemmaraju N, Kadia TM, Jabbour E, Pierce S, Ravandi F, Garcia-Manero G, O'Brien SM, Cortes JE, Kantarjian HM, Konopleva M. Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients. 2014 ASCO Annual Meeting, 2014. e-Pub 2014.
Aad SA, Daver NG, Strati P, Cortes JE, Garcia-Manero G, Mathisen M, Ravandi F, Kadia TM, O'Brien SM, Bivins C, Pierce S, Kantarjian HM, Jabbour E. ASCO 2014: High prevalence of FLT-3 ITD mutations in patients (pts) with AML who present with CNS relapse. 2014 ASCO Annual Meeting, 2014. e-Pub 2014.
Shetty A, Bueso-Ramos CE, Cortes JE, Borthakur G, Pierce S, Kadia TM, Daver N, Thomas DA, Kantarjian HM, Ravandi F. Outcomes of patients (pts) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) with bone marrow necrosis (BMN) at initial diagnosis. 2014 ASCO Annual Meeting, 2014. e-Pub 2014.
DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos CE, Yin C, Pierce SR, Jabbour E, Quintas-Cardamo A, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/Meloprliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural Hisory and Clinical Outcome By Therapeutic Approach. Blood 122(21):2825, 2013. e-Pub 2013.
Borthakur G, Verstovsek S, Jabbour E, Matthews J, Kadia TM, Daver N, Kantarjian HM, Cortes J. Eltrombopag For The Management Of Thrombocytopenia Associated With Tyrosine Kinase Therapy In Patients With Chroniv Myeloid Leukemia and Myelofibrosis. Blood 122(21):4022, 2013. e-Pub 2013.
Garcia-Manero G, Kadia TM, Daver N, Jabbour E, Jain N, Cortes JE, Estrov Z, Borthakur G, Dong XQ. A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplasitc Syndromes (MDS). Blood 122(21):2751, 2013. e-Pub 2013.
Takahashi K, Jabbour E, Ravandi F, Borthakur G, Cortes JE, Kadia T, O'Brien S, Thomas DA, Faderl S, Bass J, Wierda WG, Daver N, DiNardo CD, Pierce S, Brandt M, Kantarjian HM, Garcia-Manero G. A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations. Blood 122(21):2684, 2013. e-Pub 2013.
Kadia TM, Daver N, Virani F, Jabbour E, Pierce S, Pemmaraju N, Quintas-Cardama A, Borthakur G, O'Brien S, Kantarjian HM, Cortes JE. Incidence, Clinical Characteristics, and Prognostic Significance Of Chromosome 3q Abnormalities In Patients With CML Blast Phase. Blood 122(21):2714, 2013. e-Pub 2013.
Nazha A, Kantarjian HM, Jabbour E, DiNardo CD, Borthakur G, Daver N, Faderl SH, Ning J, Wei. Outcome Of Patients With Myelodysplasic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating AGents Versus Intensive Chemotherapy. Blood 122(21):2788, 2013. e-Pub 2013.
Strati P, Kantarjian HM, Nazha A, Borthakur G, Daver N, Kadia TM, Estrov Z, Garcia-Manero G, Rajkhowa T, Ravandi F, Durand M, Levis M, Cortes JE. Early Results Of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 122(21):3949, 2013. e-Pub 2013.
Badar T, Mattiuzzi G, Kantarjian HM, Ravandi F, Daver N, Garcia-Manero G, Kadia TM, Jabbour EJ, Borthakur G, Cortes JE. Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For the Prevention of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine. Blood 122(21):3887, 2013. e-Pub 2013.
Pemmaraju N, Shah D, Kantarjian HM, WAgner V, Orlowski RZ, Garcia-Manero G, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour EJ, de Lima MJ, Champlin RE, Cortes JE, Qazilbash MH. Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) WHo Develop Therapy (t)-Related Myelodysplstic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). Blood 122(21):1424, 2013. e-Pub 2013.
Kornblau SM, Hu CW, Yoo SY, Qiu Y, Zhang N, Borthakur G, Daver N, Qutub AA, Coombes KR. Classification Of Acute Myelogenous Leukemia (AML) Based On Functionally Related Proteins Groups. Blood 122(21):492, 2013. e-Pub 2013.
Kantarjian HM, Jabbour E, Yee K, Kropf P, O'Connell C, Stock W, Tibes R, Rizzieri D, Walsh K, Griffiths EA, Roboz GJ, Savona M, Ervin T, Podoltsev N, Pemmaraju N, Daver N, Garcia-Manero G, Borthakur G, Wierda WG, Ravandi F, Cortes JE, Brandwein J, Odenike O, Feldman EJ, Chung W, Naim S, Choy G, Taverna P, Hao Y, Dimitrov G, Azab M, Issa J. First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating AGent (HMA), In Adult Patients With Acute Myeloid dLeukemia (AML). Blood 122(21):497, 2013. e-Pub 2013.
Jabbour E, Kantarjian HM, Qiao W, Strati P, Khan NF, Cortes JE, Hoehn D, Hu J, Obrien S, Bryan J, Prescott H, DiNardo CD, Daver N, Kadia TM, Garcia-Manero G. Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplasic Syndromes (MDS) Treated With Hypomethylating Agents (HMA). Blood 122(21):2801, 2013. e-Pub 2013.
Nazha A, Garcia-Manero G, Kantarjian HM, Ravandi F, Borthakur G, Kadia TM, Jabbour E, Pemmaraju N, Daver N, DiNardo CD, Miller D, Faderl SH. CLofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy. Blood 122(21):1525, 2013. e-Pub 2013.
Rytting ME, Thomas DA, O'Brien S, Schroeder K, Garris R, Cortes JE, Ravandi F, Pemmaraju N, Daver N, Faderl SH, Franklin AR, Borthakur G, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL). Blood 122(21):1400, 2013. e-Pub 2013.
Cortes JE, Borthakur G, Pemmaraju N, Daver N, uintas-Cardama A, Ravandi F, Gachimova E, Estrov Z, Jabbour E. Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP). Blood 122(21):1483, 2013. e-Pub 2013.
Jain P, Kantarjian H, Patel KP, Jabbour E, Daver N, Pierce S, Benjamini O, Borthakur G, DiNardo CD, Faderl SH. Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR*) Populations In Patients With Myelodysplastic Syndrome (MDS). Blood 122(21):5231, 2013. e-Pub 2013.
DiNardo CD, Kantarjian HM, Ravandi F, Konopleva M, Kadia TM, Borthakur G, Daver N, Durand M, Rivera S, Quintas-Cardama A, Garcia-Manero G. A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS. Blood 122(21):2698, 2013. e-Pub 2013.
Ohanian M, Levis M, Faderl SH, Garcia-Manero G, Jabbour E, Daver N, Dellasala SE, Pierce S, Burger JA, Cortes JE, Kantarjian HM. Final Report Of Phase II Study Of Sorafenib and 5-Acacytidine In Patients With Relapsed Or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. Blood 122(21):3934, 2013. e-Pub 2013.
Daver NG, Kantarjian H, Faderl S, Garcia-Manero G, O’Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Kadia T, Cortes J, Ravandi F. Clinical Characteristics and Outcomes In Patients With Acute Promyelocytic Leukemia (APL) and Hyperleukocytosis.2013 ASH Annual Meeting and Exposition. Blood 15, 2013. e-Pub 2013.
Daver NG, Kantarjian H, Thomas D, Rytting M, Ravandi F, Jain N, Cortes J, Kar J, Culotta K, Garris R, Richie M, Lu H, Konopleva M. A Phase I/II Study Of Hyper-CVAD Plus Everolimus In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia . 2013 ASH Annual Meeting and Exposition. Blood 15, 2013. e-Pub 2013.
Daver NG, Naqvi K, Pierce S, Kadia T, Dinardo C, Ravandi F, Jabbour E, Nazha A, Borthakur G, Pemmarajau N, Brandt M, O’Brien S, Cortes J, Kantarjian H, Garcia-Manero G. Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age. 2013 ASH Annual Meeting and Exposition. Blood 15, 2013. e-Pub 2013.
Kadia TM, Daver N, Ravandi F, Jabbour E, Pemmaraju N, Pierce S, Cortes JE, Kantarjian HM. Results of omacetaxine plus low-dose cytarabine (LD-araC) in older patients with acute myeloid leukemia (AML). 2013 ASCO Annual Meeting, 2013. e-Pub 2013.
Arana Yi CY, Borthakur G, Thall PF, Coveler AL, Ravandi F, Jabbour E, Faderl S, Thomas DA, Cortes JE, Kadia TM, Kornblau SM, Daver N, Pemmaraju N, Nguyen HQ, Wilson WR, Melink TJ, Gutheil J, Kantarjian HM, Estey E, Konopleva M. Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia. 2013 ASCO Annual Meeing, 2013. e-Pub 2013.
Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 Study of an Anti-CD33 Immunotoxin, Humanized Monoclonal Antibody M195 Conjugated to Recombinant Gelonin (HUM-195/RGEL), in Patients with Advanced Myeloid Malignancies. Haematologica 98(2):217-221, 2013. e-Pub 2013.
Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver NG, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23):4655-4662, 2013. e-Pub 2013.
Jain P, Kantarjian H M, Faderl S, Patel K P, Garcia Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T M, Daver NG, Nazha A, Luthra R, Pierce S, Cortes J E, Ravandi F. Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia. 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Strati P, Kantarjian H, Cortes J E, Ravandi F, Pemmaraju N, Garcia-Manero G, Kadia T M, Jabbour E J, Nazha A, Borthakur G, Faderl S, Quintás-Cardama A, Daver NG. Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Ghanem H, Garcia Manero G, Faderl S, Takahashi K, Ravandi F, Cortes J E, O'Brien S, Daver NG, Katragadda L, Pemmaraju N, Pierce S, Quintás-Cardama A, Kadia T, Kantarjian H M, JabbourE J. Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure.2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Faderl S, Garcia-Manero G, Ravandi F, Cortes JE, Estrov Z, Borthakur G, O'Brien S, Kadia TM, Konopleva M, Daver NG, Brandt M, Schroeder H, Kantarjian H M. A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily x 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS). Blood 120, 2012. e-Pub 2012.
Daver NG, Kantarjian H, Garcia-Manero G, Estrov Z, Konopleva M, Burger J, O'Brien S, Ferrajoli A, Verstovsek S, Kadia T, Jabbour E, Faderl S, Diaz-Pines-Mateo M, Pemmaraju N, Pierce S, Cortes JE, Borthakur G. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Alattar M, Kantarjian H, Cortes J E, Kadia T, Borthakur G, Ohanian, M, Ravandi F, Garcia-Manero G, Quintas-Cardamas A, Jabbour E, Daver NG, Pierce S, Brandt M, Faderl S, Pemmaraju N. Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Ravandi F, Patel K P, Luthra R, Pierce S, Borthakur G, Jabbour E J, Kadia T M, Pemmaraju N, Daver NG, Konopleva M, Faderl S, Garcia-Manero G, Cortes J E, Kantarjian H M. Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors).2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Ghanem H, Kantarjian H M, Faderl S, Jabbour E, Daver N, Pierce S, Brandt M, Quintás-Cardama A, Luthra R, Garcia-Manero G, Cortes J E, Ravandi F. Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO). 2012 Annual Meeting. Blood 120, 2012. e-Pub 2012.
Jabbour E, Daver NG, (Xiao Qin) DT, Kadia T, O'Brien S, Cortes J E, Ravandi F, Pemmaraju N, Ghanem H, Faderl S, Borthakur G, Kantarjian H, Garcia-Manero G. Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure. 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Takahashi K, Pemmaraju N, Beran M, Quintás-Cardama A, Cortes J E, Ravandi F, Faderl S, Verstovsek S, Kadia T M, Borthakur G, Jabbour E J, Daver N, Estrov Z, Pierce S, Garcia-Manero G. Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML). 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Kazmi S, Kantarjian H M, Tran K, Cortes J E, Ravandi F, Borthakur G, Jabbour E, Faderl S, Garcia-Manero G, Kadia T M, Daver NG, Pierce S, Nazha A, Quintas-Cardama A, Pemmaraju N. Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia. 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Pemmaraju N, Thomas D, Kantarjian H M, Cortes J E, Manning John T, Medeiros l J, O'Brien S, Daver NG, Nazha A, Pierce S, Garcia-Manero G, Jabbour E, Faderl S. Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Daver NG, Kantarjian H M, Garcia-Manero G, Cortes J E, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T M, Burger J A, Konopleva M, Brandt M, Huang X, Jabbour E. Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia. 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Mathisen M, Kantarjian H, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, O'Brien S, Quintas-Cardama A, Ghanem H, Daver N, Pierce S, Lira C, Faderl S, Jabbour E. Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML). 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Ravandi F, Alattar M L, Levis M J, Garcia-Manero G, Richie M A, Daver NG, Faderl S, Andreeff M, Borthakur G, Burger J A, Kadia T M, Grunwald M R, Dellasala S E, Cortes J E, Annual Meeting KHMA. Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. 2012 ASH Annual Meeting. Blood 20, 2012. e-Pub 2012.
Nazha A, Kantarjian H M, Cortes J E, Faderl S, Pierce S, Daver NG, Pemmaraju N, Ravandi F, Borthakur G, Kadia T M, Quintas-Cardama A, Garcia-Manero G. Outcome of Patients with Myelodysplastic Syndrome (MDS) with Bone Marrow (BM) Blasts Between 10 to 30% Treated with Hypomethylating Agents Versus Intensive Chemotherapy. 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Kadia T, Cortes J, Thomas D, Ravandi F, Pemmaraju N, Daver NG, Quintás-Cardama A, Baccus M, Garris R, Jabbour E, Kantarjian H, Borthakur G. A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL). 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Quintás-Cardama A, Kantarjian H M, Ravandi F, Foudray C, Pemmaraju N, Kadia T M, Borthakur G, Daver N, Faderl S, Jabbour E, Cortes J E, Garcia-Manero G. Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome. 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Nazha A, Ravandi F, Kantarjian H, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Andreeff M, Estrov Z, Daver NG, Pemmaraju N, Du M, Brandt M, Faderl S. Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Jain P, Kantarjian H, Thomas D A, Ravandi F, Kadia T M, Burger J A, Borthakur G, Cortes J E, Daver N, Jabbour E J, Koller C A, Konopleva M, Pemmaraju N, Kelly M A, Garris R, O'Brien S, Faderl S. Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL). 2012 ASH Annual Meeting. Blood 120, 2012. e-Pub 2012.
Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating Internal Tandem Duplication Mutations of the Fms-Like Tyrosine Kinase-3 (FLT3-ITD) at Complete Response and Relapse in Patients with Acute Myeloid Leukemia. Haematologica 97(8):1242-1245, 2012. e-Pub 2012.
Pemmaraju N, Thomas DA, Kantarjian H, O'Brien SM, Daver N, Nazha A, Pierce S, Garcia-Manero G, Cortes JE, Faderl S. Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN). 2012 ASCO Annual Meeting, 2012. e-Pub 2012.
Mathisen M, Kantarjian H, Faderl S, Garcia-Manero G, Ravandi F, Kadia TM, Daver N, O'Brien SM, Dorkhom SJ, Pierce S, Lira C, Cortes JE, Jabbour E. Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia (AML). 2012 ASCO Annual Meeting, 2012. e-Pub 2012.
Alattar ML, Kantarjian H, Burger JA, Richie MA, Garcia-Manero G, Konopleva M, Faderl S, Borthakur G, Daver N, Kadia TM, Cortes JE, Ravandi F. Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib. 2012 ASCO Annual Meeting, 2012. e-Pub 2012.
Bhamidipati PK, Daver N, Kantarjian H, Pierce S, Daver R, Cortes JE, Ravandi F, Mathisen M, Pemmaraju N, Nazha A, Kadia TM, Jabbour E, Borthakur G, Faderl S, Garcia-Manero G. FLT3 mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). 2012 ASCO Annual Meeting, 2012. e-Pub 2012.
Kadia T, Jabbour E, Pemmaraju N, Faderl S, Borthakur G, Thomas DA, Daver NG, Ravandi F, Kantarjian H. Phase II Study of Omacetaxine (OM) & Low Dose AraC (LDAC) in Older Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15), 2012. e-Pub 2012.
Pemmaraju N, Thomas DA, Kantarjian H, O'Brien S, Daver NG, Nazha A, Pierce S, Garcia-Manero G, Cortes JE, Faderl S. Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN). 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15), 2012. e-Pub 2012.
Daver NG, De Lima M, Kantarjian H, Ravandi F, Bilen M, Pierce S, Khouri I, Dorkhom S, Giralt S, Garcia-Manero G, Nazha A, Mathisen M, Pemmaraju N, Cortes JE, Faderl S, Jabbour E. Allogeneic stem cell transplant as initial salvage for patients with acute myeloid leukemia(AML) refractory to high-dose cytarabine-based induction chemotherapy. 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15), 2012. e-Pub 2012.
Bhamidipati P, Daver NG, Kantarjian H, Pierce S, Daver R, Cortes JE, Ravandi F, Mathisen M, Pemmaraju N, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Garcia-Manero G. FLT3 mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15), 2012. e-Pub 2012.
Alattar M, Kantarjian H, Burger J, Richie M, Garcia-Manero G, Konopleva M, Faderl S, Borthakur G, Daver NG, Kadia T, Cortes JE, Ravandi F. Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib. 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15), 2012. e-Pub 2012.
Mathisen M, Kantarjian H, Faderl S, Garcia-Manero G, Ravandi F, Kadia T, Daver NG, O'Brien S, Dorkhom S, Pierce S, Lira C, Cortes JE, Jabbour E. Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia. 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15), 2012. e-Pub 2012.
Daver NG, Kantarjian H, Garcia-Manero G, Borthakur G, Ravandi F, Kadia T, Estrov Z, Konopleva M, Faderl S, Cortes JE. AR-67, a DNA Topo-Isomerase I Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase II Trial of Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). Blood 118, 2011. e-Pub 2011.
Nazha A, Bhatt VR, Nogueras-Gonzalez G, Kadia T, Cortes JE, Daver NG, Garcia-Manero G, Kantarjian H, Borthakur G. Prognostic Implication of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype (MK) in Patients with Acute Myeloid Leukemia (AML) and Complex Cytogenetics. Blood 118, 2011. e-Pub 2011.
Garcia-Manero G, Daver NG, Borthakur G, Konopleva M, Ravandi F, Wierda W, Estrov Z, Faderl S, Kadia T, Rey K, Cheung C, Kantarjian H. Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). Blood 118, 2011. e-Pub 2011.
Daver NG, Kantarjian H, Garcia - Manero G, Cortes JE, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, huang X, Jabbour E. Twice Daily Fludarabine and Cytarabine Combination is Effective in Patients with Relapsed / Refractory Acute Myeloid Leukemia, High - Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia. Blood 118, 2011. e-Pub 2011.

Book Chapters

Alotaibi, AS, Daver, N. Immune-Based Approaches in AML, 145-153, 2021.
Daver NG, Udden M. Acute Lymphoblastic Leukemia. In: Hematology Oncology.

Letters to the Editor

Akiyama, H, Nishida, Y, Chang, KH, Bedoy, AD, Muftuoglu, M, Ma, W, Basyal, M, Hirschi, Z, Honma, D, Tsutsumi, S, Wang, J, Zhang, W, Huang, X, Rampal, R, Oluwole, OO, Bixby, D, Daver, NG, Andreeff, M. Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia. Blood cancer journal 15, 2025.
Bouligny, IM, MontalbanBravo, G, Sasaki, K, Daver, N, Jabbour, EJ, Alvarado, Y, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, Bose, P, Pemmaraju, N, Kornblau, SM, Kadia, TM, Masarova, L, Takahashi, K, Andreeff, M, Bazinet, A, Yang, H, KanagalShamanna, R, Hosing, C, Pierce, S, Meyer, M, Huang, X, Garcia-Manero, G. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica 110: 1628-1633, 2025.
Senapati, J, Garcia-Manero, G, DiNardo, C, Deshmukh, I, Borthakur, G, Kadia, TM, Jabbour, EJ, Short, NJ, Abbas, HA, Pemmaraju, N, Jain, N, Haddad, FG, Issa, GC, Maiti, A, Shpall, E, Popat, UR, Loghavi, S, Tang, G, Yilmaz, M, Alvarado, Y, Montalban Bravo, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, NG. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone marrow transplantation 60: 910-913, 2025.
Kawedia, J, Rausch, C, Liu, X, Qiao, W, DiNardo, C, Daver, NG, Borthakur, G, Pemmaraju, N, Reville, PK, Kontoyiannis, DP, Short, NJ, Konopleva, M, Jabbour, EJ, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals. American journal of hematology 100: 740-743, 2025.
Bouligny, IM, Montalban-Bravo, G, Sasaki, K, Daver, NG, Jabbour, EJ, Alvarado, Y, DiNardo, CD, Ravandi, F, Borthakur, G, Pemmaraju, N, Kadia, TM, Masarova, L, Takahashi, K, Andreeff, M, Bazinet, A, Yang, H, Kanagal, R, Pierce, S, Meyer, M, Huang, X, Garcia-Manero, G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39: 524-528, 2025.
Jen, WY, Jabbour, EJ, Short, NJ, Issa, GC, Haddad, FG, Jain, N, Pemmaraju, N, Daver, NG, Masarova, L, Borthakur, G, Chien, KS, Garris, R, Kantarjian, H. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. American journal of hematology 99: 2229-2232, 2024.

Less

CV information above last modified October 09, 2025

Naval G. Daver, M.D.

About Dr. Naval G. Daver

In the News

Second-generation inhibitors may change prognosis for patients with FLT3-positive acute myeloid leukemia

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Related Links

Leukemia

Leukemia Center

Leukemia Department

Cancer Medicine Division

Help #EndCancer

Naval G. Daver, M.D.

About Dr. Naval G. Daver

In the News

Second-generation inhibitors may change prognosis for patients with FLT3-positive acute myeloid leukemia

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Leukemia

Leukemia Center

Leukemia Department

Cancer Medicine Division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop MD Anderson